false chemical chemical Laboratory Tests Response to entity1begin Plenaxis entity1end should be monitored by measuring serum total entity2begin testosterone entity2end concentrations just prior to administration on Day 29 and every 8 weeks thereafter . 
false chemical chemical Population pharmacokinetic analyses revealed that entity1begin MTX entity1end , entity2begin NSAIDs entity2end , corticosteroids , and TNF blocking agents did not influence abatacept clearance . 
false chemical chemical Population pharmacokinetic analyses revealed that entity1begin MTX entity1end , NSAIDs , entity2begin corticosteroids entity2end , and TNF blocking agents did not influence abatacept clearance . 
false chemical chemical Population pharmacokinetic analyses revealed that entity1begin MTX entity1end , NSAIDs , corticosteroids , and entity2begin TNF blocking agents entity2end did not influence abatacept clearance . 
false chemical chemical Population pharmacokinetic analyses revealed that entity1begin MTX entity1end , NSAIDs , corticosteroids , and TNF blocking agents did not influence entity2begin abatacept entity2end clearance . 
false chemical chemical Population pharmacokinetic analyses revealed that MTX , entity1begin NSAIDs entity1end , entity2begin corticosteroids entity2end , and TNF blocking agents did not influence abatacept clearance . 
false chemical chemical Population pharmacokinetic analyses revealed that MTX , entity1begin NSAIDs entity1end , corticosteroids , and entity2begin TNF blocking agents entity2end did not influence abatacept clearance . 
false chemical chemical Population pharmacokinetic analyses revealed that MTX , entity1begin NSAIDs entity1end , corticosteroids , and TNF blocking agents did not influence entity2begin abatacept entity2end clearance . 
false chemical chemical Population pharmacokinetic analyses revealed that MTX , NSAIDs , entity1begin corticosteroids entity1end , and entity2begin TNF blocking agents entity2end did not influence abatacept clearance . 
false chemical chemical Population pharmacokinetic analyses revealed that MTX , NSAIDs , entity1begin corticosteroids entity1end , and TNF blocking agents did not influence entity2begin abatacept entity2end clearance . 
false chemical chemical Population pharmacokinetic analyses revealed that MTX , NSAIDs , corticosteroids , and entity1begin TNF blocking agents entity1end did not influence entity2begin abatacept entity2end clearance . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with entity1begin ORENCIA entity1end : entity2begin MTX entity2end , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with entity1begin ORENCIA entity1end : MTX , entity2begin NSAIDs entity2end , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with entity1begin ORENCIA entity1end : MTX , NSAIDs , entity2begin corticosteroids entity2end , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with entity1begin ORENCIA entity1end : MTX , NSAIDs , corticosteroids , entity2begin TNF blocking agents entity2end , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with entity1begin ORENCIA entity1end : MTX , NSAIDs , corticosteroids , TNF blocking agents , entity2begin azathioprine entity2end , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with entity1begin ORENCIA entity1end : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , entity2begin chloroquine entity2end , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with entity1begin ORENCIA entity1end : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , entity2begin gold entity2end , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with entity1begin ORENCIA entity1end : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , entity2begin hydroxychloroquine entity2end , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with entity1begin ORENCIA entity1end : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , entity2begin leflunomide entity2end , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with entity1begin ORENCIA entity1end : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , entity2begin sulfasalazine entity2end , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with entity1begin ORENCIA entity1end : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and entity2begin anakinra entity2end . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : entity1begin MTX entity1end , entity2begin NSAIDs entity2end , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : entity1begin MTX entity1end , NSAIDs , entity2begin corticosteroids entity2end , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : entity1begin MTX entity1end , NSAIDs , corticosteroids , entity2begin TNF blocking agents entity2end , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : entity1begin MTX entity1end , NSAIDs , corticosteroids , TNF blocking agents , entity2begin azathioprine entity2end , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : entity1begin MTX entity1end , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , entity2begin chloroquine entity2end , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : entity1begin MTX entity1end , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , entity2begin gold entity2end , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : entity1begin MTX entity1end , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , entity2begin hydroxychloroquine entity2end , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : entity1begin MTX entity1end , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , entity2begin leflunomide entity2end , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : entity1begin MTX entity1end , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , entity2begin sulfasalazine entity2end , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : entity1begin MTX entity1end , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and entity2begin anakinra entity2end . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , entity1begin NSAIDs entity1end , entity2begin corticosteroids entity2end , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , entity1begin NSAIDs entity1end , corticosteroids , entity2begin TNF blocking agents entity2end , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , entity1begin NSAIDs entity1end , corticosteroids , TNF blocking agents , entity2begin azathioprine entity2end , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , entity1begin NSAIDs entity1end , corticosteroids , TNF blocking agents , azathioprine , entity2begin chloroquine entity2end , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , entity1begin NSAIDs entity1end , corticosteroids , TNF blocking agents , azathioprine , chloroquine , entity2begin gold entity2end , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , entity1begin NSAIDs entity1end , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , entity2begin hydroxychloroquine entity2end , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , entity1begin NSAIDs entity1end , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , entity2begin leflunomide entity2end , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , entity1begin NSAIDs entity1end , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , entity2begin sulfasalazine entity2end , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , entity1begin NSAIDs entity1end , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and entity2begin anakinra entity2end . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , entity1begin corticosteroids entity1end , entity2begin TNF blocking agents entity2end , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , entity1begin corticosteroids entity1end , TNF blocking agents , entity2begin azathioprine entity2end , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , entity1begin corticosteroids entity1end , TNF blocking agents , azathioprine , entity2begin chloroquine entity2end , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , entity1begin corticosteroids entity1end , TNF blocking agents , azathioprine , chloroquine , entity2begin gold entity2end , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , entity1begin corticosteroids entity1end , TNF blocking agents , azathioprine , chloroquine , gold , entity2begin hydroxychloroquine entity2end , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , entity1begin corticosteroids entity1end , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , entity2begin leflunomide entity2end , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , entity1begin corticosteroids entity1end , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , entity2begin sulfasalazine entity2end , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , entity1begin corticosteroids entity1end , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and entity2begin anakinra entity2end . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , entity1begin TNF blocking agents entity1end , entity2begin azathioprine entity2end , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , entity1begin TNF blocking agents entity1end , azathioprine , entity2begin chloroquine entity2end , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , entity1begin TNF blocking agents entity1end , azathioprine , chloroquine , entity2begin gold entity2end , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , entity1begin TNF blocking agents entity1end , azathioprine , chloroquine , gold , entity2begin hydroxychloroquine entity2end , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , entity1begin TNF blocking agents entity1end , azathioprine , chloroquine , gold , hydroxychloroquine , entity2begin leflunomide entity2end , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , entity1begin TNF blocking agents entity1end , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , entity2begin sulfasalazine entity2end , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , entity1begin TNF blocking agents entity1end , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and entity2begin anakinra entity2end . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , entity1begin azathioprine entity1end , entity2begin chloroquine entity2end , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , entity1begin azathioprine entity1end , chloroquine , entity2begin gold entity2end , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , entity1begin azathioprine entity1end , chloroquine , gold , entity2begin hydroxychloroquine entity2end , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , entity1begin azathioprine entity1end , chloroquine , gold , hydroxychloroquine , entity2begin leflunomide entity2end , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , entity1begin azathioprine entity1end , chloroquine , gold , hydroxychloroquine , leflunomide , entity2begin sulfasalazine entity2end , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , entity1begin azathioprine entity1end , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and entity2begin anakinra entity2end . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , entity1begin chloroquine entity1end , entity2begin gold entity2end , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , entity1begin chloroquine entity1end , gold , entity2begin hydroxychloroquine entity2end , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , entity1begin chloroquine entity1end , gold , hydroxychloroquine , entity2begin leflunomide entity2end , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , entity1begin chloroquine entity1end , gold , hydroxychloroquine , leflunomide , entity2begin sulfasalazine entity2end , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , entity1begin chloroquine entity1end , gold , hydroxychloroquine , leflunomide , sulfasalazine , and entity2begin anakinra entity2end . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , entity1begin gold entity1end , entity2begin hydroxychloroquine entity2end , leflunomide , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , entity1begin gold entity1end , hydroxychloroquine , entity2begin leflunomide entity2end , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , entity1begin gold entity1end , hydroxychloroquine , leflunomide , entity2begin sulfasalazine entity2end , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , entity1begin gold entity1end , hydroxychloroquine , leflunomide , sulfasalazine , and entity2begin anakinra entity2end . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , entity1begin hydroxychloroquine entity1end , entity2begin leflunomide entity2end , sulfasalazine , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , entity1begin hydroxychloroquine entity1end , leflunomide , entity2begin sulfasalazine entity2end , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , entity1begin hydroxychloroquine entity1end , leflunomide , sulfasalazine , and entity2begin anakinra entity2end . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , entity1begin leflunomide entity1end , entity2begin sulfasalazine entity2end , and anakinra . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , entity1begin leflunomide entity1end , sulfasalazine , and entity2begin anakinra entity2end . 
false chemical chemical The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , entity1begin sulfasalazine entity1end , and entity2begin anakinra entity2end . 
true chemical chemical Concurrent administration of a entity1begin TNF antagonist entity1end with entity2begin ORENCIA entity2end has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone . 
false chemical chemical Concurrent administration of a entity1begin TNF antagonist entity1end with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the entity2begin TNF antagonists entity2end alone . 
false chemical chemical Concurrent administration of a TNF antagonist with entity1begin ORENCIA entity1end has been associated with an increased risk of serious infections and no significant additional efficacy over use of the entity2begin TNF antagonists entity2end alone . 
true chemical chemical Concurrent therapy with entity1begin ORENCIA entity1end and entity2begin TNF antagonists entity2end is not recommended . 
true chemical chemical There is insufficient experience to assess the safety and efficacy of entity1begin ORENCIA entity1end administered concurrently with entity2begin anakinra entity2end , and therefore such use is not recommended . 
false chemical chemical These medications have included entity1begin heparin entity1end , entity2begin warfarin entity2end , beta - adrenergic receptor blockers , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin . 
false chemical chemical These medications have included entity1begin heparin entity1end , warfarin , entity2begin beta - adrenergic receptor blockers entity2end , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin . 
false chemical chemical These medications have included entity1begin heparin entity1end , warfarin , beta - adrenergic receptor blockers , entity2begin calcium channel antagonists entity2end , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin . 
false chemical chemical These medications have included entity1begin heparin entity1end , warfarin , beta - adrenergic receptor blockers , calcium channel antagonists , entity2begin angiotensin converting enzyme inhibitors entity2end , intravenous and oral nitrates , ticlopidine , and aspirin . 
false chemical chemical These medications have included entity1begin heparin entity1end , warfarin , beta - adrenergic receptor blockers , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral entity2begin nitrates entity2end , ticlopidine , and aspirin . 
false chemical chemical These medications have included entity1begin heparin entity1end , warfarin , beta - adrenergic receptor blockers , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , entity2begin ticlopidine entity2end , and aspirin . 
false chemical chemical These medications have included entity1begin heparin entity1end , warfarin , beta - adrenergic receptor blockers , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , ticlopidine , and entity2begin aspirin entity2end . 
false chemical chemical These medications have included heparin , entity1begin warfarin entity1end , entity2begin beta - adrenergic receptor blockers entity2end , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin . 
false chemical chemical These medications have included heparin , entity1begin warfarin entity1end , beta - adrenergic receptor blockers , entity2begin calcium channel antagonists entity2end , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin . 
false chemical chemical These medications have included heparin , entity1begin warfarin entity1end , beta - adrenergic receptor blockers , calcium channel antagonists , entity2begin angiotensin converting enzyme inhibitors entity2end , intravenous and oral nitrates , ticlopidine , and aspirin . 
false chemical chemical These medications have included heparin , entity1begin warfarin entity1end , beta - adrenergic receptor blockers , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral entity2begin nitrates entity2end , ticlopidine , and aspirin . 
false chemical chemical These medications have included heparin , entity1begin warfarin entity1end , beta - adrenergic receptor blockers , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , entity2begin ticlopidine entity2end , and aspirin . 
false chemical chemical These medications have included heparin , entity1begin warfarin entity1end , beta - adrenergic receptor blockers , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , ticlopidine , and entity2begin aspirin entity2end . 
false chemical chemical These medications have included heparin , warfarin , entity1begin beta - adrenergic receptor blockers entity1end , entity2begin calcium channel antagonists entity2end , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , ticlopidine , and aspirin . 
false chemical chemical These medications have included heparin , warfarin , entity1begin beta - adrenergic receptor blockers entity1end , calcium channel antagonists , entity2begin angiotensin converting enzyme inhibitors entity2end , intravenous and oral nitrates , ticlopidine , and aspirin . 
false chemical chemical These medications have included heparin , warfarin , entity1begin beta - adrenergic receptor blockers entity1end , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral entity2begin nitrates entity2end , ticlopidine , and aspirin . 
false chemical chemical These medications have included heparin , warfarin , entity1begin beta - adrenergic receptor blockers entity1end , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , entity2begin ticlopidine entity2end , and aspirin . 
false chemical chemical These medications have included heparin , warfarin , entity1begin beta - adrenergic receptor blockers entity1end , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , ticlopidine , and entity2begin aspirin entity2end . 
false chemical chemical These medications have included heparin , warfarin , beta - adrenergic receptor blockers , entity1begin calcium channel antagonists entity1end , entity2begin angiotensin converting enzyme inhibitors entity2end , intravenous and oral nitrates , ticlopidine , and aspirin . 
false chemical chemical These medications have included heparin , warfarin , beta - adrenergic receptor blockers , entity1begin calcium channel antagonists entity1end , angiotensin converting enzyme inhibitors , intravenous and oral entity2begin nitrates entity2end , ticlopidine , and aspirin . 
false chemical chemical These medications have included heparin , warfarin , beta - adrenergic receptor blockers , entity1begin calcium channel antagonists entity1end , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , entity2begin ticlopidine entity2end , and aspirin . 
false chemical chemical These medications have included heparin , warfarin , beta - adrenergic receptor blockers , entity1begin calcium channel antagonists entity1end , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , ticlopidine , and entity2begin aspirin entity2end . 
false chemical chemical These medications have included heparin , warfarin , beta - adrenergic receptor blockers , calcium channel antagonists , entity1begin angiotensin converting enzyme inhibitors entity1end , intravenous and oral entity2begin nitrates entity2end , ticlopidine , and aspirin . 
false chemical chemical These medications have included heparin , warfarin , beta - adrenergic receptor blockers , calcium channel antagonists , entity1begin angiotensin converting enzyme inhibitors entity1end , intravenous and oral nitrates , entity2begin ticlopidine entity2end , and aspirin . 
false chemical chemical These medications have included heparin , warfarin , beta - adrenergic receptor blockers , calcium channel antagonists , entity1begin angiotensin converting enzyme inhibitors entity1end , intravenous and oral nitrates , ticlopidine , and entity2begin aspirin entity2end . 
false chemical chemical These medications have included heparin , warfarin , beta - adrenergic receptor blockers , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral entity1begin nitrates entity1end , entity2begin ticlopidine entity2end , and aspirin . 
false chemical chemical These medications have included heparin , warfarin , beta - adrenergic receptor blockers , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral entity1begin nitrates entity1end , ticlopidine , and entity2begin aspirin entity2end . 
false chemical chemical These medications have included heparin , warfarin , beta - adrenergic receptor blockers , calcium channel antagonists , angiotensin converting enzyme inhibitors , intravenous and oral nitrates , entity1begin ticlopidine entity1end , and entity2begin aspirin entity2end . 
false chemical chemical entity1begin Heparin entity1end , other entity2begin anticoagulants entity2end , thrombolytics , and anti platelet agents are associated with an increase in bleeding . 
false chemical chemical entity1begin Heparin entity1end , other anticoagulants , entity2begin thrombolytics entity2end , and anti platelet agents are associated with an increase in bleeding . 
false chemical chemical entity1begin Heparin entity1end , other anticoagulants , thrombolytics , and entity2begin anti platelet agents entity2end are associated with an increase in bleeding . 
false chemical chemical Heparin , other entity1begin anticoagulants entity1end , entity2begin thrombolytics entity2end , and anti platelet agents are associated with an increase in bleeding . 
false chemical chemical Heparin , other entity1begin anticoagulants entity1end , thrombolytics , and entity2begin anti platelet agents entity2end are associated with an increase in bleeding . 
false chemical chemical Heparin , other anticoagulants , entity1begin thrombolytics entity1end , and entity2begin anti platelet agents entity2end are associated with an increase in bleeding . 
false chemical chemical The concomitant intake of entity1begin alcohol entity1end and entity2begin Acamprosate entity2end does not affect the pharmacokinetics of either alcohol or acamprosate . 
false chemical chemical The concomitant intake of entity1begin alcohol entity1end and Acamprosate does not affect the pharmacokinetics of either entity2begin alcohol entity2end or acamprosate . 
false chemical chemical The concomitant intake of entity1begin alcohol entity1end and Acamprosate does not affect the pharmacokinetics of either alcohol or entity2begin acamprosate entity2end . 
false chemical chemical The concomitant intake of alcohol and entity1begin Acamprosate entity1end does not affect the pharmacokinetics of either entity2begin alcohol entity2end or acamprosate . 
false chemical chemical The concomitant intake of alcohol and entity1begin Acamprosate entity1end does not affect the pharmacokinetics of either alcohol or entity2begin acamprosate entity2end . 
false chemical chemical The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either entity1begin alcohol entity1end or entity2begin acamprosate entity2end . 
false chemical chemical Pharmacokinetic studies indicate that administration of entity1begin disulfiram entity1end or entity2begin diazepam entity2end does not affect the pharmacokinetics of acamprosate . 
false chemical chemical Pharmacokinetic studies indicate that administration of entity1begin disulfiram entity1end or diazepam does not affect the pharmacokinetics of entity2begin acamprosate entity2end . 
false chemical chemical Pharmacokinetic studies indicate that administration of disulfiram or entity1begin diazepam entity1end does not affect the pharmacokinetics of entity2begin acamprosate entity2end . 
true chemical chemical Co - administration of entity1begin naltrexone entity1end with entity2begin Acamprosate entity2end produced a 25 % increase in AUC and a 33 % increase in the Cmax of acamprosate . 
false chemical chemical Co - administration of entity1begin naltrexone entity1end with Acamprosate produced a 25 % increase in AUC and a 33 % increase in the Cmax of entity2begin acamprosate entity2end . 
false chemical chemical Co - administration of naltrexone with entity1begin Acamprosate entity1end produced a 25 % increase in AUC and a 33 % increase in the Cmax of entity2begin acamprosate entity2end . 
false chemical chemical The pharmacokinetics of entity1begin naltrexone entity1end and its major metabolite entity2begin 6 - beta - naltrexol entity2end were unaffected following co - administration with Acamprosate . 
false chemical chemical The pharmacokinetics of entity1begin naltrexone entity1end and its major metabolite 6 - beta - naltrexol were unaffected following co - administration with entity2begin Acamprosate entity2end . 
false chemical chemical The pharmacokinetics of naltrexone and its major metabolite entity1begin 6 - beta - naltrexol entity1end were unaffected following co - administration with entity2begin Acamprosate entity2end . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with entity1begin Acamprosate entity1end concomitantly with entity2begin anxiolytics entity2end , hypnotics and sedatives ( including benzodiazepines ) , or non - opioid analgesics was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with entity1begin Acamprosate entity1end concomitantly with anxiolytics , entity2begin hypnotics entity2end and sedatives ( including benzodiazepines ) , or non - opioid analgesics was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with entity1begin Acamprosate entity1end concomitantly with anxiolytics , hypnotics and entity2begin sedatives entity2end ( including benzodiazepines ) , or non - opioid analgesics was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with entity1begin Acamprosate entity1end concomitantly with anxiolytics , hypnotics and sedatives ( including entity2begin benzodiazepines entity2end ) , or non - opioid analgesics was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with entity1begin Acamprosate entity1end concomitantly with anxiolytics , hypnotics and sedatives ( including benzodiazepines ) , or entity2begin non - opioid analgesics entity2end was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with entity1begin anxiolytics entity1end , entity2begin hypnotics entity2end and sedatives ( including benzodiazepines ) , or non - opioid analgesics was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with entity1begin anxiolytics entity1end , hypnotics and entity2begin sedatives entity2end ( including benzodiazepines ) , or non - opioid analgesics was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with entity1begin anxiolytics entity1end , hypnotics and sedatives ( including entity2begin benzodiazepines entity2end ) , or non - opioid analgesics was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with entity1begin anxiolytics entity1end , hypnotics and sedatives ( including benzodiazepines ) , or entity2begin non - opioid analgesics entity2end was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , entity1begin hypnotics entity1end and entity2begin sedatives entity2end ( including benzodiazepines ) , or non - opioid analgesics was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , entity1begin hypnotics entity1end and sedatives ( including entity2begin benzodiazepines entity2end ) , or non - opioid analgesics was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , entity1begin hypnotics entity1end and sedatives ( including benzodiazepines ) , or entity2begin non - opioid analgesics entity2end was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and entity1begin sedatives entity1end ( including entity2begin benzodiazepines entity2end ) , or non - opioid analgesics was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and entity1begin sedatives entity1end ( including benzodiazepines ) , or entity2begin non - opioid analgesics entity2end was similar to that of subjects taking placebo with these concomitant medications . 
false chemical chemical Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and sedatives ( including entity1begin benzodiazepines entity1end ) , or entity2begin non - opioid analgesics entity2end was similar to that of subjects taking placebo with these concomitant medications . 
true chemical chemical Patients taking entity1begin Acamprosate entity1end concomitantly with entity2begin antidepressants entity2end more commonly reported both weight gain and weight loss , compared with patients taking either medication alone . 
false chemical chemical These drugs include the entity1begin thiazides entity1end and other entity2begin diuretics entity2end , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the entity1begin thiazides entity1end and other diuretics , entity2begin corticosteroids entity2end , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the entity1begin thiazides entity1end and other diuretics , corticosteroids , entity2begin phenothiazines entity2end , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the entity1begin thiazides entity1end and other diuretics , corticosteroids , phenothiazines , entity2begin thyroid products entity2end , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the entity1begin thiazides entity1end and other diuretics , corticosteroids , phenothiazines , thyroid products , entity2begin estrogens entity2end , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the entity1begin thiazides entity1end and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral entity2begin contraceptives entity2end , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the entity1begin thiazides entity1end and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , entity2begin phenytoin entity2end , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the entity1begin thiazides entity1end and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , entity2begin nicotinic acid entity2end , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the entity1begin thiazides entity1end and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , entity2begin sympathomimetics entity2end , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the entity1begin thiazides entity1end and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , entity2begin calcium channel - blocking drugs entity2end , and isoniazid . 
false chemical chemical These drugs include the entity1begin thiazides entity1end and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and entity2begin isoniazid entity2end . 
false chemical chemical These drugs include the thiazides and other entity1begin diuretics entity1end , entity2begin corticosteroids entity2end , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other entity1begin diuretics entity1end , corticosteroids , entity2begin phenothiazines entity2end , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other entity1begin diuretics entity1end , corticosteroids , phenothiazines , entity2begin thyroid products entity2end , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other entity1begin diuretics entity1end , corticosteroids , phenothiazines , thyroid products , entity2begin estrogens entity2end , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other entity1begin diuretics entity1end , corticosteroids , phenothiazines , thyroid products , estrogens , oral entity2begin contraceptives entity2end , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other entity1begin diuretics entity1end , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , entity2begin phenytoin entity2end , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other entity1begin diuretics entity1end , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , entity2begin nicotinic acid entity2end , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other entity1begin diuretics entity1end , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , entity2begin sympathomimetics entity2end , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other entity1begin diuretics entity1end , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , entity2begin calcium channel - blocking drugs entity2end , and isoniazid . 
false chemical chemical These drugs include the thiazides and other entity1begin diuretics entity1end , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and entity2begin isoniazid entity2end . 
false chemical chemical These drugs include the thiazides and other diuretics , entity1begin corticosteroids entity1end , entity2begin phenothiazines entity2end , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , entity1begin corticosteroids entity1end , phenothiazines , entity2begin thyroid products entity2end , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , entity1begin corticosteroids entity1end , phenothiazines , thyroid products , entity2begin estrogens entity2end , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , entity1begin corticosteroids entity1end , phenothiazines , thyroid products , estrogens , oral entity2begin contraceptives entity2end , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , entity1begin corticosteroids entity1end , phenothiazines , thyroid products , estrogens , oral contraceptives , entity2begin phenytoin entity2end , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , entity1begin corticosteroids entity1end , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , entity2begin nicotinic acid entity2end , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , entity1begin corticosteroids entity1end , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , entity2begin sympathomimetics entity2end , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , entity1begin corticosteroids entity1end , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , entity2begin calcium channel - blocking drugs entity2end , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , entity1begin corticosteroids entity1end , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and entity2begin isoniazid entity2end . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , entity1begin phenothiazines entity1end , entity2begin thyroid products entity2end , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , entity1begin phenothiazines entity1end , thyroid products , entity2begin estrogens entity2end , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , entity1begin phenothiazines entity1end , thyroid products , estrogens , oral entity2begin contraceptives entity2end , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , entity1begin phenothiazines entity1end , thyroid products , estrogens , oral contraceptives , entity2begin phenytoin entity2end , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , entity1begin phenothiazines entity1end , thyroid products , estrogens , oral contraceptives , phenytoin , entity2begin nicotinic acid entity2end , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , entity1begin phenothiazines entity1end , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , entity2begin sympathomimetics entity2end , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , entity1begin phenothiazines entity1end , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , entity2begin calcium channel - blocking drugs entity2end , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , entity1begin phenothiazines entity1end , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and entity2begin isoniazid entity2end . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , entity1begin thyroid products entity1end , entity2begin estrogens entity2end , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , entity1begin thyroid products entity1end , estrogens , oral entity2begin contraceptives entity2end , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , entity1begin thyroid products entity1end , estrogens , oral contraceptives , entity2begin phenytoin entity2end , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , entity1begin thyroid products entity1end , estrogens , oral contraceptives , phenytoin , entity2begin nicotinic acid entity2end , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , entity1begin thyroid products entity1end , estrogens , oral contraceptives , phenytoin , nicotinic acid , entity2begin sympathomimetics entity2end , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , entity1begin thyroid products entity1end , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , entity2begin calcium channel - blocking drugs entity2end , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , entity1begin thyroid products entity1end , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and entity2begin isoniazid entity2end . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , entity1begin estrogens entity1end , oral entity2begin contraceptives entity2end , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , entity1begin estrogens entity1end , oral contraceptives , entity2begin phenytoin entity2end , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , entity1begin estrogens entity1end , oral contraceptives , phenytoin , entity2begin nicotinic acid entity2end , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , entity1begin estrogens entity1end , oral contraceptives , phenytoin , nicotinic acid , entity2begin sympathomimetics entity2end , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , entity1begin estrogens entity1end , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , entity2begin calcium channel - blocking drugs entity2end , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , entity1begin estrogens entity1end , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and entity2begin isoniazid entity2end . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral entity1begin contraceptives entity1end , entity2begin phenytoin entity2end , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral entity1begin contraceptives entity1end , phenytoin , entity2begin nicotinic acid entity2end , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral entity1begin contraceptives entity1end , phenytoin , nicotinic acid , entity2begin sympathomimetics entity2end , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral entity1begin contraceptives entity1end , phenytoin , nicotinic acid , sympathomimetics , entity2begin calcium channel - blocking drugs entity2end , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral entity1begin contraceptives entity1end , phenytoin , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and entity2begin isoniazid entity2end . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , entity1begin phenytoin entity1end , entity2begin nicotinic acid entity2end , sympathomimetics , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , entity1begin phenytoin entity1end , nicotinic acid , entity2begin sympathomimetics entity2end , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , entity1begin phenytoin entity1end , nicotinic acid , sympathomimetics , entity2begin calcium channel - blocking drugs entity2end , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , entity1begin phenytoin entity1end , nicotinic acid , sympathomimetics , calcium channel - blocking drugs , and entity2begin isoniazid entity2end . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , entity1begin nicotinic acid entity1end , entity2begin sympathomimetics entity2end , calcium channel - blocking drugs , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , entity1begin nicotinic acid entity1end , sympathomimetics , entity2begin calcium channel - blocking drugs entity2end , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , entity1begin nicotinic acid entity1end , sympathomimetics , calcium channel - blocking drugs , and entity2begin isoniazid entity2end . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , entity1begin sympathomimetics entity1end , entity2begin calcium channel - blocking drugs entity2end , and isoniazid . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , entity1begin sympathomimetics entity1end , calcium channel - blocking drugs , and entity2begin isoniazid entity2end . 
false chemical chemical These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , entity1begin calcium channel - blocking drugs entity1end , and entity2begin isoniazid entity2end . 
false chemical chemical When such drugs are withdrawn from patients receiving entity1begin Acarbose entity1end in combination with entity2begin sulfonylureas entity2end or insulin , patients should be observed closely for any evidence of hypoglycemia . 
false chemical chemical When such drugs are withdrawn from patients receiving entity1begin Acarbose entity1end in combination with sulfonylureas or entity2begin insulin entity2end , patients should be observed closely for any evidence of hypoglycemia . 
false chemical chemical When such drugs are withdrawn from patients receiving Acarbose in combination with entity1begin sulfonylureas entity1end or entity2begin insulin entity2end , patients should be observed closely for any evidence of hypoglycemia . 
false chemical chemical entity1begin Intestinal adsorbents entity1end ( e. g. , entity2begin charcoal entity2end ) and digestive enzyme preparations containing carbohydrate - splitting enzymes ( e. g. , amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly . 
false chemical chemical entity1begin Intestinal adsorbents entity1end ( e. g. , charcoal ) and entity2begin digestive enzyme preparations entity2end containing carbohydrate - splitting enzymes ( e. g. , amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly . 
false chemical chemical entity1begin Intestinal adsorbents entity1end ( e. g. , charcoal ) and digestive enzyme preparations containing carbohydrate - splitting enzymes ( e. g. , entity2begin amylase entity2end , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly . 
false chemical chemical entity1begin Intestinal adsorbents entity1end ( e. g. , charcoal ) and digestive enzyme preparations containing carbohydrate - splitting enzymes ( e. g. , amylase , entity2begin pancreatin entity2end ) may reduce the effect of Acarbose and should not be taken concomitantly . 
true chemical chemical entity1begin Intestinal adsorbents entity1end ( e. g. , charcoal ) and digestive enzyme preparations containing carbohydrate - splitting enzymes ( e. g. , amylase , pancreatin ) may reduce the effect of entity2begin Acarbose entity2end and should not be taken concomitantly . 
false chemical chemical Intestinal adsorbents ( e. g. , entity1begin charcoal entity1end ) and entity2begin digestive enzyme preparations entity2end containing carbohydrate - splitting enzymes ( e. g. , amylase , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly . 
false chemical chemical Intestinal adsorbents ( e. g. , entity1begin charcoal entity1end ) and digestive enzyme preparations containing carbohydrate - splitting enzymes ( e. g. , entity2begin amylase entity2end , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly . 
false chemical chemical Intestinal adsorbents ( e. g. , entity1begin charcoal entity1end ) and digestive enzyme preparations containing carbohydrate - splitting enzymes ( e. g. , amylase , entity2begin pancreatin entity2end ) may reduce the effect of Acarbose and should not be taken concomitantly . 
true chemical chemical Intestinal adsorbents ( e. g. , entity1begin charcoal entity1end ) and digestive enzyme preparations containing carbohydrate - splitting enzymes ( e. g. , amylase , pancreatin ) may reduce the effect of entity2begin Acarbose entity2end and should not be taken concomitantly . 
false chemical chemical Intestinal adsorbents ( e. g. , charcoal ) and entity1begin digestive enzyme preparations entity1end containing carbohydrate - splitting enzymes ( e. g. , entity2begin amylase entity2end , pancreatin ) may reduce the effect of Acarbose and should not be taken concomitantly . 
false chemical chemical Intestinal adsorbents ( e. g. , charcoal ) and entity1begin digestive enzyme preparations entity1end containing carbohydrate - splitting enzymes ( e. g. , amylase , entity2begin pancreatin entity2end ) may reduce the effect of Acarbose and should not be taken concomitantly . 
false chemical chemical Intestinal adsorbents ( e. g. , charcoal ) and entity1begin digestive enzyme preparations entity1end containing carbohydrate - splitting enzymes ( e. g. , amylase , pancreatin ) may reduce the effect of entity2begin Acarbose entity2end and should not be taken concomitantly . 
false chemical chemical Intestinal adsorbents ( e. g. , charcoal ) and digestive enzyme preparations containing carbohydrate - splitting enzymes ( e. g. , entity1begin amylase entity1end , entity2begin pancreatin entity2end ) may reduce the effect of Acarbose and should not be taken concomitantly . 
true chemical chemical Intestinal adsorbents ( e. g. , charcoal ) and digestive enzyme preparations containing carbohydrate - splitting enzymes ( e. g. , entity1begin amylase entity1end , pancreatin ) may reduce the effect of entity2begin Acarbose entity2end and should not be taken concomitantly . 
true chemical chemical Intestinal adsorbents ( e. g. , charcoal ) and digestive enzyme preparations containing carbohydrate - splitting enzymes ( e. g. , amylase , entity1begin pancreatin entity1end ) may reduce the effect of entity2begin Acarbose entity2end and should not be taken concomitantly . 
true chemical chemical entity1begin Acarbose entity1end has been shown to change the bioavailabillty entity2begin digoxin entity2end when they are co - administered , which may require digoxin dose adjustment . 
false chemical chemical entity1begin Acarbose entity1end has been shown to change the bioavailabillty digoxin when they are co - administered , which may require entity2begin digoxin entity2end dose adjustment . 
false chemical chemical Acarbose has been shown to change the bioavailabillty entity1begin digoxin entity1end when they are co - administered , which may require entity2begin digoxin entity2end dose adjustment . 
false chemical chemical Studies in healthy volunteers have shown that entity1begin Acarbose entity1end has no effect on either the pharmacokinetics or pharmacodynamics of entity2begin digoxin entity2end , nifedipine , propranolol , or ranitidine . 
false chemical chemical Studies in healthy volunteers have shown that entity1begin Acarbose entity1end has no effect on either the pharmacokinetics or pharmacodynamics of digoxin , entity2begin nifedipine entity2end , propranolol , or ranitidine . 
false chemical chemical Studies in healthy volunteers have shown that entity1begin Acarbose entity1end has no effect on either the pharmacokinetics or pharmacodynamics of digoxin , nifedipine , entity2begin propranolol entity2end , or ranitidine . 
false chemical chemical Studies in healthy volunteers have shown that entity1begin Acarbose entity1end has no effect on either the pharmacokinetics or pharmacodynamics of digoxin , nifedipine , propranolol , or entity2begin ranitidine entity2end . 
false chemical chemical Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of entity1begin digoxin entity1end , entity2begin nifedipine entity2end , propranolol , or ranitidine . 
false chemical chemical Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of entity1begin digoxin entity1end , nifedipine , entity2begin propranolol entity2end , or ranitidine . 
false chemical chemical Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of entity1begin digoxin entity1end , nifedipine , propranolol , or entity2begin ranitidine entity2end . 
false chemical chemical Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin , entity1begin nifedipine entity1end , entity2begin propranolol entity2end , or ranitidine . 
false chemical chemical Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin , entity1begin nifedipine entity1end , propranolol , or entity2begin ranitidine entity2end . 
false chemical chemical Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin , nifedipine , entity1begin propranolol entity1end , or entity2begin ranitidine entity2end . 
false chemical chemical entity1begin Acarbose entity1end did not interfere with the absorption or disposition of the entity2begin sulfonylurea entity2end glyburide in diabetic patients . 
false chemical chemical entity1begin Acarbose entity1end did not interfere with the absorption or disposition of the sulfonylurea entity2begin glyburide entity2end in diabetic patients . 
false chemical chemical Acarbose did not interfere with the absorption or disposition of the entity1begin sulfonylurea entity1end entity2begin glyburide entity2end in diabetic patients . 
false chemical chemical entity1begin Acarbose entity1end may affect entity2begin digoxin entity2end bioavailabillty and may require dose adjustment of digoxin by 16 % ( 90 % confidence interval : 8 - 23 % ) , decrease mean C max digoxin by 26 % ( 90 % confidence interval : 16 - 34 % ) and decrease mean trough concentrations of digoxin by 9 % ( 90 % confidence limit : 19 % decrease to 2 % increase ) . 
false chemical chemical entity1begin Acarbose entity1end may affect digoxin bioavailabillty and may require dose adjustment of entity2begin digoxin entity2end by 16 % ( 90 % confidence interval : 8 - 23 % ) , decrease mean C max digoxin by 26 % ( 90 % confidence interval : 16 - 34 % ) and decrease mean trough concentrations of digoxin by 9 % ( 90 % confidence limit : 19 % decrease to 2 % increase ) . 
false chemical chemical entity1begin Acarbose entity1end may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16 % ( 90 % confidence interval : 8 - 23 % ) , decrease mean C max entity2begin digoxin entity2end by 26 % ( 90 % confidence interval : 16 - 34 % ) and decrease mean trough concentrations of digoxin by 9 % ( 90 % confidence limit : 19 % decrease to 2 % increase ) . 
false chemical chemical entity1begin Acarbose entity1end may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16 % ( 90 % confidence interval : 8 - 23 % ) , decrease mean C max digoxin by 26 % ( 90 % confidence interval : 16 - 34 % ) and decrease mean trough concentrations of entity2begin digoxin entity2end by 9 % ( 90 % confidence limit : 19 % decrease to 2 % increase ) . 
false chemical chemical Acarbose may affect entity1begin digoxin entity1end bioavailabillty and may require dose adjustment of entity2begin digoxin entity2end by 16 % ( 90 % confidence interval : 8 - 23 % ) , decrease mean C max digoxin by 26 % ( 90 % confidence interval : 16 - 34 % ) and decrease mean trough concentrations of digoxin by 9 % ( 90 % confidence limit : 19 % decrease to 2 % increase ) . 
false chemical chemical Acarbose may affect entity1begin digoxin entity1end bioavailabillty and may require dose adjustment of digoxin by 16 % ( 90 % confidence interval : 8 - 23 % ) , decrease mean C max entity2begin digoxin entity2end by 26 % ( 90 % confidence interval : 16 - 34 % ) and decrease mean trough concentrations of digoxin by 9 % ( 90 % confidence limit : 19 % decrease to 2 % increase ) . 
false chemical chemical Acarbose may affect entity1begin digoxin entity1end bioavailabillty and may require dose adjustment of digoxin by 16 % ( 90 % confidence interval : 8 - 23 % ) , decrease mean C max digoxin by 26 % ( 90 % confidence interval : 16 - 34 % ) and decrease mean trough concentrations of entity2begin digoxin entity2end by 9 % ( 90 % confidence limit : 19 % decrease to 2 % increase ) . 
false chemical chemical Acarbose may affect digoxin bioavailabillty and may require dose adjustment of entity1begin digoxin entity1end by 16 % ( 90 % confidence interval : 8 - 23 % ) , decrease mean C max entity2begin digoxin entity2end by 26 % ( 90 % confidence interval : 16 - 34 % ) and decrease mean trough concentrations of digoxin by 9 % ( 90 % confidence limit : 19 % decrease to 2 % increase ) . 
false chemical chemical Acarbose may affect digoxin bioavailabillty and may require dose adjustment of entity1begin digoxin entity1end by 16 % ( 90 % confidence interval : 8 - 23 % ) , decrease mean C max digoxin by 26 % ( 90 % confidence interval : 16 - 34 % ) and decrease mean trough concentrations of entity2begin digoxin entity2end by 9 % ( 90 % confidence limit : 19 % decrease to 2 % increase ) . 
false chemical chemical Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16 % ( 90 % confidence interval : 8 - 23 % ) , decrease mean C max entity1begin digoxin entity1end by 26 % ( 90 % confidence interval : 16 - 34 % ) and decrease mean trough concentrations of entity2begin digoxin entity2end by 9 % ( 90 % confidence limit : 19 % decrease to 2 % increase ) . 
false chemical chemical The amount of entity1begin metformin entity1end absorbed while taking entity2begin Acarbose entity2end was bioequivalent to the amount absorbed when taking placebo , as indicated by the plasma AUC values . 
true chemical chemical However , the peak plasma level of entity1begin metformin entity1end was reduced by approximately 20 % when taking entity2begin Acarbose entity2end due to a slight delay in the absorption of metformin . 
false chemical chemical However , the peak plasma level of entity1begin metformin entity1end was reduced by approximately 20 % when taking Acarbose due to a slight delay in the absorption of entity2begin metformin entity2end . 
true chemical chemical However , the peak plasma level of metformin was reduced by approximately 20 % when taking entity1begin Acarbose entity1end due to a slight delay in the absorption of entity2begin metformin entity2end . 
false chemical chemical There is little if any clinically significant interaction between entity1begin Acarbose entity1end and entity2begin metformin entity2end . 
false chemical chemical entity1begin Catecholamine - depleting drugs entity1end , such as entity2begin reserpine entity2end , may have an additive effect when given with beta - blocking agents . 
true chemical chemical entity1begin Catecholamine - depleting drugs entity1end , such as reserpine , may have an additive effect when given with entity2begin beta - blocking agents entity2end . 
true chemical chemical Catecholamine - depleting drugs , such as entity1begin reserpine entity1end , may have an additive effect when given with entity2begin beta - blocking agents entity2end . 
true chemical chemical Patients treated with entity1begin acebutolol entity1end plus entity2begin catecholamine depletors entity2end should , therefore , be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo , syncope / presyncope , or orthostatic changes in blood pressure without compensatory tachycardia . 
true chemical chemical Exaggerated hypertensive responses have been reported from the combined use of entity1begin beta - adrenergic antagonists entity1end and entity2begin alpha - adrenergic stimulants entity2end , including those contained in proprietary cold remedies and vasoconstrictive nasal drops . 
true chemical chemical Blunting of the antihypertensive effect of entity1begin beta - adrenoceptor blocking agents entity1end by entity2begin nonsteroidal anti - inflammatory drugs entity2end has been reported . 
false chemical chemical No significant interactions with entity1begin digoxin entity1end , entity2begin hydrochlorothiazide entity2end , hydralazine , sulfinpyrazone , oral contraceptives , tolbutamide , or warfarin have been observed . 
false chemical chemical No significant interactions with entity1begin digoxin entity1end , hydrochlorothiazide , entity2begin hydralazine entity2end , sulfinpyrazone , oral contraceptives , tolbutamide , or warfarin have been observed . 
false chemical chemical No significant interactions with entity1begin digoxin entity1end , hydrochlorothiazide , hydralazine , entity2begin sulfinpyrazone entity2end , oral contraceptives , tolbutamide , or warfarin have been observed . 
false chemical chemical No significant interactions with entity1begin digoxin entity1end , hydrochlorothiazide , hydralazine , sulfinpyrazone , oral entity2begin contraceptives entity2end , tolbutamide , or warfarin have been observed . 
false chemical chemical No significant interactions with entity1begin digoxin entity1end , hydrochlorothiazide , hydralazine , sulfinpyrazone , oral contraceptives , entity2begin tolbutamide entity2end , or warfarin have been observed . 
false chemical chemical No significant interactions with entity1begin digoxin entity1end , hydrochlorothiazide , hydralazine , sulfinpyrazone , oral contraceptives , tolbutamide , or entity2begin warfarin entity2end have been observed . 
false chemical chemical No significant interactions with digoxin , entity1begin hydrochlorothiazide entity1end , entity2begin hydralazine entity2end , sulfinpyrazone , oral contraceptives , tolbutamide , or warfarin have been observed . 
false chemical chemical No significant interactions with digoxin , entity1begin hydrochlorothiazide entity1end , hydralazine , entity2begin sulfinpyrazone entity2end , oral contraceptives , tolbutamide , or warfarin have been observed . 
false chemical chemical No significant interactions with digoxin , entity1begin hydrochlorothiazide entity1end , hydralazine , sulfinpyrazone , oral entity2begin contraceptives entity2end , tolbutamide , or warfarin have been observed . 
false chemical chemical No significant interactions with digoxin , entity1begin hydrochlorothiazide entity1end , hydralazine , sulfinpyrazone , oral contraceptives , entity2begin tolbutamide entity2end , or warfarin have been observed . 
false chemical chemical No significant interactions with digoxin , entity1begin hydrochlorothiazide entity1end , hydralazine , sulfinpyrazone , oral contraceptives , tolbutamide , or entity2begin warfarin entity2end have been observed . 
false chemical chemical No significant interactions with digoxin , hydrochlorothiazide , entity1begin hydralazine entity1end , entity2begin sulfinpyrazone entity2end , oral contraceptives , tolbutamide , or warfarin have been observed . 
false chemical chemical No significant interactions with digoxin , hydrochlorothiazide , entity1begin hydralazine entity1end , sulfinpyrazone , oral entity2begin contraceptives entity2end , tolbutamide , or warfarin have been observed . 
false chemical chemical No significant interactions with digoxin , hydrochlorothiazide , entity1begin hydralazine entity1end , sulfinpyrazone , oral contraceptives , entity2begin tolbutamide entity2end , or warfarin have been observed . 
false chemical chemical No significant interactions with digoxin , hydrochlorothiazide , entity1begin hydralazine entity1end , sulfinpyrazone , oral contraceptives , tolbutamide , or entity2begin warfarin entity2end have been observed . 
false chemical chemical No significant interactions with digoxin , hydrochlorothiazide , hydralazine , entity1begin sulfinpyrazone entity1end , oral entity2begin contraceptives entity2end , tolbutamide , or warfarin have been observed . 
false chemical chemical No significant interactions with digoxin , hydrochlorothiazide , hydralazine , entity1begin sulfinpyrazone entity1end , oral contraceptives , entity2begin tolbutamide entity2end , or warfarin have been observed . 
false chemical chemical No significant interactions with digoxin , hydrochlorothiazide , hydralazine , entity1begin sulfinpyrazone entity1end , oral contraceptives , tolbutamide , or entity2begin warfarin entity2end have been observed . 
false chemical chemical No significant interactions with digoxin , hydrochlorothiazide , hydralazine , sulfinpyrazone , oral entity1begin contraceptives entity1end , entity2begin tolbutamide entity2end , or warfarin have been observed . 
false chemical chemical No significant interactions with digoxin , hydrochlorothiazide , hydralazine , sulfinpyrazone , oral entity1begin contraceptives entity1end , tolbutamide , or entity2begin warfarin entity2end have been observed . 
false chemical chemical No significant interactions with digoxin , hydrochlorothiazide , hydralazine , sulfinpyrazone , oral contraceptives , entity1begin tolbutamide entity1end , or entity2begin warfarin entity2end have been observed . 
true chemical chemical entity1begin DIAMOX entity1end modifies entity2begin phenytoin entity2end metabolism with increased serum levels of phenytoin . 
true chemical chemical entity1begin DIAMOX entity1end modifies phenytoin metabolism with increased serum levels of entity2begin phenytoin entity2end . 
false chemical chemical DIAMOX modifies entity1begin phenytoin entity1end metabolism with increased serum levels of entity2begin phenytoin entity2end . 
false chemical chemical By decreasing the gastrointestinal absorption of entity1begin primidone entity1end , entity2begin DIAMOX entity2end may decrease serum concentrations of primidone and its metabolites , with a consequent possible decrease in anticonvulsant effect . 
false chemical chemical By decreasing the gastrointestinal absorption of entity1begin primidone entity1end , DIAMOX may decrease serum concentrations of entity2begin primidone entity2end and its metabolites , with a consequent possible decrease in anticonvulsant effect . 
true chemical chemical By decreasing the gastrointestinal absorption of primidone , entity1begin DIAMOX entity1end may decrease serum concentrations of entity2begin primidone entity2end and its metabolites , with a consequent possible decrease in anticonvulsant effect . 
true chemical chemical Caution is advised when beginning , discontinuing , or changing the dose of entity1begin DIAMOX entity1end in patients receiving entity2begin primidone entity2end . 
true chemical chemical entity1begin Acetazolamide entity1end may increase the effects of other entity2begin folic acid antagonists entity2end . 
true chemical chemical entity1begin Acetazolamide entity1end decreases urinary excretion of entity2begin amphetamine entity2end and may enhance the magnitude and duration of their effect . 
true chemical chemical entity1begin Acetazolamide entity1end reduces urinary excretion of entity2begin quinidine entity2end and may enhance its effect . 
true chemical chemical entity1begin Acetazolamide entity1end may prevent the urinary antiseptic effect of entity2begin methenamine entity2end . 
true chemical chemical entity1begin Acetazolamide entity1end increases entity2begin lithium entity2end excretion and the lithium may be decreased . 
false chemical chemical entity1begin Acetazolamide entity1end increases lithium excretion and the entity2begin lithium entity2end may be decreased . 
false chemical chemical Acetazolamide increases entity1begin lithium entity1end excretion and the entity2begin lithium entity2end may be decreased . 
true chemical chemical entity1begin Acetazolamide entity1end and entity2begin sodium bicarbonate entity2end used concurrently increases the risk of renal calculus formation . 
true chemical chemical entity1begin Acetazolamide entity1end may elevate entity2begin cyclosporine entity2end levels . 
false chemical chemical Concomitant use with entity1begin iron supplement entity1end s may result in the reduced absorption of entity2begin iron entity2end . 
true chemical chemical Co - administration of entity1begin probenecid entity1end with entity2begin acyclovir entity2end has been shown to increase the mean half - life and the area under the concentration - time curve . 
false chemical chemical entity1begin Ethanol entity1end : Clinical evidence has shown that entity2begin etretinate entity2end can be formed with concurrent ingestion of acitretin and ethanol . 
false chemical chemical entity1begin Ethanol entity1end : Clinical evidence has shown that etretinate can be formed with concurrent ingestion of entity2begin acitretin entity2end and ethanol . 
false chemical chemical entity1begin Ethanol entity1end : Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and entity2begin ethanol entity2end . 
false chemical chemical Ethanol : Clinical evidence has shown that entity1begin etretinate entity1end can be formed with concurrent ingestion of entity2begin acitretin entity2end and ethanol . 
false chemical chemical Ethanol : Clinical evidence has shown that entity1begin etretinate entity1end can be formed with concurrent ingestion of acitretin and entity2begin ethanol entity2end . 
true chemical chemical Ethanol : Clinical evidence has shown that etretinate can be formed with concurrent ingestion of entity1begin acitretin entity1end and entity2begin ethanol entity2end . 
false chemical chemical entity1begin Glibenclamide entity1end : In a study of 7 healthy male volunteers , entity2begin acitretin entity2end treatment potentiated the blood glucose lowering effect of glibenclamide ( a sulfonylurea similar to chlorpropamide ) in 3 of the 7 subjects . 
false chemical chemical entity1begin Glibenclamide entity1end : In a study of 7 healthy male volunteers , acitretin treatment potentiated the blood glucose lowering effect of entity2begin glibenclamide entity2end ( a sulfonylurea similar to chlorpropamide ) in 3 of the 7 subjects . 
false chemical chemical entity1begin Glibenclamide entity1end : In a study of 7 healthy male volunteers , acitretin treatment potentiated the blood glucose lowering effect of glibenclamide ( a entity2begin sulfonylurea entity2end similar to chlorpropamide ) in 3 of the 7 subjects . 
false chemical chemical entity1begin Glibenclamide entity1end : In a study of 7 healthy male volunteers , acitretin treatment potentiated the blood glucose lowering effect of glibenclamide ( a sulfonylurea similar to entity2begin chlorpropamide entity2end ) in 3 of the 7 subjects . 
true chemical chemical Glibenclamide : In a study of 7 healthy male volunteers , entity1begin acitretin entity1end treatment potentiated the blood glucose lowering effect of entity2begin glibenclamide entity2end ( a sulfonylurea similar to chlorpropamide ) in 3 of the 7 subjects . 
false chemical chemical Glibenclamide : In a study of 7 healthy male volunteers , entity1begin acitretin entity1end treatment potentiated the blood glucose lowering effect of glibenclamide ( a entity2begin sulfonylurea entity2end similar to chlorpropamide ) in 3 of the 7 subjects . 
false chemical chemical Glibenclamide : In a study of 7 healthy male volunteers , entity1begin acitretin entity1end treatment potentiated the blood glucose lowering effect of glibenclamide ( a sulfonylurea similar to entity2begin chlorpropamide entity2end ) in 3 of the 7 subjects . 
false chemical chemical Glibenclamide : In a study of 7 healthy male volunteers , acitretin treatment potentiated the blood glucose lowering effect of entity1begin glibenclamide entity1end ( a entity2begin sulfonylurea entity2end similar to chlorpropamide ) in 3 of the 7 subjects . 
false chemical chemical Glibenclamide : In a study of 7 healthy male volunteers , acitretin treatment potentiated the blood glucose lowering effect of entity1begin glibenclamide entity1end ( a sulfonylurea similar to entity2begin chlorpropamide entity2end ) in 3 of the 7 subjects . 
false chemical chemical Glibenclamide : In a study of 7 healthy male volunteers , acitretin treatment potentiated the blood glucose lowering effect of glibenclamide ( a entity1begin sulfonylurea entity1end similar to entity2begin chlorpropamide entity2end ) in 3 of the 7 subjects . 
false chemical chemical Repeating the study with 6 healthy male volunteers in the absence of entity1begin glibenclamide entity1end did not detect an effect of entity2begin acitretin entity2end on glucose tolerance . 
false chemical chemical entity1begin Hormonal Contraceptives entity1end : It has not been established if there is a pharmacokinetic interaction between entity2begin acitretin entity2end and combined oral contraceptives . 
false chemical chemical entity1begin Hormonal Contraceptives entity1end : It has not been established if there is a pharmacokinetic interaction between acitretin and entity2begin combined oral contraceptives entity2end . 
false chemical chemical Hormonal Contraceptives : It has not been established if there is a pharmacokinetic interaction between entity1begin acitretin entity1end and entity2begin combined oral contraceptives entity2end . 
true chemical chemical However , it has been established that entity1begin acitretin entity1end interferes with the contraceptive effect of microdosed entity2begin progestin entity2end minipill preparations . 
true chemical chemical Microdosed minipill entity1begin progestin entity1end preparations are not recommended for use with entity2begin Soriatane entity2end . 
false chemical chemical It is not known whether other entity1begin progestational contraceptives entity1end , such as implants and injectables , are adequate methods of contraception during entity2begin acitretin entity2end therapy . 
false chemical chemical entity1begin Methotrexate entity1end : An increased risk of hepatitis has been reported to result from combined use of entity2begin methotrexate entity2end and etretinate . 
false chemical chemical entity1begin Methotrexate entity1end : An increased risk of hepatitis has been reported to result from combined use of methotrexate and entity2begin etretinate entity2end . 
true chemical chemical Methotrexate : An increased risk of hepatitis has been reported to result from combined use of entity1begin methotrexate entity1end and entity2begin etretinate entity2end . 
true chemical chemical Consequently , the combination of entity1begin methotrexate entity1end with entity2begin acitretin entity2end is also contraindicated . 
false chemical chemical entity1begin Phenytoin entity1end : If entity2begin acitretin entity2end is given concurrently with phenytoin , the protein binding of phenytoin may be reduced . 
false chemical chemical entity1begin Phenytoin entity1end : If acitretin is given concurrently with entity2begin phenytoin entity2end , the protein binding of phenytoin may be reduced . 
false chemical chemical entity1begin Phenytoin entity1end : If acitretin is given concurrently with phenytoin , the protein binding of entity2begin phenytoin entity2end may be reduced . 
true chemical chemical Phenytoin : If entity1begin acitretin entity1end is given concurrently with entity2begin phenytoin entity2end , the protein binding of phenytoin may be reduced . 
false chemical chemical Phenytoin : If entity1begin acitretin entity1end is given concurrently with phenytoin , the protein binding of entity2begin phenytoin entity2end may be reduced . 
false chemical chemical Phenytoin : If acitretin is given concurrently with entity1begin phenytoin entity1end , the protein binding of entity2begin phenytoin entity2end may be reduced . 
false chemical chemical entity1begin Tetracyclines entity1end : Since both entity2begin acitretin entity2end and tetracyclines can cause increased intracranial pressure , their combined use is contraindicated . 
false chemical chemical entity1begin Tetracyclines entity1end : Since both acitretin and entity2begin tetracyclines entity2end can cause increased intracranial pressure , their combined use is contraindicated . 
true chemical chemical Tetracyclines : Since both entity1begin acitretin entity1end and entity2begin tetracyclines entity2end can cause increased intracranial pressure , their combined use is contraindicated . 
false chemical chemical entity1begin Vitamin A entity1end and oral entity2begin retinoids entity2end : Concomitant administration of vitamin A and / or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A . 
false chemical chemical entity1begin Vitamin A entity1end and oral retinoids : Concomitant administration of entity2begin vitamin A entity2end and / or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A . 
false chemical chemical entity1begin Vitamin A entity1end and oral retinoids : Concomitant administration of vitamin A and / or other oral entity2begin retinoids entity2end with acitretin must be avoided because of the risk of hypervitaminosis A . 
false chemical chemical entity1begin Vitamin A entity1end and oral retinoids : Concomitant administration of vitamin A and / or other oral retinoids with entity2begin acitretin entity2end must be avoided because of the risk of hypervitaminosis A . 
false chemical chemical Vitamin A and oral entity1begin retinoids entity1end : Concomitant administration of entity2begin vitamin A entity2end and / or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A . 
false chemical chemical Vitamin A and oral entity1begin retinoids entity1end : Concomitant administration of vitamin A and / or other oral entity2begin retinoids entity2end with acitretin must be avoided because of the risk of hypervitaminosis A . 
false chemical chemical Vitamin A and oral entity1begin retinoids entity1end : Concomitant administration of vitamin A and / or other oral retinoids with entity2begin acitretin entity2end must be avoided because of the risk of hypervitaminosis A . 
false chemical chemical Vitamin A and oral retinoids : Concomitant administration of entity1begin vitamin A entity1end and / or other oral entity2begin retinoids entity2end with acitretin must be avoided because of the risk of hypervitaminosis A . 
true chemical chemical Vitamin A and oral retinoids : Concomitant administration of entity1begin vitamin A entity1end and / or other oral retinoids with entity2begin acitretin entity2end must be avoided because of the risk of hypervitaminosis A . 
true chemical chemical Vitamin A and oral retinoids : Concomitant administration of vitamin A and / or other oral entity1begin retinoids entity1end with entity2begin acitretin entity2end must be avoided because of the risk of hypervitaminosis A . 
false chemical chemical Other : There appears to be no pharmacokinetic interaction between entity1begin acitretin entity1end and entity2begin cimetidine entity2end , digoxin , or glyburide . 
false chemical chemical Other : There appears to be no pharmacokinetic interaction between entity1begin acitretin entity1end and cimetidine , entity2begin digoxin entity2end , or glyburide . 
false chemical chemical Other : There appears to be no pharmacokinetic interaction between entity1begin acitretin entity1end and cimetidine , digoxin , or entity2begin glyburide entity2end . 
false chemical chemical Other : There appears to be no pharmacokinetic interaction between acitretin and entity1begin cimetidine entity1end , entity2begin digoxin entity2end , or glyburide . 
false chemical chemical Other : There appears to be no pharmacokinetic interaction between acitretin and entity1begin cimetidine entity1end , digoxin , or entity2begin glyburide entity2end . 
false chemical chemical Other : There appears to be no pharmacokinetic interaction between acitretin and cimetidine , entity1begin digoxin entity1end , or entity2begin glyburide entity2end . 
false chemical chemical Investigations into the effect of entity1begin acitretin entity1end on the protein binding of entity2begin anticoagulants of the coumarin type entity2end ( warfarin ) revealed no interaction . 
false chemical chemical Investigations into the effect of entity1begin acitretin entity1end on the protein binding of anticoagulants of the coumarin type ( entity2begin warfarin entity2end ) revealed no interaction . 
false chemical chemical Investigations into the effect of acitretin on the protein binding of entity1begin anticoagulants of the coumarin type entity1end ( entity2begin warfarin entity2end ) revealed no interaction . 
false chemical chemical entity1begin Methotrexate entity1end : entity2begin HUMIRA entity2end has been studied in rheumatoid arthritis patients taking concomitant MTX . 
false chemical chemical entity1begin Methotrexate entity1end : HUMIRA has been studied in rheumatoid arthritis patients taking concomitant entity2begin MTX entity2end . 
false chemical chemical Methotrexate : entity1begin HUMIRA entity1end has been studied in rheumatoid arthritis patients taking concomitant entity2begin MTX entity2end . 
false chemical chemical The data do not suggest the need for dose adjustment of either entity1begin HUMIRA entity1end or entity2begin MTX entity2end . 
false chemical chemical entity1begin Anakinra entity1end : Concurrent administration of entity2begin anakinra entity2end ( an interleukin - 1 antagonist ) and another TNF - blocking agent has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone . 
false chemical chemical entity1begin Anakinra entity1end : Concurrent administration of anakinra ( an entity2begin interleukin - 1 antagonist entity2end ) and another TNF - blocking agent has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone . 
false chemical chemical entity1begin Anakinra entity1end : Concurrent administration of anakinra ( an interleukin - 1 antagonist ) and another entity2begin TNF - blocking agent entity2end has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone . 
false chemical chemical Anakinra : Concurrent administration of entity1begin anakinra entity1end ( an entity2begin interleukin - 1 antagonist entity2end ) and another TNF - blocking agent has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone . 
true chemical chemical Anakinra : Concurrent administration of entity1begin anakinra entity1end ( an interleukin - 1 antagonist ) and another entity2begin TNF - blocking agent entity2end has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone . 
true chemical chemical Anakinra : Concurrent administration of anakinra ( an entity1begin interleukin - 1 antagonist entity1end ) and another entity2begin TNF - blocking agent entity2end has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone . 
false chemical chemical The safety and efficacy of entity1begin anakinra entity1end used in combination with entity2begin HUMIRA entity2end has not been studied . 
true chemical chemical Therefore the , combination of entity1begin anakinra entity1end with other entity2begin TNF - blocking agents entity2end , including HUMIRA , may also result i n similar toxicities . 
true chemical chemical Therefore the , combination of entity1begin anakinra entity1end with other TNF - blocking agents , including entity2begin HUMIRA entity2end , may also result i n similar toxicities . 
false chemical chemical Therefore the , combination of anakinra with other entity1begin TNF - blocking agents entity1end , including entity2begin HUMIRA entity2end , may also result i n similar toxicities . 
false chemical chemical Particular caution should be exercised in using preparations containing entity1begin sulfur entity1end , entity2begin resorcinol entity2end , or salicylic acid in combination with DIFFERIN Gel . 
false chemical chemical Particular caution should be exercised in using preparations containing entity1begin sulfur entity1end , resorcinol , or entity2begin salicylic acid entity2end in combination with DIFFERIN Gel . 
false chemical chemical Particular caution should be exercised in using preparations containing entity1begin sulfur entity1end , resorcinol , or salicylic acid in combination with entity2begin DIFFERIN entity2end Gel . 
false chemical chemical Particular caution should be exercised in using preparations containing sulfur , entity1begin resorcinol entity1end , or entity2begin salicylic acid entity2end in combination with DIFFERIN Gel . 
false chemical chemical Particular caution should be exercised in using preparations containing sulfur , entity1begin resorcinol entity1end , or salicylic acid in combination with entity2begin DIFFERIN entity2end Gel . 
false chemical chemical Particular caution should be exercised in using preparations containing sulfur , resorcinol , or entity1begin salicylic acid entity1end in combination with entity2begin DIFFERIN entity2end Gel . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : entity1begin aminoglycosides entity1end ( e.g. , entity2begin gentamicin entity2end , amikacin ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : entity1begin aminoglycosides entity1end ( e.g. , gentamicin , entity2begin amikacin entity2end ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : entity1begin aminoglycosides entity1end ( e.g. , gentamicin , amikacin ) , entity2begin amphotericin B entity2end , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : entity1begin aminoglycosides entity1end ( e.g. , gentamicin , amikacin ) , amphotericin B , entity2begin cyclosporine entity2end , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : entity1begin aminoglycosides entity1end ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , entity2begin non - steroidal anti - inflammatory entity2end drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : entity1begin aminoglycosides entity1end ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , entity2begin ibuprofen entity2end ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : entity1begin aminoglycosides entity1end ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , entity2begin tacrolimus entity2end , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : entity1begin aminoglycosides entity1end ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , entity2begin vancomycin entity2end . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , entity1begin gentamicin entity1end , entity2begin amikacin entity2end ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , entity1begin gentamicin entity1end , amikacin ) , entity2begin amphotericin B entity2end , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , entity1begin gentamicin entity1end , amikacin ) , amphotericin B , entity2begin cyclosporine entity2end , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , entity1begin gentamicin entity1end , amikacin ) , amphotericin B , cyclosporine , entity2begin non - steroidal anti - inflammatory entity2end drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , entity1begin gentamicin entity1end , amikacin ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , entity2begin ibuprofen entity2end ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , entity1begin gentamicin entity1end , amikacin ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , entity2begin tacrolimus entity2end , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , entity1begin gentamicin entity1end , amikacin ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , entity2begin vancomycin entity2end . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , entity1begin amikacin entity1end ) , entity2begin amphotericin B entity2end , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , entity1begin amikacin entity1end ) , amphotericin B , entity2begin cyclosporine entity2end , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , entity1begin amikacin entity1end ) , amphotericin B , cyclosporine , entity2begin non - steroidal anti - inflammatory entity2end drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , entity1begin amikacin entity1end ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , entity2begin ibuprofen entity2end ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , entity1begin amikacin entity1end ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , entity2begin tacrolimus entity2end , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , entity1begin amikacin entity1end ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , entity2begin vancomycin entity2end . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , entity1begin amphotericin B entity1end , entity2begin cyclosporine entity2end , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , entity1begin amphotericin B entity1end , cyclosporine , entity2begin non - steroidal anti - inflammatory entity2end drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , entity1begin amphotericin B entity1end , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , entity2begin ibuprofen entity2end ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , entity1begin amphotericin B entity1end , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , entity2begin tacrolimus entity2end , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , entity1begin amphotericin B entity1end , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , entity2begin vancomycin entity2end . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , entity1begin cyclosporine entity1end , entity2begin non - steroidal anti - inflammatory entity2end drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , entity1begin cyclosporine entity1end , non - steroidal anti - inflammatory drugs ( e.g. , entity2begin ibuprofen entity2end ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , entity1begin cyclosporine entity1end , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , entity2begin tacrolimus entity2end , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , entity1begin cyclosporine entity1end , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , entity2begin vancomycin entity2end . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , entity1begin non - steroidal anti - inflammatory entity1end drugs ( e.g. , entity2begin ibuprofen entity2end ) , tacrolimus , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , entity1begin non - steroidal anti - inflammatory entity1end drugs ( e.g. , ibuprofen ) , entity2begin tacrolimus entity2end , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , entity1begin non - steroidal anti - inflammatory entity1end drugs ( e.g. , ibuprofen ) , tacrolimus , entity2begin vancomycin entity2end . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , entity1begin ibuprofen entity1end ) , entity2begin tacrolimus entity2end , vancomycin . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , entity1begin ibuprofen entity1end ) , tacrolimus , entity2begin vancomycin entity2end . 
false chemical chemical Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , non - steroidal anti - inflammatory drugs ( e.g. , ibuprofen ) , entity1begin tacrolimus entity1end , entity2begin vancomycin entity2end . 
false chemical chemical Intravenous entity1begin Adenocard entity1end ( entity2begin adenosine entity2end ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , beta - adrenergic blocking agents , calcium channel blocking agents , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile . 
false chemical chemical Intravenous entity1begin Adenocard entity1end ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as entity2begin quinidine entity2end , beta - adrenergic blocking agents , calcium channel blocking agents , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile . 
false chemical chemical Intravenous entity1begin Adenocard entity1end ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , entity2begin beta - adrenergic blocking agents entity2end , calcium channel blocking agents , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile . 
false chemical chemical Intravenous entity1begin Adenocard entity1end ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , beta - adrenergic blocking agents , entity2begin calcium channel blocking agents entity2end , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile . 
false chemical chemical Intravenous entity1begin Adenocard entity1end ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , beta - adrenergic blocking agents , calcium channel blocking agents , and entity2begin angiotensin converting enzyme inhibitors entity2end , without any change in the adverse reaction profile . 
false chemical chemical Intravenous Adenocard ( entity1begin adenosine entity1end ) has been effectively administered in the presence of other cardioactive drugs , such as entity2begin quinidine entity2end , beta - adrenergic blocking agents , calcium channel blocking agents , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile . 
false chemical chemical Intravenous Adenocard ( entity1begin adenosine entity1end ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , entity2begin beta - adrenergic blocking agents entity2end , calcium channel blocking agents , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile . 
false chemical chemical Intravenous Adenocard ( entity1begin adenosine entity1end ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , beta - adrenergic blocking agents , entity2begin calcium channel blocking agents entity2end , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile . 
false chemical chemical Intravenous Adenocard ( entity1begin adenosine entity1end ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , beta - adrenergic blocking agents , calcium channel blocking agents , and entity2begin angiotensin converting enzyme inhibitors entity2end , without any change in the adverse reaction profile . 
false chemical chemical Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as entity1begin quinidine entity1end , entity2begin beta - adrenergic blocking agents entity2end , calcium channel blocking agents , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile . 
false chemical chemical Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as entity1begin quinidine entity1end , beta - adrenergic blocking agents , entity2begin calcium channel blocking agents entity2end , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile . 
false chemical chemical Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as entity1begin quinidine entity1end , beta - adrenergic blocking agents , calcium channel blocking agents , and entity2begin angiotensin converting enzyme inhibitors entity2end , without any change in the adverse reaction profile . 
false chemical chemical Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , entity1begin beta - adrenergic blocking agents entity1end , entity2begin calcium channel blocking agents entity2end , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile . 
false chemical chemical Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , entity1begin beta - adrenergic blocking agents entity1end , calcium channel blocking agents , and entity2begin angiotensin converting enzyme inhibitors entity2end , without any change in the adverse reaction profile . 
false chemical chemical Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , beta - adrenergic blocking agents , entity1begin calcium channel blocking agents entity1end , and entity2begin angiotensin converting enzyme inhibitors entity2end , without any change in the adverse reaction profile . 
false chemical chemical entity1begin Digoxin entity1end and entity2begin verapamil entity2end use may be rarely associated with ventricular fibrillation when combined with Adenocard . 
true chemical chemical entity1begin Digoxin entity1end and verapamil use may be rarely associated with ventricular fibrillation when combined with entity2begin Adenocard entity2end . 
true chemical chemical Digoxin and entity1begin verapamil entity1end use may be rarely associated with ventricular fibrillation when combined with entity2begin Adenocard entity2end . 
true chemical chemical The use of entity1begin Adenocard entity1end in patients receiving entity2begin digitalis entity2end may be rarely associated with ventricular fibrillation . 
true chemical chemical The effects of entity1begin adenosine entity1end are antagonized by entity2begin methylxanthines entity2end such as caffeine and theophylline . 
true chemical chemical The effects of entity1begin adenosine entity1end are antagonized by methylxanthines such as entity2begin caffeine entity2end and theophylline . 
true chemical chemical The effects of entity1begin adenosine entity1end are antagonized by methylxanthines such as caffeine and entity2begin theophylline entity2end . 
false chemical chemical The effects of adenosine are antagonized by entity1begin methylxanthines entity1end such as entity2begin caffeine entity2end and theophylline . 
false chemical chemical The effects of adenosine are antagonized by entity1begin methylxanthines entity1end such as caffeine and entity2begin theophylline entity2end . 
false chemical chemical The effects of adenosine are antagonized by methylxanthines such as entity1begin caffeine entity1end and entity2begin theophylline entity2end . 
true chemical chemical In the presence of these entity1begin methylxanthines entity1end , larger doses of entity2begin adenosine entity2end may be required or adenosine may not be effective . 
true chemical chemical In the presence of these entity1begin methylxanthines entity1end , larger doses of adenosine may be required or entity2begin adenosine entity2end may not be effective . 
false chemical chemical In the presence of these methylxanthines , larger doses of entity1begin adenosine entity1end may be required or entity2begin adenosine entity2end may not be effective . 
true chemical chemical entity1begin Adenosine entity1end effects are potentiated by entity2begin dipyridamole entity2end . 
true chemical chemical Thus , smaller doses of entity1begin adenosine entity1end may be effective in the presence of entity2begin dipyridamole entity2end . 
true chemical chemical As the primary effect of entity1begin adenosine entity1end is to decrease conduction through the A - V node , higher degrees of heart block may be produced in the presence of entity2begin carbamazepine entity2end . 
false chemical chemical Co - administration with entity1begin antifungal agents entity1end such as entity2begin ketoconazole entity2end or itraconazole is not recommended . 
false chemical chemical Co - administration with entity1begin antifungal agents entity1end such as ketoconazole or entity2begin itraconazole entity2end is not recommended . 
false chemical chemical Co - administration with antifungal agents such as entity1begin ketoconazole entity1end or entity2begin itraconazole entity2end is not recommended . 
false chemical chemical entity1begin Nafazodone entity1end , entity2begin fluvoxamine entity2end , cimetidine ( consider Xanax dose reduction ) . 
false chemical chemical entity1begin Nafazodone entity1end , fluvoxamine , entity2begin cimetidine entity2end ( consider Xanax dose reduction ) . 
true chemical chemical entity1begin Nafazodone entity1end , fluvoxamine , cimetidine ( consider entity2begin Xanax entity2end dose reduction ) . 
false chemical chemical Nafazodone , entity1begin fluvoxamine entity1end , entity2begin cimetidine entity2end ( consider Xanax dose reduction ) . 
true chemical chemical Nafazodone , entity1begin fluvoxamine entity1end , cimetidine ( consider entity2begin Xanax entity2end dose reduction ) . 
true chemical chemical Nafazodone , fluvoxamine , entity1begin cimetidine entity1end ( consider entity2begin Xanax entity2end dose reduction ) . 
false chemical chemical entity1begin Fluoxetine entity1end , entity2begin OCs entity2end , sertraline , diltiazem , macrolide antibiotics ( exercise caution ) . 
false chemical chemical entity1begin Fluoxetine entity1end , OCs , entity2begin sertraline entity2end , diltiazem , macrolide antibiotics ( exercise caution ) . 
false chemical chemical entity1begin Fluoxetine entity1end , OCs , sertraline , entity2begin diltiazem entity2end , macrolide antibiotics ( exercise caution ) . 
false chemical chemical entity1begin Fluoxetine entity1end , OCs , sertraline , diltiazem , entity2begin macrolide antibiotics entity2end ( exercise caution ) . 
false chemical chemical Fluoxetine , entity1begin OCs entity1end , entity2begin sertraline entity2end , diltiazem , macrolide antibiotics ( exercise caution ) . 
false chemical chemical Fluoxetine , entity1begin OCs entity1end , sertraline , entity2begin diltiazem entity2end , macrolide antibiotics ( exercise caution ) . 
false chemical chemical Fluoxetine , entity1begin OCs entity1end , sertraline , diltiazem , entity2begin macrolide antibiotics entity2end ( exercise caution ) . 
false chemical chemical Fluoxetine , OCs , entity1begin sertraline entity1end , entity2begin diltiazem entity2end , macrolide antibiotics ( exercise caution ) . 
false chemical chemical Fluoxetine , OCs , entity1begin sertraline entity1end , diltiazem , entity2begin macrolide antibiotics entity2end ( exercise caution ) . 
false chemical chemical Fluoxetine , OCs , sertraline , entity1begin diltiazem entity1end , entity2begin macrolide antibiotics entity2end ( exercise caution ) . 
false chemical chemical entity1begin Dexamethasone entity1end : Steady - state trough concentrations of entity2begin albendazole sulfoxide entity2end were about 56 % higher when 8 mg dexamethasone was coadministered with each dose of albendazole ( 15 mg / kg / day ) in eight neurocysticercosis patients . 
false chemical chemical entity1begin Dexamethasone entity1end : Steady - state trough concentrations of albendazole sulfoxide were about 56 % higher when 8 mg entity2begin dexamethasone entity2end was coadministered with each dose of albendazole ( 15 mg / kg / day ) in eight neurocysticercosis patients . 
false chemical chemical entity1begin Dexamethasone entity1end : Steady - state trough concentrations of albendazole sulfoxide were about 56 % higher when 8 mg dexamethasone was coadministered with each dose of entity2begin albendazole entity2end ( 15 mg / kg / day ) in eight neurocysticercosis patients . 
false chemical chemical Dexamethasone : Steady - state trough concentrations of entity1begin albendazole sulfoxide entity1end were about 56 % higher when 8 mg entity2begin dexamethasone entity2end was coadministered with each dose of albendazole ( 15 mg / kg / day ) in eight neurocysticercosis patients . 
false chemical chemical Dexamethasone : Steady - state trough concentrations of entity1begin albendazole sulfoxide entity1end were about 56 % higher when 8 mg dexamethasone was coadministered with each dose of entity2begin albendazole entity2end ( 15 mg / kg / day ) in eight neurocysticercosis patients . 
true chemical chemical Dexamethasone : Steady - state trough concentrations of albendazole sulfoxide were about 56 % higher when 8 mg entity1begin dexamethasone entity1end was coadministered with each dose of entity2begin albendazole entity2end ( 15 mg / kg / day ) in eight neurocysticercosis patients . 
false chemical chemical entity1begin Praziquantel entity1end : In the fed state , entity2begin praziquantel entity2end ( 40 mg / kg ) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50 % in healthy subjects ( n = 10 ) compared with a separate group of subjects ( n = 6 ) given albendazole alone . 
false chemical chemical entity1begin Praziquantel entity1end : In the fed state , praziquantel ( 40 mg / kg ) increased mean maximum plasma concentration and area under the curve of entity2begin albendazole sulfoxide entity2end by about 50 % in healthy subjects ( n = 10 ) compared with a separate group of subjects ( n = 6 ) given albendazole alone . 
false chemical chemical entity1begin Praziquantel entity1end : In the fed state , praziquantel ( 40 mg / kg ) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50 % in healthy subjects ( n = 10 ) compared with a separate group of subjects ( n = 6 ) given entity2begin albendazole entity2end alone . 
true chemical chemical Praziquantel : In the fed state , entity1begin praziquantel entity1end ( 40 mg / kg ) increased mean maximum plasma concentration and area under the curve of entity2begin albendazole sulfoxide entity2end by about 50 % in healthy subjects ( n = 10 ) compared with a separate group of subjects ( n = 6 ) given albendazole alone . 
false chemical chemical Praziquantel : In the fed state , entity1begin praziquantel entity1end ( 40 mg / kg ) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50 % in healthy subjects ( n = 10 ) compared with a separate group of subjects ( n = 6 ) given entity2begin albendazole entity2end alone . 
false chemical chemical Praziquantel : In the fed state , praziquantel ( 40 mg / kg ) increased mean maximum plasma concentration and area under the curve of entity1begin albendazole sulfoxide entity1end by about 50 % in healthy subjects ( n = 10 ) compared with a separate group of subjects ( n = 6 ) given entity2begin albendazole entity2end alone . 
false chemical chemical The pharmacokinetics of entity1begin praziquantel entity1end were unchanged following coadministration with entity2begin albendazole entity2end ( 400 mg ) . 
false chemical chemical entity1begin Cimetidine entity1end : entity2begin Albendazole sulfoxide entity2end concentrations in bile and cystic fluid were increased ( about 2 - fold ) in hydatid cyst patients treated with cimetidine ( 10 mg / kg / day ) ( n = 7 ) compared with albendazole ( 20 mg / kg / day ) alone ( n = 12 ) . 
false chemical chemical entity1begin Cimetidine entity1end : Albendazole sulfoxide concentrations in bile and cystic fluid were increased ( about 2 - fold ) in hydatid cyst patients treated with entity2begin cimetidine entity2end ( 10 mg / kg / day ) ( n = 7 ) compared with albendazole ( 20 mg / kg / day ) alone ( n = 12 ) . 
false chemical chemical entity1begin Cimetidine entity1end : Albendazole sulfoxide concentrations in bile and cystic fluid were increased ( about 2 - fold ) in hydatid cyst patients treated with cimetidine ( 10 mg / kg / day ) ( n = 7 ) compared with entity2begin albendazole entity2end ( 20 mg / kg / day ) alone ( n = 12 ) . 
true chemical chemical Cimetidine : entity1begin Albendazole sulfoxide entity1end concentrations in bile and cystic fluid were increased ( about 2 - fold ) in hydatid cyst patients treated with entity2begin cimetidine entity2end ( 10 mg / kg / day ) ( n = 7 ) compared with albendazole ( 20 mg / kg / day ) alone ( n = 12 ) . 
false chemical chemical Cimetidine : entity1begin Albendazole sulfoxide entity1end concentrations in bile and cystic fluid were increased ( about 2 - fold ) in hydatid cyst patients treated with cimetidine ( 10 mg / kg / day ) ( n = 7 ) compared with entity2begin albendazole entity2end ( 20 mg / kg / day ) alone ( n = 12 ) . 
false chemical chemical Cimetidine : Albendazole sulfoxide concentrations in bile and cystic fluid were increased ( about 2 - fold ) in hydatid cyst patients treated with entity1begin cimetidine entity1end ( 10 mg / kg / day ) ( n = 7 ) compared with entity2begin albendazole entity2end ( 20 mg / kg / day ) alone ( n = 12 ) . 
false chemical chemical entity1begin Theophylline entity1end : The pharmacokinetics of entity2begin theophylline entity2end ( aminophylline 5.8 mg / kg infused over 20 minutes ) were unchanged following a single oral dose of albendazole ( 400 mg ) in 6 healthy subjects . 
false chemical chemical entity1begin Theophylline entity1end : The pharmacokinetics of theophylline ( entity2begin aminophylline entity2end 5.8 mg / kg infused over 20 minutes ) were unchanged following a single oral dose of albendazole ( 400 mg ) in 6 healthy subjects . 
false chemical chemical entity1begin Theophylline entity1end : The pharmacokinetics of theophylline ( aminophylline 5.8 mg / kg infused over 20 minutes ) were unchanged following a single oral dose of entity2begin albendazole entity2end ( 400 mg ) in 6 healthy subjects . 
false chemical chemical Theophylline : The pharmacokinetics of entity1begin theophylline entity1end ( entity2begin aminophylline entity2end 5.8 mg / kg infused over 20 minutes ) were unchanged following a single oral dose of albendazole ( 400 mg ) in 6 healthy subjects . 
false chemical chemical Theophylline : The pharmacokinetics of entity1begin theophylline entity1end ( aminophylline 5.8 mg / kg infused over 20 minutes ) were unchanged following a single oral dose of entity2begin albendazole entity2end ( 400 mg ) in 6 healthy subjects . 
false chemical chemical Theophylline : The pharmacokinetics of theophylline ( entity1begin aminophylline entity1end 5.8 mg / kg infused over 20 minutes ) were unchanged following a single oral dose of entity2begin albendazole entity2end ( 400 mg ) in 6 healthy subjects . 
false chemical chemical Therefore , interactions could occur following concomitant administration of entity1begin psychotropic drugs entity1end ( e.g. , entity2begin narcotics entity2end , analgesics , antiemetics , sedatives , tranquilizers ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of entity1begin psychotropic drugs entity1end ( e.g. , narcotics , entity2begin analgesics entity2end , antiemetics , sedatives , tranquilizers ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of entity1begin psychotropic drugs entity1end ( e.g. , narcotics , analgesics , entity2begin antiemetics entity2end , sedatives , tranquilizers ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of entity1begin psychotropic drugs entity1end ( e.g. , narcotics , analgesics , antiemetics , entity2begin sedatives entity2end , tranquilizers ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of entity1begin psychotropic drugs entity1end ( e.g. , narcotics , analgesics , antiemetics , sedatives , entity2begin tranquilizers entity2end ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , entity1begin narcotics entity1end , entity2begin analgesics entity2end , antiemetics , sedatives , tranquilizers ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , entity1begin narcotics entity1end , analgesics , entity2begin antiemetics entity2end , sedatives , tranquilizers ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , entity1begin narcotics entity1end , analgesics , antiemetics , entity2begin sedatives entity2end , tranquilizers ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , entity1begin narcotics entity1end , analgesics , antiemetics , sedatives , entity2begin tranquilizers entity2end ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , entity1begin analgesics entity1end , entity2begin antiemetics entity2end , sedatives , tranquilizers ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , entity1begin analgesics entity1end , antiemetics , entity2begin sedatives entity2end , tranquilizers ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , entity1begin analgesics entity1end , antiemetics , sedatives , entity2begin tranquilizers entity2end ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , analgesics , entity1begin antiemetics entity1end , entity2begin sedatives entity2end , tranquilizers ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , analgesics , entity1begin antiemetics entity1end , sedatives , entity2begin tranquilizers entity2end ) . 
false chemical chemical Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , analgesics , antiemetics , entity1begin sedatives entity1end , entity2begin tranquilizers entity2end ) . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , entity1begin aminoglycosides entity1end , entity2begin indomethacin entity2end ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , entity1begin aminoglycosides entity1end , indomethacin ) , myelotoxic ( e.g. , entity2begin cytotoxic entity2end chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , entity1begin aminoglycosides entity1end , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , entity2begin doxorubicin entity2end ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , entity1begin aminoglycosides entity1end , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , entity2begin methotrexate entity2end , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , entity1begin aminoglycosides entity1end , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , entity2begin asparaginase entity2end ) effects with PROLEUKIN may increase toxicity in these organ systems . 
true chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , entity1begin aminoglycosides entity1end , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with entity2begin PROLEUKIN entity2end may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , entity1begin indomethacin entity1end ) , myelotoxic ( e.g. , entity2begin cytotoxic entity2end chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , entity1begin indomethacin entity1end ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , entity2begin doxorubicin entity2end ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , entity1begin indomethacin entity1end ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , entity2begin methotrexate entity2end , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , entity1begin indomethacin entity1end ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , entity2begin asparaginase entity2end ) effects with PROLEUKIN may increase toxicity in these organ systems . 
true chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , entity1begin indomethacin entity1end ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with entity2begin PROLEUKIN entity2end may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , entity1begin cytotoxic entity1end chemotherapy ) , cardiotoxic ( e.g. , entity2begin doxorubicin entity2end ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , entity1begin cytotoxic entity1end chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , entity2begin methotrexate entity2end , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , entity1begin cytotoxic entity1end chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , entity2begin asparaginase entity2end ) effects with PROLEUKIN may increase toxicity in these organ systems . 
true chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , entity1begin cytotoxic entity1end chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with entity2begin PROLEUKIN entity2end may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , entity1begin doxorubicin entity1end ) or hepatotoxic ( e.g. , entity2begin methotrexate entity2end , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , entity1begin doxorubicin entity1end ) or hepatotoxic ( e.g. , methotrexate , entity2begin asparaginase entity2end ) effects with PROLEUKIN may increase toxicity in these organ systems . 
true chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , entity1begin doxorubicin entity1end ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with entity2begin PROLEUKIN entity2end may increase toxicity in these organ systems . 
false chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , entity1begin methotrexate entity1end , entity2begin asparaginase entity2end ) effects with PROLEUKIN may increase toxicity in these organ systems . 
true chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , entity1begin methotrexate entity1end , asparaginase ) effects with entity2begin PROLEUKIN entity2end may increase toxicity in these organ systems . 
true chemical chemical Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , entity1begin asparaginase entity1end ) effects with entity2begin PROLEUKIN entity2end may increase toxicity in these organ systems . 
false chemical chemical The safety and efficacy of entity1begin PROLEUKIN entity1end in combination with any entity2begin antineoplastic agents entity2end have not been established . 
true chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose entity1begin PROLEUKIN entity1end and entity2begin antineoplastic agents entity2end , specifically , dacarbazine , cis - platinum , tamoxifen and interferon - alfa . 
true chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose entity1begin PROLEUKIN entity1end and antineoplastic agents , specifically , entity2begin dacarbazine entity2end , cis - platinum , tamoxifen and interferon - alfa . 
true chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose entity1begin PROLEUKIN entity1end and antineoplastic agents , specifically , dacarbazine , entity2begin cis - platinum entity2end , tamoxifen and interferon - alfa . 
true chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose entity1begin PROLEUKIN entity1end and antineoplastic agents , specifically , dacarbazine , cis - platinum , entity2begin tamoxifen entity2end and interferon - alfa . 
true chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose entity1begin PROLEUKIN entity1end and antineoplastic agents , specifically , dacarbazine , cis - platinum , tamoxifen and entity2begin interferon - alfa entity2end . 
false chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and entity1begin antineoplastic agents entity1end , specifically , entity2begin dacarbazine entity2end , cis - platinum , tamoxifen and interferon - alfa . 
false chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and entity1begin antineoplastic agents entity1end , specifically , dacarbazine , entity2begin cis - platinum entity2end , tamoxifen and interferon - alfa . 
false chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and entity1begin antineoplastic agents entity1end , specifically , dacarbazine , cis - platinum , entity2begin tamoxifen entity2end and interferon - alfa . 
false chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and entity1begin antineoplastic agents entity1end , specifically , dacarbazine , cis - platinum , tamoxifen and entity2begin interferon - alfa entity2end . 
false chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically , entity1begin dacarbazine entity1end , entity2begin cis - platinum entity2end , tamoxifen and interferon - alfa . 
false chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically , entity1begin dacarbazine entity1end , cis - platinum , entity2begin tamoxifen entity2end and interferon - alfa . 
false chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically , entity1begin dacarbazine entity1end , cis - platinum , tamoxifen and entity2begin interferon - alfa entity2end . 
false chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically , dacarbazine , entity1begin cis - platinum entity1end , entity2begin tamoxifen entity2end and interferon - alfa . 
false chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically , dacarbazine , entity1begin cis - platinum entity1end , tamoxifen and entity2begin interferon - alfa entity2end . 
false chemical chemical Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically , dacarbazine , cis - platinum , entity1begin tamoxifen entity1end and entity2begin interferon - alfa entity2end . 
true chemical chemical Myocardial injury , including myocardial infarction , myocarditis , ventricular hypokinesia , and severe rhabdomyolysis appear to be increased in patients receiving entity1begin PROLEUKIN entity1end and entity2begin interferon - alfa entity2end concurrently . 
true chemical chemical Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of entity1begin interferon - alfa entity1end and entity2begin PROLEUKIN entity2end , including crescentic IgA glomerulonephritis , oculo - bulbar myasthenia gravis , inflammatory arthritis , thyroiditis , bullous pemphigoid , and Stevens - Johnson syndrome . 
true chemical chemical Although entity1begin glucocorticoids entity1end have been shown to reduce entity2begin PROLEUKIN entity2end - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta - blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although entity1begin glucocorticoids entity1end have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with entity2begin PROLEUKIN entity2end may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta - blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although entity1begin glucocorticoids entity1end have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of entity2begin PROLEUKIN entity2end and thus should be avoided. 12 Beta - blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although entity1begin glucocorticoids entity1end have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 entity2begin Beta - blockers entity2end and other antihypertensives may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although entity1begin glucocorticoids entity1end have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta - blockers and other entity2begin antihypertensives entity2end may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although entity1begin glucocorticoids entity1end have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta - blockers and other antihypertensives may potentiate the hypotension seen with entity2begin PROLEUKIN entity2end . 
false chemical chemical Although glucocorticoids have been shown to reduce entity1begin PROLEUKIN entity1end - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with entity2begin PROLEUKIN entity2end may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta - blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although glucocorticoids have been shown to reduce entity1begin PROLEUKIN entity1end - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of entity2begin PROLEUKIN entity2end and thus should be avoided. 12 Beta - blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although glucocorticoids have been shown to reduce entity1begin PROLEUKIN entity1end - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 entity2begin Beta - blockers entity2end and other antihypertensives may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although glucocorticoids have been shown to reduce entity1begin PROLEUKIN entity1end - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta - blockers and other entity2begin antihypertensives entity2end may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although glucocorticoids have been shown to reduce entity1begin PROLEUKIN entity1end - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta - blockers and other antihypertensives may potentiate the hypotension seen with entity2begin PROLEUKIN entity2end . 
false chemical chemical Although glucocorticoids have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with entity1begin PROLEUKIN entity1end may reduce the antitumor effectiveness of entity2begin PROLEUKIN entity2end and thus should be avoided. 12 Beta - blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although glucocorticoids have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with entity1begin PROLEUKIN entity1end may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 entity2begin Beta - blockers entity2end and other antihypertensives may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although glucocorticoids have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with entity1begin PROLEUKIN entity1end may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta - blockers and other entity2begin antihypertensives entity2end may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although glucocorticoids have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with entity1begin PROLEUKIN entity1end may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta - blockers and other antihypertensives may potentiate the hypotension seen with entity2begin PROLEUKIN entity2end . 
false chemical chemical Although glucocorticoids have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of entity1begin PROLEUKIN entity1end and thus should be avoided. 12 entity2begin Beta - blockers entity2end and other antihypertensives may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although glucocorticoids have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of entity1begin PROLEUKIN entity1end and thus should be avoided. 12 Beta - blockers and other entity2begin antihypertensives entity2end may potentiate the hypotension seen with PROLEUKIN . 
false chemical chemical Although glucocorticoids have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of entity1begin PROLEUKIN entity1end and thus should be avoided. 12 Beta - blockers and other antihypertensives may potentiate the hypotension seen with entity2begin PROLEUKIN entity2end . 
false chemical chemical Although glucocorticoids have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 entity1begin Beta - blockers entity1end and other entity2begin antihypertensives entity2end may potentiate the hypotension seen with PROLEUKIN . 
true chemical chemical Although glucocorticoids have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 entity1begin Beta - blockers entity1end and other antihypertensives may potentiate the hypotension seen with entity2begin PROLEUKIN entity2end . 
true chemical chemical Although glucocorticoids have been shown to reduce PROLEUKIN - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta - blockers and other entity1begin antihypertensives entity1end may potentiate the hypotension seen with entity2begin PROLEUKIN entity2end . 
false chemical chemical Delayed Adverse Reactions to entity1begin Iodinated Contrast Media entity1end : A review of the literature revealed that 12.6 % ( range 11 - 28 % ) of 501 patients treated with various entity2begin interleukin - 2 entity2end containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute , atypical adverse reactions . 
false chemical chemical Delayed Adverse Reactions to entity1begin Iodinated Contrast Media entity1end : A review of the literature revealed that 12.6 % ( range 11 - 28 % ) of 501 patients treated with various interleukin - 2 containing regimens who were subsequently administered entity2begin radiographic iodinated contrast media entity2end experienced acute , atypical adverse reactions . 
true chemical chemical Delayed Adverse Reactions to Iodinated Contrast Media : A review of the literature revealed that 12.6 % ( range 11 - 28 % ) of 501 patients treated with various entity1begin interleukin - 2 entity1end containing regimens who were subsequently administered entity2begin radiographic iodinated contrast media entity2end experienced acute , atypical adverse reactions . 
false chemical chemical The duration of the period following treatment with entity1begin AMEVIVE entity1end before one should consider starting other entity2begin immunosuppressive entity2end therapy has not been evaluated . 
false chemical chemical Since the effect of entity1begin AMEVIVE entity1end on pregnancy and fetal development , including immune system development , is not known , health care providers are encouraged to enroll patients currently taking entity2begin AMEVIVE entity2end who become pregnant into the Biogen Pregnancy Registry by calling 1 - 866 - AMEVIVE ( 1 - 866 - 263 - 8483 ) . 
false chemical chemical Since the effect of entity1begin AMEVIVE entity1end on pregnancy and fetal development , including immune system development , is not known , health care providers are encouraged to enroll patients currently taking AMEVIVE who become pregnant into the Biogen Pregnancy Registry by calling 1 - 866 - entity2begin AMEVIVE entity2end ( 1 - 866 - 263 - 8483 ) . 
false chemical chemical Since the effect of AMEVIVE on pregnancy and fetal development , including immune system development , is not known , health care providers are encouraged to enroll patients currently taking entity1begin AMEVIVE entity1end who become pregnant into the Biogen Pregnancy Registry by calling 1 - 866 - entity2begin AMEVIVE entity2end ( 1 - 866 - 263 - 8483 ) . 
false chemical chemical An immune response to entity1begin Campath entity1end may interfere with subsequent diagnostic serum tests that utilize entity2begin antibodies entity2end 
true chemical chemical Intravenous entity1begin ranitidine entity1end was shown to double the bioavailability of oral entity2begin alendronate entity2end . 
false chemical chemical Products containing entity1begin calcium entity1end and other entity2begin multivalent cations entity2end likely will interfere with absorption of alendronate . 
true chemical chemical Products containing entity1begin calcium entity1end and other multivalent cations likely will interfere with absorption of entity2begin alendronate entity2end . 
true chemical chemical Products containing calcium and other entity1begin multivalent cations entity1end likely will interfere with absorption of entity2begin alendronate entity2end . 
true chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when entity1begin ALFENTA entity1end is administered in combination with other entity2begin CNS depressants entity2end such as barbiturates , tranquilizers , opioids , or inhalation general anesthetics . 
true chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when entity1begin ALFENTA entity1end is administered in combination with other CNS depressants such as entity2begin barbiturates entity2end , tranquilizers , opioids , or inhalation general anesthetics . 
true chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when entity1begin ALFENTA entity1end is administered in combination with other CNS depressants such as barbiturates , entity2begin tranquilizers entity2end , opioids , or inhalation general anesthetics . 
true chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when entity1begin ALFENTA entity1end is administered in combination with other CNS depressants such as barbiturates , tranquilizers , entity2begin opioids entity2end , or inhalation general anesthetics . 
true chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when entity1begin ALFENTA entity1end is administered in combination with other CNS depressants such as barbiturates , tranquilizers , opioids , or inhalation general entity2begin anesthetics entity2end . 
false chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other entity1begin CNS depressants entity1end such as entity2begin barbiturates entity2end , tranquilizers , opioids , or inhalation general anesthetics . 
false chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other entity1begin CNS depressants entity1end such as barbiturates , entity2begin tranquilizers entity2end , opioids , or inhalation general anesthetics . 
false chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other entity1begin CNS depressants entity1end such as barbiturates , tranquilizers , entity2begin opioids entity2end , or inhalation general anesthetics . 
false chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other entity1begin CNS depressants entity1end such as barbiturates , tranquilizers , opioids , or inhalation general entity2begin anesthetics entity2end . 
false chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as entity1begin barbiturates entity1end , entity2begin tranquilizers entity2end , opioids , or inhalation general anesthetics . 
false chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as entity1begin barbiturates entity1end , tranquilizers , entity2begin opioids entity2end , or inhalation general anesthetics . 
false chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as entity1begin barbiturates entity1end , tranquilizers , opioids , or inhalation general entity2begin anesthetics entity2end . 
false chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates , entity1begin tranquilizers entity1end , entity2begin opioids entity2end , or inhalation general anesthetics . 
false chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates , entity1begin tranquilizers entity1end , opioids , or inhalation general entity2begin anesthetics entity2end . 
false chemical chemical Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates , tranquilizers , entity1begin opioids entity1end , or inhalation general entity2begin anesthetics entity2end . 
true chemical chemical Limited clinical experience indicates that requirements for entity1begin volatile inhalation anesthetics entity1end are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following entity2begin ALFENTA entity2end induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression . 
false chemical chemical Limited clinical experience indicates that requirements for entity1begin volatile inhalation anesthetics entity1end are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following ALFENTA induction The concomitant use of entity2begin erythromycin entity2end with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression . 
false chemical chemical Limited clinical experience indicates that requirements for entity1begin volatile inhalation anesthetics entity1end are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following ALFENTA induction The concomitant use of erythromycin with entity2begin ALFENTA entity2end can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression . 
false chemical chemical Limited clinical experience indicates that requirements for entity1begin volatile inhalation anesthetics entity1end are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit entity2begin ALFENTA entity2end clearance and may increase the risk of prolonged or delayed respiratory depression . 
false chemical chemical Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following entity1begin ALFENTA entity1end induction The concomitant use of entity2begin erythromycin entity2end with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression . 
false chemical chemical Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following entity1begin ALFENTA entity1end induction The concomitant use of erythromycin with entity2begin ALFENTA entity2end can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression . 
false chemical chemical Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following entity1begin ALFENTA entity1end induction The concomitant use of erythromycin with ALFENTA can significantly inhibit entity2begin ALFENTA entity2end clearance and may increase the risk of prolonged or delayed respiratory depression . 
true chemical chemical Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following ALFENTA induction The concomitant use of entity1begin erythromycin entity1end with entity2begin ALFENTA entity2end can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression . 
false chemical chemical Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following ALFENTA induction The concomitant use of entity1begin erythromycin entity1end with ALFENTA can significantly inhibit entity2begin ALFENTA entity2end clearance and may increase the risk of prolonged or delayed respiratory depression . 
false chemical chemical Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following ALFENTA induction The concomitant use of erythromycin with entity1begin ALFENTA entity1end can significantly inhibit entity2begin ALFENTA entity2end clearance and may increase the risk of prolonged or delayed respiratory depression . 
true chemical chemical entity1begin Cimetidine entity1end reduces the clearance of entity2begin ALFENTA entity2end . 
false chemical chemical Therefore smaller entity1begin ALFENTA entity1end doses will be required with prolonged administration and the duration of action of entity2begin ALFENTA entity2end my be extended . 
false chemical chemical Drug - Drug Interactions : The pharmacokinetic and pharmacodynamic interactions between entity1begin UROXATRAL entity1end and other entity2begin alpha - blockers entity2end have not been determined . 
true chemical chemical However , interactions may be expected , and entity1begin UROXATRAL entity1end should NOT be used in combination with other entity2begin alpha - blockers entity2end . 
false chemical chemical Effects of Other Drugs on entity1begin Aliskiren entity1end Based on in - vitro studies , entity2begin aliskiren entity2end is metabolized by CYP 3A4 . 
false chemical chemical Co - administration of entity1begin lovastatin entity1end , entity2begin atenolol entity2end , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of entity1begin lovastatin entity1end , atenolol , entity2begin warfarin entity2end , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of entity1begin lovastatin entity1end , atenolol , warfarin , entity2begin furosemide entity2end , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of entity1begin lovastatin entity1end , atenolol , warfarin , furosemide , entity2begin digoxin entity2end , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of entity1begin lovastatin entity1end , atenolol , warfarin , furosemide , digoxin , entity2begin celecoxib entity2end , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of entity1begin lovastatin entity1end , atenolol , warfarin , furosemide , digoxin , celecoxib , entity2begin hydrochlorothiazide entity2end , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of entity1begin lovastatin entity1end , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , entity2begin ramipril entity2end , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of entity1begin lovastatin entity1end , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , entity2begin valsartan entity2end , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of entity1begin lovastatin entity1end , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , entity2begin metformin entity2end and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of entity1begin lovastatin entity1end , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and entity2begin amlodipine entity2end did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of entity1begin lovastatin entity1end , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in entity2begin aliskiren entity2end exposure . 
false chemical chemical Co - administration of lovastatin , entity1begin atenolol entity1end , entity2begin warfarin entity2end , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , entity1begin atenolol entity1end , warfarin , entity2begin furosemide entity2end , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , entity1begin atenolol entity1end , warfarin , furosemide , entity2begin digoxin entity2end , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , entity1begin atenolol entity1end , warfarin , furosemide , digoxin , entity2begin celecoxib entity2end , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , entity1begin atenolol entity1end , warfarin , furosemide , digoxin , celecoxib , entity2begin hydrochlorothiazide entity2end , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , entity1begin atenolol entity1end , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , entity2begin ramipril entity2end , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , entity1begin atenolol entity1end , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , entity2begin valsartan entity2end , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , entity1begin atenolol entity1end , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , entity2begin metformin entity2end and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , entity1begin atenolol entity1end , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and entity2begin amlodipine entity2end did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , entity1begin atenolol entity1end , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in entity2begin aliskiren entity2end exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , entity1begin warfarin entity1end , entity2begin furosemide entity2end , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , entity1begin warfarin entity1end , furosemide , entity2begin digoxin entity2end , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , entity1begin warfarin entity1end , furosemide , digoxin , entity2begin celecoxib entity2end , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , entity1begin warfarin entity1end , furosemide , digoxin , celecoxib , entity2begin hydrochlorothiazide entity2end , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , entity1begin warfarin entity1end , furosemide , digoxin , celecoxib , hydrochlorothiazide , entity2begin ramipril entity2end , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , entity1begin warfarin entity1end , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , entity2begin valsartan entity2end , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , entity1begin warfarin entity1end , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , entity2begin metformin entity2end and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , entity1begin warfarin entity1end , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and entity2begin amlodipine entity2end did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , entity1begin warfarin entity1end , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in entity2begin aliskiren entity2end exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , entity1begin furosemide entity1end , entity2begin digoxin entity2end , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , entity1begin furosemide entity1end , digoxin , entity2begin celecoxib entity2end , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , entity1begin furosemide entity1end , digoxin , celecoxib , entity2begin hydrochlorothiazide entity2end , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , entity1begin furosemide entity1end , digoxin , celecoxib , hydrochlorothiazide , entity2begin ramipril entity2end , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , entity1begin furosemide entity1end , digoxin , celecoxib , hydrochlorothiazide , ramipril , entity2begin valsartan entity2end , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , entity1begin furosemide entity1end , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , entity2begin metformin entity2end and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , entity1begin furosemide entity1end , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and entity2begin amlodipine entity2end did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , entity1begin furosemide entity1end , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in entity2begin aliskiren entity2end exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , entity1begin digoxin entity1end , entity2begin celecoxib entity2end , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , entity1begin digoxin entity1end , celecoxib , entity2begin hydrochlorothiazide entity2end , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , entity1begin digoxin entity1end , celecoxib , hydrochlorothiazide , entity2begin ramipril entity2end , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , entity1begin digoxin entity1end , celecoxib , hydrochlorothiazide , ramipril , entity2begin valsartan entity2end , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , entity1begin digoxin entity1end , celecoxib , hydrochlorothiazide , ramipril , valsartan , entity2begin metformin entity2end and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , entity1begin digoxin entity1end , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and entity2begin amlodipine entity2end did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , entity1begin digoxin entity1end , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in entity2begin aliskiren entity2end exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , entity1begin celecoxib entity1end , entity2begin hydrochlorothiazide entity2end , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , entity1begin celecoxib entity1end , hydrochlorothiazide , entity2begin ramipril entity2end , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , entity1begin celecoxib entity1end , hydrochlorothiazide , ramipril , entity2begin valsartan entity2end , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , entity1begin celecoxib entity1end , hydrochlorothiazide , ramipril , valsartan , entity2begin metformin entity2end and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , entity1begin celecoxib entity1end , hydrochlorothiazide , ramipril , valsartan , metformin and entity2begin amlodipine entity2end did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , entity1begin celecoxib entity1end , hydrochlorothiazide , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in entity2begin aliskiren entity2end exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , entity1begin hydrochlorothiazide entity1end , entity2begin ramipril entity2end , valsartan , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , entity1begin hydrochlorothiazide entity1end , ramipril , entity2begin valsartan entity2end , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , entity1begin hydrochlorothiazide entity1end , ramipril , valsartan , entity2begin metformin entity2end and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , entity1begin hydrochlorothiazide entity1end , ramipril , valsartan , metformin and entity2begin amlodipine entity2end did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , entity1begin hydrochlorothiazide entity1end , ramipril , valsartan , metformin and amlodipine did not result in clinically significant increases in entity2begin aliskiren entity2end exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , entity1begin ramipril entity1end , entity2begin valsartan entity2end , metformin and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , entity1begin ramipril entity1end , valsartan , entity2begin metformin entity2end and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , entity1begin ramipril entity1end , valsartan , metformin and entity2begin amlodipine entity2end did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , entity1begin ramipril entity1end , valsartan , metformin and amlodipine did not result in clinically significant increases in entity2begin aliskiren entity2end exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , entity1begin valsartan entity1end , entity2begin metformin entity2end and amlodipine did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , entity1begin valsartan entity1end , metformin and entity2begin amlodipine entity2end did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , entity1begin valsartan entity1end , metformin and amlodipine did not result in clinically significant increases in entity2begin aliskiren entity2end exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , entity1begin metformin entity1end and entity2begin amlodipine entity2end did not result in clinically significant increases in aliskiren exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , entity1begin metformin entity1end and amlodipine did not result in clinically significant increases in entity2begin aliskiren entity2end exposure . 
false chemical chemical Co - administration of lovastatin , atenolol , warfarin , furosemide , digoxin , celecoxib , hydrochlorothiazide , ramipril , valsartan , metformin and entity1begin amlodipine entity1end did not result in clinically significant increases in entity2begin aliskiren entity2end exposure . 
true chemical chemical Co - administration of entity1begin irbesartan entity1end reduced entity2begin aliskiren entity2end Cmax up to 50 % after multiple dosing . 
true chemical chemical Co - administration of entity1begin atorvastatin entity1end resulted in about a 50 % increase in entity2begin aliskiren entity2end Cmax and AUC after multiple dosing . 
false chemical chemical entity1begin Ketoconazole entity1end : Co - administration of 200 mg twice - daily entity2begin ketoconazole entity2end with aliskiren resulted in an approximate 80 % increase in plasma levels of aliskiren . 
false chemical chemical entity1begin Ketoconazole entity1end : Co - administration of 200 mg twice - daily ketoconazole with entity2begin aliskiren entity2end resulted in an approximate 80 % increase in plasma levels of aliskiren . 
false chemical chemical entity1begin Ketoconazole entity1end : Co - administration of 200 mg twice - daily ketoconazole with aliskiren resulted in an approximate 80 % increase in plasma levels of entity2begin aliskiren entity2end . 
true chemical chemical Ketoconazole : Co - administration of 200 mg twice - daily entity1begin ketoconazole entity1end with entity2begin aliskiren entity2end resulted in an approximate 80 % increase in plasma levels of aliskiren . 
false chemical chemical Ketoconazole : Co - administration of 200 mg twice - daily entity1begin ketoconazole entity1end with aliskiren resulted in an approximate 80 % increase in plasma levels of entity2begin aliskiren entity2end . 
false chemical chemical Ketoconazole : Co - administration of 200 mg twice - daily ketoconazole with entity1begin aliskiren entity1end resulted in an approximate 80 % increase in plasma levels of entity2begin aliskiren entity2end . 
false chemical chemical Effects of entity1begin Aliskiren entity1end on Other Drugs entity2begin Aliskiren entity2end does not inhibit the CYP450 isoenzymes ( CYP1A2 , 2C8 , 2C9 , 2C19 , 2D6 , 2E1 , and CYP 3A ) or induce CYP 3A4 . 
false chemical chemical Co - administration of entity1begin aliskiren entity1end did not significantly affect the pharmacokinetics of entity2begin lovastatin entity2end , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of entity1begin aliskiren entity1end did not significantly affect the pharmacokinetics of lovastatin , entity2begin digoxin entity2end , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of entity1begin aliskiren entity1end did not significantly affect the pharmacokinetics of lovastatin , digoxin , entity2begin valsartan entity2end , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of entity1begin aliskiren entity1end did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , entity2begin amlodipine entity2end , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of entity1begin aliskiren entity1end did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , entity2begin metformin entity2end , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of entity1begin aliskiren entity1end did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , entity2begin celecoxib entity2end , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of entity1begin aliskiren entity1end did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , entity2begin atenolol entity2end , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of entity1begin aliskiren entity1end did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , entity2begin atorvastatin entity2end , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of entity1begin aliskiren entity1end did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , entity2begin ramipril entity2end or hydrochlorothiazide . 
false chemical chemical Co - administration of entity1begin aliskiren entity1end did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or entity2begin hydrochlorothiazide entity2end . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of entity1begin lovastatin entity1end , entity2begin digoxin entity2end , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of entity1begin lovastatin entity1end , digoxin , entity2begin valsartan entity2end , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of entity1begin lovastatin entity1end , digoxin , valsartan , entity2begin amlodipine entity2end , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of entity1begin lovastatin entity1end , digoxin , valsartan , amlodipine , entity2begin metformin entity2end , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of entity1begin lovastatin entity1end , digoxin , valsartan , amlodipine , metformin , entity2begin celecoxib entity2end , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of entity1begin lovastatin entity1end , digoxin , valsartan , amlodipine , metformin , celecoxib , entity2begin atenolol entity2end , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of entity1begin lovastatin entity1end , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , entity2begin atorvastatin entity2end , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of entity1begin lovastatin entity1end , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , entity2begin ramipril entity2end or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of entity1begin lovastatin entity1end , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or entity2begin hydrochlorothiazide entity2end . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , entity1begin digoxin entity1end , entity2begin valsartan entity2end , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , entity1begin digoxin entity1end , valsartan , entity2begin amlodipine entity2end , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , entity1begin digoxin entity1end , valsartan , amlodipine , entity2begin metformin entity2end , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , entity1begin digoxin entity1end , valsartan , amlodipine , metformin , entity2begin celecoxib entity2end , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , entity1begin digoxin entity1end , valsartan , amlodipine , metformin , celecoxib , entity2begin atenolol entity2end , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , entity1begin digoxin entity1end , valsartan , amlodipine , metformin , celecoxib , atenolol , entity2begin atorvastatin entity2end , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , entity1begin digoxin entity1end , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , entity2begin ramipril entity2end or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , entity1begin digoxin entity1end , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or entity2begin hydrochlorothiazide entity2end . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , entity1begin valsartan entity1end , entity2begin amlodipine entity2end , metformin , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , entity1begin valsartan entity1end , amlodipine , entity2begin metformin entity2end , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , entity1begin valsartan entity1end , amlodipine , metformin , entity2begin celecoxib entity2end , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , entity1begin valsartan entity1end , amlodipine , metformin , celecoxib , entity2begin atenolol entity2end , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , entity1begin valsartan entity1end , amlodipine , metformin , celecoxib , atenolol , entity2begin atorvastatin entity2end , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , entity1begin valsartan entity1end , amlodipine , metformin , celecoxib , atenolol , atorvastatin , entity2begin ramipril entity2end or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , entity1begin valsartan entity1end , amlodipine , metformin , celecoxib , atenolol , atorvastatin , ramipril or entity2begin hydrochlorothiazide entity2end . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , entity1begin amlodipine entity1end , entity2begin metformin entity2end , celecoxib , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , entity1begin amlodipine entity1end , metformin , entity2begin celecoxib entity2end , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , entity1begin amlodipine entity1end , metformin , celecoxib , entity2begin atenolol entity2end , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , entity1begin amlodipine entity1end , metformin , celecoxib , atenolol , entity2begin atorvastatin entity2end , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , entity1begin amlodipine entity1end , metformin , celecoxib , atenolol , atorvastatin , entity2begin ramipril entity2end or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , entity1begin amlodipine entity1end , metformin , celecoxib , atenolol , atorvastatin , ramipril or entity2begin hydrochlorothiazide entity2end . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , entity1begin metformin entity1end , entity2begin celecoxib entity2end , atenolol , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , entity1begin metformin entity1end , celecoxib , entity2begin atenolol entity2end , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , entity1begin metformin entity1end , celecoxib , atenolol , entity2begin atorvastatin entity2end , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , entity1begin metformin entity1end , celecoxib , atenolol , atorvastatin , entity2begin ramipril entity2end or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , entity1begin metformin entity1end , celecoxib , atenolol , atorvastatin , ramipril or entity2begin hydrochlorothiazide entity2end . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , entity1begin celecoxib entity1end , entity2begin atenolol entity2end , atorvastatin , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , entity1begin celecoxib entity1end , atenolol , entity2begin atorvastatin entity2end , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , entity1begin celecoxib entity1end , atenolol , atorvastatin , entity2begin ramipril entity2end or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , entity1begin celecoxib entity1end , atenolol , atorvastatin , ramipril or entity2begin hydrochlorothiazide entity2end . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , entity1begin atenolol entity1end , entity2begin atorvastatin entity2end , ramipril or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , entity1begin atenolol entity1end , atorvastatin , entity2begin ramipril entity2end or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , entity1begin atenolol entity1end , atorvastatin , ramipril or entity2begin hydrochlorothiazide entity2end . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , entity1begin atorvastatin entity1end , entity2begin ramipril entity2end or hydrochlorothiazide . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , entity1begin atorvastatin entity1end , ramipril or entity2begin hydrochlorothiazide entity2end . 
false chemical chemical Co - administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin , digoxin , valsartan , amlodipine , metformin , celecoxib , atenolol , atorvastatin , entity1begin ramipril entity1end or entity2begin hydrochlorothiazide entity2end . 
false chemical chemical entity1begin Warfarin entity1end : The effects of entity2begin aliskiren entity2end on warfarin pharmacokinetics have not been evaluated in a well - controlled clinical trial . 
false chemical chemical entity1begin Warfarin entity1end : The effects of aliskiren on entity2begin warfarin entity2end pharmacokinetics have not been evaluated in a well - controlled clinical trial . 
false chemical chemical Warfarin : The effects of entity1begin aliskiren entity1end on entity2begin warfarin entity2end pharmacokinetics have not been evaluated in a well - controlled clinical trial . 
false chemical chemical entity1begin Furosemide entity1end : When entity2begin aliskiren entity2end was co - administered with furosemide , the AUC and Cmax of furosemide were reduced by about 30 % and 50 % , respectively . 
false chemical chemical entity1begin Furosemide entity1end : When aliskiren was co - administered with entity2begin furosemide entity2end , the AUC and Cmax of furosemide were reduced by about 30 % and 50 % , respectively . 
false chemical chemical entity1begin Furosemide entity1end : When aliskiren was co - administered with furosemide , the AUC and Cmax of entity2begin furosemide entity2end were reduced by about 30 % and 50 % , respectively . 
true chemical chemical Furosemide : When entity1begin aliskiren entity1end was co - administered with entity2begin furosemide entity2end , the AUC and Cmax of furosemide were reduced by about 30 % and 50 % , respectively . 
false chemical chemical Furosemide : When entity1begin aliskiren entity1end was co - administered with furosemide , the AUC and Cmax of entity2begin furosemide entity2end were reduced by about 30 % and 50 % , respectively . 
false chemical chemical Furosemide : When aliskiren was co - administered with entity1begin furosemide entity1end , the AUC and Cmax of entity2begin furosemide entity2end were reduced by about 30 % and 50 % , respectively . 
true chemical chemical Patients who are applying entity1begin Panretin entity1end gel should not concurrently use products that contain entity2begin DEET entity2end ( N , N - diethyl - m - toluamide ) , a common component of insect repellent products . 
true chemical chemical Patients who are applying entity1begin Panretin entity1end gel should not concurrently use products that contain DEET ( N , entity2begin N - diethyl - m - toluamide entity2end ) , a common component of insect repellent products . 
false chemical chemical Patients who are applying Panretin gel should not concurrently use products that contain entity1begin DEET entity1end ( N , entity2begin N - diethyl - m - toluamide entity2end ) , a common component of insect repellent products . 
false chemical chemical Animal toxicology studies showed increased entity1begin DEET entity1end toxicity when entity2begin DEET entity2end was included as proof of the formulation . 
false chemical chemical Although there was no clinical evidence in the vehicle - controlled studies of drug interactions with systemic entity1begin antiretroviral agents entity1end , including entity2begin protease inhibitors entity2end , macrolide antibiotics , and azole antifungals , the effect of Panretin gel on the steady - state concentrations of these drugs is not known . 
false chemical chemical Although there was no clinical evidence in the vehicle - controlled studies of drug interactions with systemic entity1begin antiretroviral agents entity1end , including protease inhibitors , entity2begin macrolide antibiotics entity2end , and azole antifungals , the effect of Panretin gel on the steady - state concentrations of these drugs is not known . 
false chemical chemical Although there was no clinical evidence in the vehicle - controlled studies of drug interactions with systemic entity1begin antiretroviral agents entity1end , including protease inhibitors , macrolide antibiotics , and entity2begin azole antifungals entity2end , the effect of Panretin gel on the steady - state concentrations of these drugs is not known . 
false chemical chemical Although there was no clinical evidence in the vehicle - controlled studies of drug interactions with systemic entity1begin antiretroviral agents entity1end , including protease inhibitors , macrolide antibiotics , and azole antifungals , the effect of entity2begin Panretin entity2end gel on the steady - state concentrations of these drugs is not known . 
false chemical chemical Although there was no clinical evidence in the vehicle - controlled studies of drug interactions with systemic antiretroviral agents , including entity1begin protease inhibitors entity1end , entity2begin macrolide antibiotics entity2end , and azole antifungals , the effect of Panretin gel on the steady - state concentrations of these drugs is not known . 
false chemical chemical Although there was no clinical evidence in the vehicle - controlled studies of drug interactions with systemic antiretroviral agents , including entity1begin protease inhibitors entity1end , macrolide antibiotics , and entity2begin azole antifungals entity2end , the effect of Panretin gel on the steady - state concentrations of these drugs is not known . 
false chemical chemical Although there was no clinical evidence in the vehicle - controlled studies of drug interactions with systemic antiretroviral agents , including entity1begin protease inhibitors entity1end , macrolide antibiotics , and azole antifungals , the effect of entity2begin Panretin entity2end gel on the steady - state concentrations of these drugs is not known . 
false chemical chemical Although there was no clinical evidence in the vehicle - controlled studies of drug interactions with systemic antiretroviral agents , including protease inhibitors , entity1begin macrolide antibiotics entity1end , and entity2begin azole antifungals entity2end , the effect of Panretin gel on the steady - state concentrations of these drugs is not known . 
false chemical chemical Although there was no clinical evidence in the vehicle - controlled studies of drug interactions with systemic antiretroviral agents , including protease inhibitors , entity1begin macrolide antibiotics entity1end , and azole antifungals , the effect of entity2begin Panretin entity2end gel on the steady - state concentrations of these drugs is not known . 
false chemical chemical Although there was no clinical evidence in the vehicle - controlled studies of drug interactions with systemic antiretroviral agents , including protease inhibitors , macrolide antibiotics , and entity1begin azole antifungals entity1end , the effect of entity2begin Panretin entity2end gel on the steady - state concentrations of these drugs is not known . 
false chemical chemical entity1begin Mercaptopurine entity1end / entity2begin Azathioprine entity2end : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6 - thiouric acid . 
false chemical chemical entity1begin Mercaptopurine entity1end / Azathioprine : entity2begin Allopurinol entity2end inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6 - thiouric acid . 
false chemical chemical entity1begin Mercaptopurine entity1end / Azathioprine : Allopurinol inhibits the enzymatic oxidation of entity2begin mercaptopurine entity2end and azathioprine to 6 - thiouric acid . 
false chemical chemical entity1begin Mercaptopurine entity1end / Azathioprine : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and entity2begin azathioprine entity2end to 6 - thiouric acid . 
false chemical chemical entity1begin Mercaptopurine entity1end / Azathioprine : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to entity2begin 6 - thiouric acid entity2end . 
false chemical chemical Mercaptopurine / entity1begin Azathioprine entity1end : entity2begin Allopurinol entity2end inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6 - thiouric acid . 
false chemical chemical Mercaptopurine / entity1begin Azathioprine entity1end : Allopurinol inhibits the enzymatic oxidation of entity2begin mercaptopurine entity2end and azathioprine to 6 - thiouric acid . 
false chemical chemical Mercaptopurine / entity1begin Azathioprine entity1end : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and entity2begin azathioprine entity2end to 6 - thiouric acid . 
false chemical chemical Mercaptopurine / entity1begin Azathioprine entity1end : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to entity2begin 6 - thiouric acid entity2end . 
true chemical chemical Mercaptopurine / Azathioprine : entity1begin Allopurinol entity1end inhibits the enzymatic oxidation of entity2begin mercaptopurine entity2end and azathioprine to 6 - thiouric acid . 
true chemical chemical Mercaptopurine / Azathioprine : entity1begin Allopurinol entity1end inhibits the enzymatic oxidation of mercaptopurine and entity2begin azathioprine entity2end to 6 - thiouric acid . 
false chemical chemical Mercaptopurine / Azathioprine : entity1begin Allopurinol entity1end inhibits the enzymatic oxidation of mercaptopurine and azathioprine to entity2begin 6 - thiouric acid entity2end . 
false chemical chemical Mercaptopurine / Azathioprine : Allopurinol inhibits the enzymatic oxidation of entity1begin mercaptopurine entity1end and entity2begin azathioprine entity2end to 6 - thiouric acid . 
false chemical chemical Mercaptopurine / Azathioprine : Allopurinol inhibits the enzymatic oxidation of entity1begin mercaptopurine entity1end and azathioprine to entity2begin 6 - thiouric acid entity2end . 
false chemical chemical Mercaptopurine / Azathioprine : Allopurinol inhibits the enzymatic oxidation of mercaptopurine and entity1begin azathioprine entity1end to entity2begin 6 - thiouric acid entity2end . 
false chemical chemical In patients receiving entity1begin mercaptopurine entity1end ( entity2begin Purinethol entity2end ) or azathioprine ( Imuran ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or azathioprine . 
false chemical chemical In patients receiving entity1begin mercaptopurine entity1end ( Purinethol ) or entity2begin azathioprine entity2end ( Imuran ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or azathioprine . 
false chemical chemical In patients receiving entity1begin mercaptopurine entity1end ( Purinethol ) or azathioprine ( entity2begin Imuran entity2end ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or azathioprine . 
false chemical chemical In patients receiving entity1begin mercaptopurine entity1end ( Purinethol ) or azathioprine ( Imuran ) , the concomitant administration of 300 - 600 mg of entity2begin allopurinol entity2end per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or azathioprine . 
false chemical chemical In patients receiving entity1begin mercaptopurine entity1end ( Purinethol ) or azathioprine ( Imuran ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of entity2begin mercaptopurine entity2end or azathioprine . 
false chemical chemical In patients receiving entity1begin mercaptopurine entity1end ( Purinethol ) or azathioprine ( Imuran ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or entity2begin azathioprine entity2end . 
false chemical chemical In patients receiving mercaptopurine ( entity1begin Purinethol entity1end ) or entity2begin azathioprine entity2end ( Imuran ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or azathioprine . 
false chemical chemical In patients receiving mercaptopurine ( entity1begin Purinethol entity1end ) or azathioprine ( entity2begin Imuran entity2end ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or azathioprine . 
false chemical chemical In patients receiving mercaptopurine ( entity1begin Purinethol entity1end ) or azathioprine ( Imuran ) , the concomitant administration of 300 - 600 mg of entity2begin allopurinol entity2end per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or azathioprine . 
false chemical chemical In patients receiving mercaptopurine ( entity1begin Purinethol entity1end ) or azathioprine ( Imuran ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of entity2begin mercaptopurine entity2end or azathioprine . 
false chemical chemical In patients receiving mercaptopurine ( entity1begin Purinethol entity1end ) or azathioprine ( Imuran ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or entity2begin azathioprine entity2end . 
false chemical chemical In patients receiving mercaptopurine ( Purinethol ) or entity1begin azathioprine entity1end ( entity2begin Imuran entity2end ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or azathioprine . 
false chemical chemical In patients receiving mercaptopurine ( Purinethol ) or entity1begin azathioprine entity1end ( Imuran ) , the concomitant administration of 300 - 600 mg of entity2begin allopurinol entity2end per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or azathioprine . 
false chemical chemical In patients receiving mercaptopurine ( Purinethol ) or entity1begin azathioprine entity1end ( Imuran ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of entity2begin mercaptopurine entity2end or azathioprine . 
false chemical chemical In patients receiving mercaptopurine ( Purinethol ) or entity1begin azathioprine entity1end ( Imuran ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or entity2begin azathioprine entity2end . 
false chemical chemical In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( entity1begin Imuran entity1end ) , the concomitant administration of 300 - 600 mg of entity2begin allopurinol entity2end per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or azathioprine . 
false chemical chemical In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( entity1begin Imuran entity1end ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of entity2begin mercaptopurine entity2end or azathioprine . 
false chemical chemical In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( entity1begin Imuran entity1end ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or entity2begin azathioprine entity2end . 
true chemical chemical In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ) , the concomitant administration of 300 - 600 mg of entity1begin allopurinol entity1end per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of entity2begin mercaptopurine entity2end or azathioprine . 
true chemical chemical In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ) , the concomitant administration of 300 - 600 mg of entity1begin allopurinol entity1end per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of mercaptopurine or entity2begin azathioprine entity2end . 
false chemical chemical In patients receiving mercaptopurine ( Purinethol ) or azathioprine ( Imuran ) , the concomitant administration of 300 - 600 mg of allopurinol per day will require a reduction in dose to approximately one - third to one - fourth of the usual dose of entity1begin mercaptopurine entity1end or entity2begin azathioprine entity2end . 
false chemical chemical Subsequent adjustment of doses of entity1begin mercaptopurine entity1end or entity2begin azathioprine entity2end should be made on the basis of therapeutic response and the appearance of toxic effects . 
false chemical chemical entity1begin Dicumarol entity1end : It has been reported that entity2begin allopurinol entity2end prolongs the half - life of the anticoagulant , dicumarol . 
false chemical chemical entity1begin Dicumarol entity1end : It has been reported that allopurinol prolongs the half - life of the entity2begin anticoagulant entity2end , dicumarol . 
false chemical chemical entity1begin Dicumarol entity1end : It has been reported that allopurinol prolongs the half - life of the anticoagulant , entity2begin dicumarol entity2end . 
false chemical chemical Dicumarol : It has been reported that entity1begin allopurinol entity1end prolongs the half - life of the entity2begin anticoagulant entity2end , dicumarol . 
true chemical chemical Dicumarol : It has been reported that entity1begin allopurinol entity1end prolongs the half - life of the anticoagulant , entity2begin dicumarol entity2end . 
false chemical chemical Dicumarol : It has been reported that allopurinol prolongs the half - life of the entity1begin anticoagulant entity1end , entity2begin dicumarol entity2end . 
false chemical chemical The clinical basis of this drug interaction has not been established but should be noted when entity1begin allopurinol entity1end is given to patients already on entity2begin dicumarol entity2end therapy . 
false chemical chemical entity1begin Uricosuric Agents entity1end : Since the excretion of entity2begin oxipurinol entity2end is similar to that of urate , uricosuric agents , which increase the excretion of urate , are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase . 
false chemical chemical entity1begin Uricosuric Agents entity1end : Since the excretion of oxipurinol is similar to that of urate , entity2begin uricosuric agents entity2end , which increase the excretion of urate , are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase . 
false chemical chemical entity1begin Uricosuric Agents entity1end : Since the excretion of oxipurinol is similar to that of urate , uricosuric agents , which increase the excretion of urate , are also likely to increase the excretion of entity2begin oxipurinol entity2end and thus lower the degree of inhibition of xanthine oxidase . 
false chemical chemical Uricosuric Agents : Since the excretion of entity1begin oxipurinol entity1end is similar to that of urate , entity2begin uricosuric agents entity2end , which increase the excretion of urate , are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase . 
false chemical chemical Uricosuric Agents : Since the excretion of entity1begin oxipurinol entity1end is similar to that of urate , uricosuric agents , which increase the excretion of urate , are also likely to increase the excretion of entity2begin oxipurinol entity2end and thus lower the degree of inhibition of xanthine oxidase . 
true chemical chemical Uricosuric Agents : Since the excretion of oxipurinol is similar to that of urate , entity1begin uricosuric agents entity1end , which increase the excretion of urate , are also likely to increase the excretion of entity2begin oxipurinol entity2end and thus lower the degree of inhibition of xanthine oxidase . 
true chemical chemical The concomitant administration of entity1begin uricosuric agents entity1end and entity2begin allopurinol entity2end has been associated with a decrease in the excretion of oxypurines ( hypoxanthine and xanthine ) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone . 
false chemical chemical The concomitant administration of entity1begin uricosuric agents entity1end and allopurinol has been associated with a decrease in the excretion of oxypurines ( hypoxanthine and xanthine ) and an increase in urinary uric acid excretion compared with that observed with entity2begin allopurinol entity2end alone . 
false chemical chemical The concomitant administration of uricosuric agents and entity1begin allopurinol entity1end has been associated with a decrease in the excretion of oxypurines ( hypoxanthine and xanthine ) and an increase in urinary uric acid excretion compared with that observed with entity2begin allopurinol entity2end alone . 
false chemical chemical Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on entity1begin allopurinol entity1end alone or in combination with entity2begin uricosuric agents entity2end , the possibility should be kept in mind . 
false chemical chemical entity1begin Thiazide Diuretics entity1end : The reports that the concomitant use of entity2begin allopurinol entity2end and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause - and - effect relationship and a mechanism of causation . 
false chemical chemical entity1begin Thiazide Diuretics entity1end : The reports that the concomitant use of allopurinol and entity2begin thiazide diuretics entity2end may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause - and - effect relationship and a mechanism of causation . 
false chemical chemical entity1begin Thiazide Diuretics entity1end : The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of entity2begin allopurinol entity2end toxicity in some patients have been reviewed in an attempt to establish a cause - and - effect relationship and a mechanism of causation . 
true chemical chemical Thiazide Diuretics : The reports that the concomitant use of entity1begin allopurinol entity1end and entity2begin thiazide diuretics entity2end may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause - and - effect relationship and a mechanism of causation . 
false chemical chemical Thiazide Diuretics : The reports that the concomitant use of entity1begin allopurinol entity1end and thiazide diuretics may contribute to the enhancement of entity2begin allopurinol entity2end toxicity in some patients have been reviewed in an attempt to establish a cause - and - effect relationship and a mechanism of causation . 
false chemical chemical Thiazide Diuretics : The reports that the concomitant use of allopurinol and entity1begin thiazide diuretics entity1end may contribute to the enhancement of entity2begin allopurinol entity2end toxicity in some patients have been reviewed in an attempt to establish a cause - and - effect relationship and a mechanism of causation . 
true chemical chemical Although a causal mechanism and a cause - and - effect relationship have not been established , current evidence suggests that renal function should be monitored in patients on entity1begin thiazide diuretics entity1end and entity2begin allopurinol entity2end even in the absence of renal failure , and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected. . 
false chemical chemical entity1begin Ampicillin entity1end / entity2begin Amoxicillin entity2end : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs . 
false chemical chemical entity1begin Ampicillin entity1end / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving entity2begin ampicillin entity2end or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs . 
false chemical chemical entity1begin Ampicillin entity1end / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or entity2begin amoxicillin entity2end concurrently with allopurinol compared to patients who are not receiving both drugs . 
false chemical chemical entity1begin Ampicillin entity1end / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with entity2begin allopurinol entity2end compared to patients who are not receiving both drugs . 
false chemical chemical Ampicillin / entity1begin Amoxicillin entity1end : An increase in the frequency of skin rash has been reported among patients receiving entity2begin ampicillin entity2end or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs . 
false chemical chemical Ampicillin / entity1begin Amoxicillin entity1end : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or entity2begin amoxicillin entity2end concurrently with allopurinol compared to patients who are not receiving both drugs . 
false chemical chemical Ampicillin / entity1begin Amoxicillin entity1end : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with entity2begin allopurinol entity2end compared to patients who are not receiving both drugs . 
false chemical chemical Ampicillin / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving entity1begin ampicillin entity1end or entity2begin amoxicillin entity2end concurrently with allopurinol compared to patients who are not receiving both drugs . 
true chemical chemical Ampicillin / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving entity1begin ampicillin entity1end or amoxicillin concurrently with entity2begin allopurinol entity2end compared to patients who are not receiving both drugs . 
true chemical chemical Ampicillin / Amoxicillin : An increase in the frequency of skin rash has been reported among patients receiving ampicillin or entity1begin amoxicillin entity1end concurrently with entity2begin allopurinol entity2end compared to patients who are not receiving both drugs . 
false chemical chemical entity1begin Cytotoxic Agents entity1end : Enhanced bone marrow suppression by entity2begin cyclophosphamide entity2end and other cytotoxic agents has been reported among patients with neoplastic disease , except leukemia , in the presence of allopurinol . 
false chemical chemical entity1begin Cytotoxic Agents entity1end : Enhanced bone marrow suppression by cyclophosphamide and other entity2begin cytotoxic agents entity2end has been reported among patients with neoplastic disease , except leukemia , in the presence of allopurinol . 
false chemical chemical entity1begin Cytotoxic Agents entity1end : Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease , except leukemia , in the presence of entity2begin allopurinol entity2end . 
false chemical chemical Cytotoxic Agents : Enhanced bone marrow suppression by entity1begin cyclophosphamide entity1end and other entity2begin cytotoxic agents entity2end has been reported among patients with neoplastic disease , except leukemia , in the presence of allopurinol . 
true chemical chemical Cytotoxic Agents : Enhanced bone marrow suppression by entity1begin cyclophosphamide entity1end and other cytotoxic agents has been reported among patients with neoplastic disease , except leukemia , in the presence of entity2begin allopurinol entity2end . 
true chemical chemical Cytotoxic Agents : Enhanced bone marrow suppression by cyclophosphamide and other entity1begin cytotoxic agents entity1end has been reported among patients with neoplastic disease , except leukemia , in the presence of entity2begin allopurinol entity2end . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , entity1begin allopurinol entity1end did not increase the marrow toxicity of patients treated with entity2begin cyclophosphamide entity2end , doxorubicin , bleomycin , procarbazine and / or mechlorethamine . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , entity1begin allopurinol entity1end did not increase the marrow toxicity of patients treated with cyclophosphamide , entity2begin doxorubicin entity2end , bleomycin , procarbazine and / or mechlorethamine . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , entity1begin allopurinol entity1end did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , entity2begin bleomycin entity2end , procarbazine and / or mechlorethamine . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , entity1begin allopurinol entity1end did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , entity2begin procarbazine entity2end and / or mechlorethamine . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , entity1begin allopurinol entity1end did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , procarbazine and / or entity2begin mechlorethamine entity2end . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , allopurinol did not increase the marrow toxicity of patients treated with entity1begin cyclophosphamide entity1end , entity2begin doxorubicin entity2end , bleomycin , procarbazine and / or mechlorethamine . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , allopurinol did not increase the marrow toxicity of patients treated with entity1begin cyclophosphamide entity1end , doxorubicin , entity2begin bleomycin entity2end , procarbazine and / or mechlorethamine . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , allopurinol did not increase the marrow toxicity of patients treated with entity1begin cyclophosphamide entity1end , doxorubicin , bleomycin , entity2begin procarbazine entity2end and / or mechlorethamine . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , allopurinol did not increase the marrow toxicity of patients treated with entity1begin cyclophosphamide entity1end , doxorubicin , bleomycin , procarbazine and / or entity2begin mechlorethamine entity2end . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , entity1begin doxorubicin entity1end , entity2begin bleomycin entity2end , procarbazine and / or mechlorethamine . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , entity1begin doxorubicin entity1end , bleomycin , entity2begin procarbazine entity2end and / or mechlorethamine . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , entity1begin doxorubicin entity1end , bleomycin , procarbazine and / or entity2begin mechlorethamine entity2end . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , entity1begin bleomycin entity1end , entity2begin procarbazine entity2end and / or mechlorethamine . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , entity1begin bleomycin entity1end , procarbazine and / or entity2begin mechlorethamine entity2end . 
false chemical chemical However , in a well - controlled study of patients with lymphoma on combination therapy , allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide , doxorubicin , bleomycin , entity1begin procarbazine entity1end and / or entity2begin mechlorethamine entity2end . 
false chemical chemical entity1begin Chlorpropamide entity1end : entity2begin Chlorpropamide entity2end s plasma half - life may be prolonged by allopurinol , since allopurinol and chlorpropamide may compete for excretion in the renal tubule . 
false chemical chemical entity1begin Chlorpropamide entity1end : Chlorpropamides plasma half - life may be prolonged by entity2begin allopurinol entity2end , since allopurinol and chlorpropamide may compete for excretion in the renal tubule . 
false chemical chemical entity1begin Chlorpropamide entity1end : Chlorpropamides plasma half - life may be prolonged by allopurinol , since entity2begin allopurinol entity2end and chlorpropamide may compete for excretion in the renal tubule . 
false chemical chemical entity1begin Chlorpropamide entity1end : Chlorpropamides plasma half - life may be prolonged by allopurinol , since allopurinol and entity2begin chlorpropamide entity2end may compete for excretion in the renal tubule . 
true chemical chemical Chlorpropamide : entity1begin Chlorpropamide entity1end s plasma half - life may be prolonged by entity2begin allopurinol entity2end , since allopurinol and chlorpropamide may compete for excretion in the renal tubule . 
false chemical chemical Chlorpropamide : entity1begin Chlorpropamide entity1end s plasma half - life may be prolonged by allopurinol , since entity2begin allopurinol entity2end and chlorpropamide may compete for excretion in the renal tubule . 
false chemical chemical Chlorpropamide : entity1begin Chlorpropamide entity1end s plasma half - life may be prolonged by allopurinol , since allopurinol and entity2begin chlorpropamide entity2end may compete for excretion in the renal tubule . 
false chemical chemical Chlorpropamide : Chlorpropamides plasma half - life may be prolonged by entity1begin allopurinol entity1end , since entity2begin allopurinol entity2end and chlorpropamide may compete for excretion in the renal tubule . 
false chemical chemical Chlorpropamide : Chlorpropamides plasma half - life may be prolonged by entity1begin allopurinol entity1end , since allopurinol and entity2begin chlorpropamide entity2end may compete for excretion in the renal tubule . 
true chemical chemical Chlorpropamide : Chlorpropamides plasma half - life may be prolonged by allopurinol , since entity1begin allopurinol entity1end and entity2begin chlorpropamide entity2end may compete for excretion in the renal tubule . 
true chemical chemical The risk of hypoglycemia secondary to this mechanism may be increased if entity1begin allopurinol entity1end and entity2begin chlorpropamide entity2end are given concomitantly in the presence of renal insufficiency . 
false chemical chemical entity1begin Cyclosporin entity1end : Reports indicate that entity2begin cyclosporine entity2end levels may be increased during concomitant treatment with allopurinol sodium for injection . 
false chemical chemical entity1begin Cyclosporin entity1end : Reports indicate that cyclosporine levels may be increased during concomitant treatment with entity2begin allopurinol sodium entity2end for injection . 
true chemical chemical Cyclosporin : Reports indicate that entity1begin cyclosporine entity1end levels may be increased during concomitant treatment with entity2begin allopurinol sodium entity2end for injection . 
false chemical chemical Monitoring of entity1begin cyclosporine entity1end levels and possible adjustment of entity2begin cyclosporine entity2end dosage should be considered when these drugs are co - administered . 
false chemical chemical Because there is a theoretical basis that these effects may be additive , use of entity1begin ergotamine entity1end - containing or entity2begin ergot - type medications entity2end ( like dihydroergotamine or methysergide ) and AXERT within 24 hours of each other should be avoided . 
false chemical chemical Because there is a theoretical basis that these effects may be additive , use of entity1begin ergotamine entity1end - containing or ergot - type medications ( like entity2begin dihydroergotamine entity2end or methysergide ) and AXERT within 24 hours of each other should be avoided . 
false chemical chemical Because there is a theoretical basis that these effects may be additive , use of entity1begin ergotamine entity1end - containing or ergot - type medications ( like dihydroergotamine or entity2begin methysergide entity2end ) and AXERT within 24 hours of each other should be avoided . 
true chemical chemical Because there is a theoretical basis that these effects may be additive , use of entity1begin ergotamine entity1end - containing or ergot - type medications ( like dihydroergotamine or methysergide ) and entity2begin AXERT entity2end within 24 hours of each other should be avoided . 
false chemical chemical Because there is a theoretical basis that these effects may be additive , use of ergotamine - containing or entity1begin ergot - type medications entity1end ( like entity2begin dihydroergotamine entity2end or methysergide ) and AXERT within 24 hours of each other should be avoided . 
false chemical chemical Because there is a theoretical basis that these effects may be additive , use of ergotamine - containing or entity1begin ergot - type medications entity1end ( like dihydroergotamine or entity2begin methysergide entity2end ) and AXERT within 24 hours of each other should be avoided . 
true chemical chemical Because there is a theoretical basis that these effects may be additive , use of ergotamine - containing or entity1begin ergot - type medications entity1end ( like dihydroergotamine or methysergide ) and entity2begin AXERT entity2end within 24 hours of each other should be avoided . 
false chemical chemical Because there is a theoretical basis that these effects may be additive , use of ergotamine - containing or ergot - type medications ( like entity1begin dihydroergotamine entity1end or entity2begin methysergide entity2end ) and AXERT within 24 hours of each other should be avoided . 
true chemical chemical Because there is a theoretical basis that these effects may be additive , use of ergotamine - containing or ergot - type medications ( like entity1begin dihydroergotamine entity1end or methysergide ) and entity2begin AXERT entity2end within 24 hours of each other should be avoided . 
true chemical chemical Because there is a theoretical basis that these effects may be additive , use of ergotamine - containing or ergot - type medications ( like dihydroergotamine or entity1begin methysergide entity1end ) and entity2begin AXERT entity2end within 24 hours of each other should be avoided . 
false chemical chemical entity1begin Monoamine Oxidase Inhibitors entity1end : Coadministration of entity2begin moclobemide entity2end resulted in a 27 % decrease in almotriptan clearance and an increase in Cmax of approximately 6 % . 
false chemical chemical entity1begin Monoamine Oxidase Inhibitors entity1end : Coadministration of moclobemide resulted in a 27 % decrease in entity2begin almotriptan entity2end clearance and an increase in Cmax of approximately 6 % . 
true chemical chemical Monoamine Oxidase Inhibitors : Coadministration of entity1begin moclobemide entity1end resulted in a 27 % decrease in entity2begin almotriptan entity2end clearance and an increase in Cmax of approximately 6 % . 
false chemical chemical Other entity1begin 5 - HT1B / 1D Agonists entity1end Concomitant use of other entity2begin 5 - HT1B / 1D agonists entity2end within 24 hours of treatment with AXERT is contraindicated . 
false chemical chemical Other entity1begin 5 - HT1B / 1D Agonists entity1end Concomitant use of other 5 - HT1B / 1D agonists within 24 hours of treatment with entity2begin AXERT entity2end is contraindicated . 
true chemical chemical Other 5 - HT1B / 1D Agonists Concomitant use of other entity1begin 5 - HT1B / 1D agonists entity1end within 24 hours of treatment with entity2begin AXERT entity2end is contraindicated . 
false chemical chemical entity1begin Propanolol entity1end : The pharmacokinetics of entity2begin almotriptan entity2end were not affected by coadministration of propranolol . 
false chemical chemical entity1begin Propanolol entity1end : The pharmacokinetics of almotriptan were not affected by coadministration of entity2begin propranolol entity2end . 
false chemical chemical Propanolol : The pharmacokinetics of entity1begin almotriptan entity1end were not affected by coadministration of entity2begin propranolol entity2end . 
false chemical chemical entity1begin Selective Serotonin Reuptake Inhibitors entity1end ( entity2begin SSRIs entity2end ) : SSRIs ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical entity1begin Selective Serotonin Reuptake Inhibitors entity1end ( SSRIs ) : entity2begin SSRIs entity2end ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical entity1begin Selective Serotonin Reuptake Inhibitors entity1end ( SSRIs ) : SSRIs ( e.g. , entity2begin fluoxetine entity2end , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical entity1begin Selective Serotonin Reuptake Inhibitors entity1end ( SSRIs ) : SSRIs ( e.g. , fluoxetine , entity2begin fluvoxamine entity2end , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical entity1begin Selective Serotonin Reuptake Inhibitors entity1end ( SSRIs ) : SSRIs ( e.g. , fluoxetine , fluvoxamine , entity2begin paroxetine entity2end , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical entity1begin Selective Serotonin Reuptake Inhibitors entity1end ( SSRIs ) : SSRIs ( e.g. , fluoxetine , fluvoxamine , paroxetine , entity2begin sertraline entity2end ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical entity1begin Selective Serotonin Reuptake Inhibitors entity1end ( SSRIs ) : SSRIs ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin 5 - HT1 agonists entity2end . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( entity1begin SSRIs entity1end ) : entity2begin SSRIs entity2end ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( entity1begin SSRIs entity1end ) : SSRIs ( e.g. , entity2begin fluoxetine entity2end , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( entity1begin SSRIs entity1end ) : SSRIs ( e.g. , fluoxetine , entity2begin fluvoxamine entity2end , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( entity1begin SSRIs entity1end ) : SSRIs ( e.g. , fluoxetine , fluvoxamine , entity2begin paroxetine entity2end , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( entity1begin SSRIs entity1end ) : SSRIs ( e.g. , fluoxetine , fluvoxamine , paroxetine , entity2begin sertraline entity2end ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( entity1begin SSRIs entity1end ) : SSRIs ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin 5 - HT1 agonists entity2end . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : entity1begin SSRIs entity1end ( e.g. , entity2begin fluoxetine entity2end , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : entity1begin SSRIs entity1end ( e.g. , fluoxetine , entity2begin fluvoxamine entity2end , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : entity1begin SSRIs entity1end ( e.g. , fluoxetine , fluvoxamine , entity2begin paroxetine entity2end , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : entity1begin SSRIs entity1end ( e.g. , fluoxetine , fluvoxamine , paroxetine , entity2begin sertraline entity2end ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
true chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : entity1begin SSRIs entity1end ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin 5 - HT1 agonists entity2end . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : SSRIs ( e.g. , entity1begin fluoxetine entity1end , entity2begin fluvoxamine entity2end , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : SSRIs ( e.g. , entity1begin fluoxetine entity1end , fluvoxamine , entity2begin paroxetine entity2end , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : SSRIs ( e.g. , entity1begin fluoxetine entity1end , fluvoxamine , paroxetine , entity2begin sertraline entity2end ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
true chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : SSRIs ( e.g. , entity1begin fluoxetine entity1end , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin 5 - HT1 agonists entity2end . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : SSRIs ( e.g. , fluoxetine , entity1begin fluvoxamine entity1end , entity2begin paroxetine entity2end , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : SSRIs ( e.g. , fluoxetine , entity1begin fluvoxamine entity1end , paroxetine , entity2begin sertraline entity2end ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
true chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : SSRIs ( e.g. , fluoxetine , entity1begin fluvoxamine entity1end , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin 5 - HT1 agonists entity2end . 
false chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : SSRIs ( e.g. , fluoxetine , fluvoxamine , entity1begin paroxetine entity1end , entity2begin sertraline entity2end ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5 - HT1 agonists . 
true chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : SSRIs ( e.g. , fluoxetine , fluvoxamine , entity1begin paroxetine entity1end , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin 5 - HT1 agonists entity2end . 
true chemical chemical Selective Serotonin Reuptake Inhibitors ( SSRIs ) : SSRIs ( e.g. , fluoxetine , fluvoxamine , paroxetine , entity1begin sertraline entity1end ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin 5 - HT1 agonists entity2end . 
true chemical chemical If concomitant treatment with entity1begin AXERT entity1end and an entity2begin SSRI entity2end is clinically warranted , appropriate observation of the patient is advised . 
false chemical chemical entity1begin Verapamil entity1end : Coadministration of entity2begin almotriptan entity2end and verapamil resulted in a 24 % increase in plasma concentrations of almotriptan . 
false chemical chemical entity1begin Verapamil entity1end : Coadministration of almotriptan and entity2begin verapamil entity2end resulted in a 24 % increase in plasma concentrations of almotriptan . 
false chemical chemical entity1begin Verapamil entity1end : Coadministration of almotriptan and verapamil resulted in a 24 % increase in plasma concentrations of entity2begin almotriptan entity2end . 
true chemical chemical Verapamil : Coadministration of entity1begin almotriptan entity1end and entity2begin verapamil entity2end resulted in a 24 % increase in plasma concentrations of almotriptan . 
false chemical chemical Verapamil : Coadministration of entity1begin almotriptan entity1end and verapamil resulted in a 24 % increase in plasma concentrations of entity2begin almotriptan entity2end . 
false chemical chemical Verapamil : Coadministration of almotriptan and entity1begin verapamil entity1end resulted in a 24 % increase in plasma concentrations of entity2begin almotriptan entity2end . 
true chemical chemical Coadministration of entity1begin almotriptan entity1end and the potent CYP3A4 inhibitor entity2begin ketoconazole entity2end ( 400 mg q.d. for 3 days ) resulted in an approximately 60 % increase in the area under the plasma concentration - time curve and maximal plasma concentrations of almotriptan . 
false chemical chemical Coadministration of entity1begin almotriptan entity1end and the potent CYP3A4 inhibitor ketoconazole ( 400 mg q.d. for 3 days ) resulted in an approximately 60 % increase in the area under the plasma concentration - time curve and maximal plasma concentrations of entity2begin almotriptan entity2end . 
false chemical chemical Coadministration of almotriptan and the potent CYP3A4 inhibitor entity1begin ketoconazole entity1end ( 400 mg q.d. for 3 days ) resulted in an approximately 60 % increase in the area under the plasma concentration - time curve and maximal plasma concentrations of entity2begin almotriptan entity2end . 
false chemical chemical Although the interaction between entity1begin almotriptan entity1end and other potent CYP3A4 inhibitors ( e.g. , entity2begin itraconazole entity2end , ritonavir , and erythromycin ) has not been studied , increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications . 
false chemical chemical Although the interaction between entity1begin almotriptan entity1end and other potent CYP3A4 inhibitors ( e.g. , itraconazole , entity2begin ritonavir entity2end , and erythromycin ) has not been studied , increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications . 
false chemical chemical Although the interaction between entity1begin almotriptan entity1end and other potent CYP3A4 inhibitors ( e.g. , itraconazole , ritonavir , and entity2begin erythromycin entity2end ) has not been studied , increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications . 
false chemical chemical Although the interaction between entity1begin almotriptan entity1end and other potent CYP3A4 inhibitors ( e.g. , itraconazole , ritonavir , and erythromycin ) has not been studied , increased exposures to entity2begin almotriptan entity2end may be expected when almotriptan is used concomitantly with these medications . 
false chemical chemical Although the interaction between entity1begin almotriptan entity1end and other potent CYP3A4 inhibitors ( e.g. , itraconazole , ritonavir , and erythromycin ) has not been studied , increased exposures to almotriptan may be expected when entity2begin almotriptan entity2end is used concomitantly with these medications . 
false chemical chemical Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , entity1begin itraconazole entity1end , entity2begin ritonavir entity2end , and erythromycin ) has not been studied , increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications . 
false chemical chemical Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , entity1begin itraconazole entity1end , ritonavir , and entity2begin erythromycin entity2end ) has not been studied , increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications . 
false chemical chemical Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , entity1begin itraconazole entity1end , ritonavir , and erythromycin ) has not been studied , increased exposures to entity2begin almotriptan entity2end may be expected when almotriptan is used concomitantly with these medications . 
true chemical chemical Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , entity1begin itraconazole entity1end , ritonavir , and erythromycin ) has not been studied , increased exposures to almotriptan may be expected when entity2begin almotriptan entity2end is used concomitantly with these medications . 
false chemical chemical Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , itraconazole , entity1begin ritonavir entity1end , and entity2begin erythromycin entity2end ) has not been studied , increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications . 
false chemical chemical Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , itraconazole , entity1begin ritonavir entity1end , and erythromycin ) has not been studied , increased exposures to entity2begin almotriptan entity2end may be expected when almotriptan is used concomitantly with these medications . 
true chemical chemical Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , itraconazole , entity1begin ritonavir entity1end , and erythromycin ) has not been studied , increased exposures to almotriptan may be expected when entity2begin almotriptan entity2end is used concomitantly with these medications . 
false chemical chemical Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , itraconazole , ritonavir , and entity1begin erythromycin entity1end ) has not been studied , increased exposures to entity2begin almotriptan entity2end may be expected when almotriptan is used concomitantly with these medications . 
true chemical chemical Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , itraconazole , ritonavir , and entity1begin erythromycin entity1end ) has not been studied , increased exposures to almotriptan may be expected when entity2begin almotriptan entity2end is used concomitantly with these medications . 
false chemical chemical Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , itraconazole , ritonavir , and erythromycin ) has not been studied , increased exposures to entity1begin almotriptan entity1end may be expected when entity2begin almotriptan entity2end is used concomitantly with these medications . 
false chemical chemical Because entity1begin alosetron entity1end is metabolized by a variety of hepatic CYP drug - metabolizing enzymes , inducers or inhibitors of these enzymes may change the clearance of entity2begin alosetron entity2end . 
false chemical chemical In a pharmacokinetic study , 40 healthy female subjects received entity1begin fluvoxamine entity1end in escalating doses from 50 to 200 mg per day for 16 days , with coadministration of entity2begin alosetron entity2end 1 mg on the last day . 
true chemical chemical entity1begin Fluvoxamine entity1end increased mean entity2begin alosetron entity2end plasma concentrations ( AUC ) approximately 6 - fold and prolonged the half - life by approximately 3 - fold . 
true chemical chemical Concomitant administration of entity1begin alosetron entity1end and entity2begin fluvoxamine entity2end is contraindicated . 
true chemical chemical Concomitant administration of entity1begin alosetron entity1end and moderate CYP1A2 inhibitors , including entity2begin quinolone antibiotics entity2end and cimetidine , has not been evaluated , but should be avoided unless clinically necessary because of similar potential drug interactions . 
true chemical chemical Concomitant administration of entity1begin alosetron entity1end and moderate CYP1A2 inhibitors , including quinolone antibiotics and entity2begin cimetidine entity2end , has not been evaluated , but should be avoided unless clinically necessary because of similar potential drug interactions . 
false chemical chemical Concomitant administration of alosetron and moderate CYP1A2 inhibitors , including entity1begin quinolone antibiotics entity1end and entity2begin cimetidine entity2end , has not been evaluated , but should be avoided unless clinically necessary because of similar potential drug interactions . 
false chemical chemical In a pharmacokinetic study , 38 healthy female subjects received entity1begin ketoconazole entity1end 200 mg twice daily for 7 days , with coadministration of entity2begin alosetron entity2end 1 mg on the last day . 
true chemical chemical entity1begin Ketoconazole entity1end increased mean entity2begin alosetron entity2end plasma concentrations ( AUC ) by 29 % . 
true chemical chemical Caution should be used when entity1begin alosetron entity1end and entity2begin ketoconazole entity2end are administered concomitantly . 
true chemical chemical Coadministration of entity1begin alosetron entity1end and strong CYP3A4 inhibitors , such as entity2begin clarithromycin entity2end , telithromycin , protease inhibitors , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
true chemical chemical Coadministration of entity1begin alosetron entity1end and strong CYP3A4 inhibitors , such as clarithromycin , entity2begin telithromycin entity2end , protease inhibitors , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
true chemical chemical Coadministration of entity1begin alosetron entity1end and strong CYP3A4 inhibitors , such as clarithromycin , telithromycin , entity2begin protease inhibitors entity2end , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
true chemical chemical Coadministration of entity1begin alosetron entity1end and strong CYP3A4 inhibitors , such as clarithromycin , telithromycin , protease inhibitors , entity2begin voriconazole entity2end , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
true chemical chemical Coadministration of entity1begin alosetron entity1end and strong CYP3A4 inhibitors , such as clarithromycin , telithromycin , protease inhibitors , voriconazole , and entity2begin itraconazole entity2end has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
false chemical chemical Coadministration of alosetron and strong CYP3A4 inhibitors , such as entity1begin clarithromycin entity1end , entity2begin telithromycin entity2end , protease inhibitors , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
false chemical chemical Coadministration of alosetron and strong CYP3A4 inhibitors , such as entity1begin clarithromycin entity1end , telithromycin , entity2begin protease inhibitors entity2end , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
false chemical chemical Coadministration of alosetron and strong CYP3A4 inhibitors , such as entity1begin clarithromycin entity1end , telithromycin , protease inhibitors , entity2begin voriconazole entity2end , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
false chemical chemical Coadministration of alosetron and strong CYP3A4 inhibitors , such as entity1begin clarithromycin entity1end , telithromycin , protease inhibitors , voriconazole , and entity2begin itraconazole entity2end has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
false chemical chemical Coadministration of alosetron and strong CYP3A4 inhibitors , such as clarithromycin , entity1begin telithromycin entity1end , entity2begin protease inhibitors entity2end , voriconazole , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
false chemical chemical Coadministration of alosetron and strong CYP3A4 inhibitors , such as clarithromycin , entity1begin telithromycin entity1end , protease inhibitors , entity2begin voriconazole entity2end , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
false chemical chemical Coadministration of alosetron and strong CYP3A4 inhibitors , such as clarithromycin , entity1begin telithromycin entity1end , protease inhibitors , voriconazole , and entity2begin itraconazole entity2end has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
false chemical chemical Coadministration of alosetron and strong CYP3A4 inhibitors , such as clarithromycin , telithromycin , entity1begin protease inhibitors entity1end , entity2begin voriconazole entity2end , and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
false chemical chemical Coadministration of alosetron and strong CYP3A4 inhibitors , such as clarithromycin , telithromycin , entity1begin protease inhibitors entity1end , voriconazole , and entity2begin itraconazole entity2end has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
false chemical chemical Coadministration of alosetron and strong CYP3A4 inhibitors , such as clarithromycin , telithromycin , protease inhibitors , entity1begin voriconazole entity1end , and entity2begin itraconazole entity2end has not been evaluated but should be undertaken with caution because of similar potential drug interactions . 
true chemical chemical Although not studied with entity1begin alosetron entity1end , inhibition of N - acetyltransferase may have clinically relevant consequences for drugs such as entity2begin isoniazid entity2end , procainamide , and hydralazine . 
true chemical chemical Although not studied with entity1begin alosetron entity1end , inhibition of N - acetyltransferase may have clinically relevant consequences for drugs such as isoniazid , entity2begin procainamide entity2end , and hydralazine . 
true chemical chemical Although not studied with entity1begin alosetron entity1end , inhibition of N - acetyltransferase may have clinically relevant consequences for drugs such as isoniazid , procainamide , and entity2begin hydralazine entity2end . 
false chemical chemical Although not studied with alosetron , inhibition of N - acetyltransferase may have clinically relevant consequences for drugs such as entity1begin isoniazid entity1end , entity2begin procainamide entity2end , and hydralazine . 
false chemical chemical Although not studied with alosetron , inhibition of N - acetyltransferase may have clinically relevant consequences for drugs such as entity1begin isoniazid entity1end , procainamide , and entity2begin hydralazine entity2end . 
false chemical chemical Although not studied with alosetron , inhibition of N - acetyltransferase may have clinically relevant consequences for drugs such as isoniazid , entity1begin procainamide entity1end , and entity2begin hydralazine entity2end . 
false chemical chemical Another study showed that entity1begin alosetron entity1end had no clinically significant effect on plasma concentrations of the oral entity2begin contraceptive agents entity2end ethinyl estradiol and levonorgestrel ( CYP3A4 substrates ) . 
false chemical chemical Another study showed that entity1begin alosetron entity1end had no clinically significant effect on plasma concentrations of the oral contraceptive agents entity2begin ethinyl estradiol entity2end and levonorgestrel ( CYP3A4 substrates ) . 
false chemical chemical Another study showed that entity1begin alosetron entity1end had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and entity2begin levonorgestrel entity2end ( CYP3A4 substrates ) . 
false chemical chemical Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral entity1begin contraceptive agents entity1end entity2begin ethinyl estradiol entity2end and levonorgestrel ( CYP3A4 substrates ) . 
false chemical chemical Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral entity1begin contraceptive agents entity1end ethinyl estradiol and entity2begin levonorgestrel entity2end ( CYP3A4 substrates ) . 
false chemical chemical Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents entity1begin ethinyl estradiol entity1end and entity2begin levonorgestrel entity2end ( CYP3A4 substrates ) . 
false chemical chemical A clinical interaction study was also conducted with entity1begin alosetron entity1end and the CYP3A4 substrate entity2begin cisapride entity2end . 
false chemical chemical The entity1begin benzodiazepines entity1end , including entity2begin alprazolam entity2end , produce additive CNS depressant effects when co - administered with other psychotropic medications , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression . 
true chemical chemical The entity1begin benzodiazepines entity1end , including alprazolam , produce additive CNS depressant effects when co - administered with other entity2begin psychotropic medications entity2end , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression . 
true chemical chemical The entity1begin benzodiazepines entity1end , including alprazolam , produce additive CNS depressant effects when co - administered with other psychotropic medications , entity2begin anticonvulsants entity2end , antihistaminics , ethanol , and other drugs which themselves produce CNS depression . 
true chemical chemical The entity1begin benzodiazepines entity1end , including alprazolam , produce additive CNS depressant effects when co - administered with other psychotropic medications , anticonvulsants , entity2begin antihistaminics entity2end , ethanol , and other drugs which themselves produce CNS depression . 
true chemical chemical The entity1begin benzodiazepines entity1end , including alprazolam , produce additive CNS depressant effects when co - administered with other psychotropic medications , anticonvulsants , antihistaminics , entity2begin ethanol entity2end , and other drugs which themselves produce CNS depression . 
true chemical chemical The benzodiazepines , including entity1begin alprazolam entity1end , produce additive CNS depressant effects when co - administered with other entity2begin psychotropic medications entity2end , anticonvulsants , antihistaminics , ethanol , and other drugs which themselves produce CNS depression . 
true chemical chemical The benzodiazepines , including entity1begin alprazolam entity1end , produce additive CNS depressant effects when co - administered with other psychotropic medications , entity2begin anticonvulsants entity2end , antihistaminics , ethanol , and other drugs which themselves produce CNS depression . 
true chemical chemical The benzodiazepines , including entity1begin alprazolam entity1end , produce additive CNS depressant effects when co - administered with other psychotropic medications , anticonvulsants , entity2begin antihistaminics entity2end , ethanol , and other drugs which themselves produce CNS depression . 
true chemical chemical The benzodiazepines , including entity1begin alprazolam entity1end , produce additive CNS depressant effects when co - administered with other psychotropic medications , anticonvulsants , antihistaminics , entity2begin ethanol entity2end , and other drugs which themselves produce CNS depression . 
false chemical chemical The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co - administered with other entity1begin psychotropic medications entity1end , entity2begin anticonvulsants entity2end , antihistaminics , ethanol , and other drugs which themselves produce CNS depression . 
false chemical chemical The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co - administered with other entity1begin psychotropic medications entity1end , anticonvulsants , entity2begin antihistaminics entity2end , ethanol , and other drugs which themselves produce CNS depression . 
false chemical chemical The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co - administered with other entity1begin psychotropic medications entity1end , anticonvulsants , antihistaminics , entity2begin ethanol entity2end , and other drugs which themselves produce CNS depression . 
false chemical chemical The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co - administered with other psychotropic medications , entity1begin anticonvulsants entity1end , entity2begin antihistaminics entity2end , ethanol , and other drugs which themselves produce CNS depression . 
false chemical chemical The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co - administered with other psychotropic medications , entity1begin anticonvulsants entity1end , antihistaminics , entity2begin ethanol entity2end , and other drugs which themselves produce CNS depression . 
false chemical chemical The benzodiazepines , including alprazolam , produce additive CNS depressant effects when co - administered with other psychotropic medications , anticonvulsants , entity1begin antihistaminics entity1end , entity2begin ethanol entity2end , and other drugs which themselves produce CNS depression . 
false chemical chemical The steady state plasma concentrations of entity1begin imipramine entity1end and entity2begin desipramine entity2end have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of alprazolam tablets in doses up to 4 mg / day . 
true chemical chemical The steady state plasma concentrations of entity1begin imipramine entity1end and desipramine have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of entity2begin alprazolam entity2end tablets in doses up to 4 mg / day . 
true chemical chemical The steady state plasma concentrations of imipramine and entity1begin desipramine entity1end have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of entity2begin alprazolam entity2end tablets in doses up to 4 mg / day . 
false chemical chemical Drugs That Inhibit entity1begin Alprazolam entity1end Metabolism Via Cytochrome P450 3A : The initial step in entity2begin alprazolam entity2end metabolism is hydroxylation catalyzed by cytochrome P450 3A ( CYP 3A ) . 
false chemical chemical Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving entity1begin Alprazolam entity1end ( caution is recommended during coadministration with entity2begin alprazolam entity2end ) : Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half - life by 17 % , and decreased measured psychomotor performance . 
false chemical chemical Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving entity1begin Alprazolam entity1end ( caution is recommended during coadministration with alprazolam ) : Coadministration of entity2begin fluoxetine entity2end with alprazolam increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half - life by 17 % , and decreased measured psychomotor performance . 
false chemical chemical Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving entity1begin Alprazolam entity1end ( caution is recommended during coadministration with alprazolam ) : Coadministration of fluoxetine with entity2begin alprazolam entity2end increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half - life by 17 % , and decreased measured psychomotor performance . 
false chemical chemical Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving entity1begin Alprazolam entity1end ( caution is recommended during coadministration with alprazolam ) : Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of entity2begin alprazolam entity2end by 46 % , decreased clearance by 21 % , increased half - life by 17 % , and decreased measured psychomotor performance . 
false chemical chemical Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam ( caution is recommended during coadministration with entity1begin alprazolam entity1end ) : Coadministration of entity2begin fluoxetine entity2end with alprazolam increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half - life by 17 % , and decreased measured psychomotor performance . 
false chemical chemical Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam ( caution is recommended during coadministration with entity1begin alprazolam entity1end ) : Coadministration of fluoxetine with entity2begin alprazolam entity2end increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half - life by 17 % , and decreased measured psychomotor performance . 
false chemical chemical Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam ( caution is recommended during coadministration with entity1begin alprazolam entity1end ) : Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of entity2begin alprazolam entity2end by 46 % , decreased clearance by 21 % , increased half - life by 17 % , and decreased measured psychomotor performance . 
true chemical chemical Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam ( caution is recommended during coadministration with alprazolam ) : Coadministration of entity1begin fluoxetine entity1end with entity2begin alprazolam entity2end increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half - life by 17 % , and decreased measured psychomotor performance . 
false chemical chemical Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam ( caution is recommended during coadministration with alprazolam ) : Coadministration of entity1begin fluoxetine entity1end with alprazolam increased the maximum plasma concentration of entity2begin alprazolam entity2end by 46 % , decreased clearance by 21 % , increased half - life by 17 % , and decreased measured psychomotor performance . 
false chemical chemical Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam ( caution is recommended during coadministration with alprazolam ) : Coadministration of fluoxetine with entity1begin alprazolam entity1end increased the maximum plasma concentration of entity2begin alprazolam entity2end by 46 % , decreased clearance by 21 % , increased half - life by 17 % , and decreased measured psychomotor performance . 
true chemical chemical Coadministration of entity1begin propoxyphene entity1end decreased the maximum plasma concentration of entity2begin alprazolam entity2end by 6 % , decreased clearance by 38 % , and increased half - life by 58 % . 
true chemical chemical Coadministration of oral entity1begin contraceptives entity1end increased the maximum plasma concentration of entity2begin alprazolam entity2end by 18 % , decreased clearance by 22 % , and increased half - life by 29 % . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving entity1begin benzodiazepines entity1end metabolized similarly to entity2begin alprazolam entity2end or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving entity1begin benzodiazepines entity1end metabolized similarly to alprazolam or on the basis of in vitro studies with entity2begin alprazolam entity2end or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving entity1begin benzodiazepines entity1end metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other entity2begin benzodiazepines entity2end ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving entity1begin benzodiazepines entity1end metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with entity2begin alprazolam entity2end ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving entity1begin benzodiazepines entity1end metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of entity2begin benzodiazepines entity2end other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving entity1begin benzodiazepines entity1end metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than entity2begin alprazolam entity2end suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving entity1begin benzodiazepines entity1end metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with entity2begin alprazolam entity2end for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving entity1begin benzodiazepines entity1end metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : entity2begin diltiazem entity2end , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving entity1begin benzodiazepines entity1end metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , entity2begin isoniazid entity2end , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving entity1begin benzodiazepines entity1end metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , entity2begin macrolide antibiotics entity2end such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving entity1begin benzodiazepines entity1end metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as entity2begin erythromycin entity2end and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving entity1begin benzodiazepines entity1end metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and entity2begin clarithromycin entity2end , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to entity1begin alprazolam entity1end or on the basis of in vitro studies with entity2begin alprazolam entity2end or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to entity1begin alprazolam entity1end or on the basis of in vitro studies with alprazolam or other entity2begin benzodiazepines entity2end ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to entity1begin alprazolam entity1end or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with entity2begin alprazolam entity2end ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to entity1begin alprazolam entity1end or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of entity2begin benzodiazepines entity2end other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to entity1begin alprazolam entity1end or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than entity2begin alprazolam entity2end suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to entity1begin alprazolam entity1end or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with entity2begin alprazolam entity2end for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to entity1begin alprazolam entity1end or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : entity2begin diltiazem entity2end , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to entity1begin alprazolam entity1end or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , entity2begin isoniazid entity2end , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to entity1begin alprazolam entity1end or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , entity2begin macrolide antibiotics entity2end such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to entity1begin alprazolam entity1end or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as entity2begin erythromycin entity2end and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to entity1begin alprazolam entity1end or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and entity2begin clarithromycin entity2end , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with entity1begin alprazolam entity1end or other entity2begin benzodiazepines entity2end ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with entity1begin alprazolam entity1end or other benzodiazepines ( caution is recommended during coadministration with entity2begin alprazolam entity2end ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with entity1begin alprazolam entity1end or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of entity2begin benzodiazepines entity2end other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with entity1begin alprazolam entity1end or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than entity2begin alprazolam entity2end suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with entity1begin alprazolam entity1end or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with entity2begin alprazolam entity2end for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with entity1begin alprazolam entity1end or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : entity2begin diltiazem entity2end , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with entity1begin alprazolam entity1end or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , entity2begin isoniazid entity2end , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with entity1begin alprazolam entity1end or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , entity2begin macrolide antibiotics entity2end such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with entity1begin alprazolam entity1end or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as entity2begin erythromycin entity2end and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with entity1begin alprazolam entity1end or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and entity2begin clarithromycin entity2end , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other entity1begin benzodiazepines entity1end ( caution is recommended during coadministration with entity2begin alprazolam entity2end ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other entity1begin benzodiazepines entity1end ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of entity2begin benzodiazepines entity2end other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other entity1begin benzodiazepines entity1end ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than entity2begin alprazolam entity2end suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other entity1begin benzodiazepines entity1end ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with entity2begin alprazolam entity2end for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other entity1begin benzodiazepines entity1end ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : entity2begin diltiazem entity2end , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other entity1begin benzodiazepines entity1end ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , entity2begin isoniazid entity2end , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other entity1begin benzodiazepines entity1end ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , entity2begin macrolide antibiotics entity2end such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other entity1begin benzodiazepines entity1end ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as entity2begin erythromycin entity2end and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other entity1begin benzodiazepines entity1end ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and entity2begin clarithromycin entity2end , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with entity1begin alprazolam entity1end ) : Available data from clinical studies of entity2begin benzodiazepines entity2end other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with entity1begin alprazolam entity1end ) : Available data from clinical studies of benzodiazepines other than entity2begin alprazolam entity2end suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with entity1begin alprazolam entity1end ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with entity2begin alprazolam entity2end for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with entity1begin alprazolam entity1end ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : entity2begin diltiazem entity2end , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with entity1begin alprazolam entity1end ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , entity2begin isoniazid entity2end , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with entity1begin alprazolam entity1end ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , entity2begin macrolide antibiotics entity2end such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with entity1begin alprazolam entity1end ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as entity2begin erythromycin entity2end and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with entity1begin alprazolam entity1end ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and entity2begin clarithromycin entity2end , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of entity1begin benzodiazepines entity1end other than entity2begin alprazolam entity2end suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of entity1begin benzodiazepines entity1end other than alprazolam suggest a possible drug interaction with entity2begin alprazolam entity2end for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of entity1begin benzodiazepines entity1end other than alprazolam suggest a possible drug interaction with alprazolam for the following : entity2begin diltiazem entity2end , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of entity1begin benzodiazepines entity1end other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , entity2begin isoniazid entity2end , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of entity1begin benzodiazepines entity1end other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , entity2begin macrolide antibiotics entity2end such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of entity1begin benzodiazepines entity1end other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as entity2begin erythromycin entity2end and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of entity1begin benzodiazepines entity1end other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and entity2begin clarithromycin entity2end , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than entity1begin alprazolam entity1end suggest a possible drug interaction with entity2begin alprazolam entity2end for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than entity1begin alprazolam entity1end suggest a possible drug interaction with alprazolam for the following : entity2begin diltiazem entity2end , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than entity1begin alprazolam entity1end suggest a possible drug interaction with alprazolam for the following : diltiazem , entity2begin isoniazid entity2end , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than entity1begin alprazolam entity1end suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , entity2begin macrolide antibiotics entity2end such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than entity1begin alprazolam entity1end suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as entity2begin erythromycin entity2end and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than entity1begin alprazolam entity1end suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and entity2begin clarithromycin entity2end , and grapefruit juice . 
true chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with entity1begin alprazolam entity1end for the following : entity2begin diltiazem entity2end , isoniazid , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
true chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with entity1begin alprazolam entity1end for the following : diltiazem , entity2begin isoniazid entity2end , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
true chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with entity1begin alprazolam entity1end for the following : diltiazem , isoniazid , entity2begin macrolide antibiotics entity2end such as erythromycin and clarithromycin , and grapefruit juice . 
true chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with entity1begin alprazolam entity1end for the following : diltiazem , isoniazid , macrolide antibiotics such as entity2begin erythromycin entity2end and clarithromycin , and grapefruit juice . 
true chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with entity1begin alprazolam entity1end for the following : diltiazem , isoniazid , macrolide antibiotics such as erythromycin and entity2begin clarithromycin entity2end , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : entity1begin diltiazem entity1end , entity2begin isoniazid entity2end , macrolide antibiotics such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : entity1begin diltiazem entity1end , isoniazid , entity2begin macrolide antibiotics entity2end such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : entity1begin diltiazem entity1end , isoniazid , macrolide antibiotics such as entity2begin erythromycin entity2end and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : entity1begin diltiazem entity1end , isoniazid , macrolide antibiotics such as erythromycin and entity2begin clarithromycin entity2end , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , entity1begin isoniazid entity1end , entity2begin macrolide antibiotics entity2end such as erythromycin and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , entity1begin isoniazid entity1end , macrolide antibiotics such as entity2begin erythromycin entity2end and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , entity1begin isoniazid entity1end , macrolide antibiotics such as erythromycin and entity2begin clarithromycin entity2end , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , entity1begin macrolide antibiotics entity1end such as entity2begin erythromycin entity2end and clarithromycin , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , entity1begin macrolide antibiotics entity1end such as erythromycin and entity2begin clarithromycin entity2end , and grapefruit juice . 
false chemical chemical Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines ( caution is recommended during coadministration with alprazolam ) : Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following : diltiazem , isoniazid , macrolide antibiotics such as entity1begin erythromycin entity1end and entity2begin clarithromycin entity2end , and grapefruit juice . 
false chemical chemical Data from in vitro studies of entity1begin alprazolam entity1end suggest a possible drug interaction with entity2begin alprazolam entity2end for the following : sertraline and paroxetine . 
false chemical chemical Data from in vitro studies of entity1begin alprazolam entity1end suggest a possible drug interaction with alprazolam for the following : entity2begin sertraline entity2end and paroxetine . 
false chemical chemical Data from in vitro studies of entity1begin alprazolam entity1end suggest a possible drug interaction with alprazolam for the following : sertraline and entity2begin paroxetine entity2end . 
true chemical chemical Data from in vitro studies of alprazolam suggest a possible drug interaction with entity1begin alprazolam entity1end for the following : entity2begin sertraline entity2end and paroxetine . 
true chemical chemical Data from in vitro studies of alprazolam suggest a possible drug interaction with entity1begin alprazolam entity1end for the following : sertraline and entity2begin paroxetine entity2end . 
false chemical chemical Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following : entity1begin sertraline entity1end and entity2begin paroxetine entity2end . 
false chemical chemical Data from in vitro studies of entity1begin benzodiazepines entity1end other than entity2begin alprazolam entity2end suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , nicardipine , and nifedipine . 
true chemical chemical Data from in vitro studies of entity1begin benzodiazepines entity1end other than alprazolam suggest a possible drug interaction for the following : entity2begin ergotamine entity2end , cyclosporine , amiodarone , nicardipine , and nifedipine . 
true chemical chemical Data from in vitro studies of entity1begin benzodiazepines entity1end other than alprazolam suggest a possible drug interaction for the following : ergotamine , entity2begin cyclosporine entity2end , amiodarone , nicardipine , and nifedipine . 
true chemical chemical Data from in vitro studies of entity1begin benzodiazepines entity1end other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , entity2begin amiodarone entity2end , nicardipine , and nifedipine . 
true chemical chemical Data from in vitro studies of entity1begin benzodiazepines entity1end other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , entity2begin nicardipine entity2end , and nifedipine . 
true chemical chemical Data from in vitro studies of entity1begin benzodiazepines entity1end other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , nicardipine , and entity2begin nifedipine entity2end . 
true chemical chemical Data from in vitro studies of benzodiazepines other than entity1begin alprazolam entity1end suggest a possible drug interaction for the following : entity2begin ergotamine entity2end , cyclosporine , amiodarone , nicardipine , and nifedipine . 
true chemical chemical Data from in vitro studies of benzodiazepines other than entity1begin alprazolam entity1end suggest a possible drug interaction for the following : ergotamine , entity2begin cyclosporine entity2end , amiodarone , nicardipine , and nifedipine . 
true chemical chemical Data from in vitro studies of benzodiazepines other than entity1begin alprazolam entity1end suggest a possible drug interaction for the following : ergotamine , cyclosporine , entity2begin amiodarone entity2end , nicardipine , and nifedipine . 
true chemical chemical Data from in vitro studies of benzodiazepines other than entity1begin alprazolam entity1end suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , entity2begin nicardipine entity2end , and nifedipine . 
true chemical chemical Data from in vitro studies of benzodiazepines other than entity1begin alprazolam entity1end suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , nicardipine , and entity2begin nifedipine entity2end . 
false chemical chemical Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : entity1begin ergotamine entity1end , entity2begin cyclosporine entity2end , amiodarone , nicardipine , and nifedipine . 
false chemical chemical Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : entity1begin ergotamine entity1end , cyclosporine , entity2begin amiodarone entity2end , nicardipine , and nifedipine . 
false chemical chemical Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : entity1begin ergotamine entity1end , cyclosporine , amiodarone , entity2begin nicardipine entity2end , and nifedipine . 
false chemical chemical Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : entity1begin ergotamine entity1end , cyclosporine , amiodarone , nicardipine , and entity2begin nifedipine entity2end . 
false chemical chemical Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , entity1begin cyclosporine entity1end , entity2begin amiodarone entity2end , nicardipine , and nifedipine . 
false chemical chemical Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , entity1begin cyclosporine entity1end , amiodarone , entity2begin nicardipine entity2end , and nifedipine . 
false chemical chemical Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , entity1begin cyclosporine entity1end , amiodarone , nicardipine , and entity2begin nifedipine entity2end . 
false chemical chemical Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , entity1begin amiodarone entity1end , entity2begin nicardipine entity2end , and nifedipine . 
false chemical chemical Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , entity1begin amiodarone entity1end , nicardipine , and entity2begin nifedipine entity2end . 
false chemical chemical Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , entity1begin nicardipine entity1end , and entity2begin nifedipine entity2end . 
false chemical chemical Standard therapy includes entity1begin antibiotics entity1end , such as entity2begin penicillin entity2end and gentamicin ; 
false chemical chemical Standard therapy includes entity1begin antibiotics entity1end , such as penicillin and entity2begin gentamicin entity2end ; 
false chemical chemical Standard therapy includes antibiotics , such as entity1begin penicillin entity1end and entity2begin gentamicin entity2end ; 
false chemical chemical entity1begin vasopressors entity1end , such as entity2begin dopamine entity2end and isoproterenol ; 
false chemical chemical entity1begin vasopressors entity1end , such as dopamine and entity2begin isoproterenol entity2end ; 
false chemical chemical vasopressors , such as entity1begin dopamine entity1end and entity2begin isoproterenol entity2end ; 
false chemical chemical and entity1begin diuretics entity1end , such as entity2begin furosemide entity2end . 
false chemical chemical entity1begin Caverject entity1end : The potential for pharmacokinetic drug - drug interactions between entity2begin alprostadil entity2end and other agents has not been formally studied . 
false chemical chemical In addition to bleeding associated with entity1begin heparin entity1end and entity2begin vitamin K antagonists entity2end , drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to , during , or after Activase therapy . 
false chemical chemical In addition to bleeding associated with entity1begin heparin entity1end and vitamin K antagonists , drugs that alter platelet function ( such as entity2begin acetylsalicylic acid entity2end , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to , during , or after Activase therapy . 
false chemical chemical In addition to bleeding associated with entity1begin heparin entity1end and vitamin K antagonists , drugs that alter platelet function ( such as acetylsalicylic acid , entity2begin dipyridamole entity2end and Abciximab ) may increase the risk of bleeding if administered prior to , during , or after Activase therapy . 
false chemical chemical In addition to bleeding associated with entity1begin heparin entity1end and vitamin K antagonists , drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole and entity2begin Abciximab entity2end ) may increase the risk of bleeding if administered prior to , during , or after Activase therapy . 
true chemical chemical In addition to bleeding associated with entity1begin heparin entity1end and vitamin K antagonists , drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to , during , or after entity2begin Activase entity2end therapy . 
false chemical chemical In addition to bleeding associated with heparin and entity1begin vitamin K antagonists entity1end , drugs that alter platelet function ( such as entity2begin acetylsalicylic acid entity2end , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to , during , or after Activase therapy . 
false chemical chemical In addition to bleeding associated with heparin and entity1begin vitamin K antagonists entity1end , drugs that alter platelet function ( such as acetylsalicylic acid , entity2begin dipyridamole entity2end and Abciximab ) may increase the risk of bleeding if administered prior to , during , or after Activase therapy . 
false chemical chemical In addition to bleeding associated with heparin and entity1begin vitamin K antagonists entity1end , drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole and entity2begin Abciximab entity2end ) may increase the risk of bleeding if administered prior to , during , or after Activase therapy . 
true chemical chemical In addition to bleeding associated with heparin and entity1begin vitamin K antagonists entity1end , drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to , during , or after entity2begin Activase entity2end therapy . 
false chemical chemical In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function ( such as entity1begin acetylsalicylic acid entity1end , entity2begin dipyridamole entity2end and Abciximab ) may increase the risk of bleeding if administered prior to , during , or after Activase therapy . 
false chemical chemical In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function ( such as entity1begin acetylsalicylic acid entity1end , dipyridamole and entity2begin Abciximab entity2end ) may increase the risk of bleeding if administered prior to , during , or after Activase therapy . 
true chemical chemical In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function ( such as entity1begin acetylsalicylic acid entity1end , dipyridamole and Abciximab ) may increase the risk of bleeding if administered prior to , during , or after entity2begin Activase entity2end therapy . 
false chemical chemical In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function ( such as acetylsalicylic acid , entity1begin dipyridamole entity1end and entity2begin Abciximab entity2end ) may increase the risk of bleeding if administered prior to , during , or after Activase therapy . 
true chemical chemical In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function ( such as acetylsalicylic acid , entity1begin dipyridamole entity1end and Abciximab ) may increase the risk of bleeding if administered prior to , during , or after entity2begin Activase entity2end therapy . 
true chemical chemical In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole and entity1begin Abciximab entity1end ) may increase the risk of bleeding if administered prior to , during , or after entity2begin Activase entity2end therapy . 
false chemical chemical Use of entity1begin Antithrombotics entity1end entity2begin Aspirin entity2end and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism . 
false chemical chemical Use of entity1begin Antithrombotics entity1end Aspirin and entity2begin heparin entity2end have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism . 
false chemical chemical Use of entity1begin Antithrombotics entity1end Aspirin and heparin have been administered concomitantly with and following infusions of entity2begin Activase entity2end in the management of acute myocardial infarction or pulmonary embolism . 
false chemical chemical Use of Antithrombotics entity1begin Aspirin entity1end and entity2begin heparin entity2end have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism . 
false chemical chemical Use of Antithrombotics entity1begin Aspirin entity1end and heparin have been administered concomitantly with and following infusions of entity2begin Activase entity2end in the management of acute myocardial infarction or pulmonary embolism . 
false chemical chemical Use of Antithrombotics Aspirin and entity1begin heparin entity1end have been administered concomitantly with and following infusions of entity2begin Activase entity2end in the management of acute myocardial infarction or pulmonary embolism . 
false chemical chemical Because entity1begin heparin entity1end , entity2begin aspirin entity2end , or Activase may cause bleeding complications , careful monitoring for bleeding is advised , especially at arterial puncture sites . 
false chemical chemical Because entity1begin heparin entity1end , aspirin , or entity2begin Activase entity2end may cause bleeding complications , careful monitoring for bleeding is advised , especially at arterial puncture sites . 
false chemical chemical Because heparin , entity1begin aspirin entity1end , or entity2begin Activase entity2end may cause bleeding complications , careful monitoring for bleeding is advised , especially at arterial puncture sites . 
false chemical chemical The concomitant use of entity1begin heparin entity1end or entity2begin aspirin entity2end during the first 24 hours following symptom onset were prohibited in The NINDS t - PA Stroke Trial . 
true chemical chemical Concurrent administration of entity1begin HEXALEN entity1end and entity2begin antidepressants of the MAO inhibitor class entity2end may cause severe orthostatic hypotension.Cimetidine , an inhibitor of microsomal drug metabolism , increased altretamines half - life and toxicity in a rat model . 
false chemical chemical Concurrent administration of entity1begin HEXALEN entity1end and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension. entity2begin Cimetidine entity2end , an inhibitor of microsomal drug metabolism , increased altretamines half - life and toxicity in a rat model . 
false chemical chemical Concurrent administration of entity1begin HEXALEN entity1end and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine , an inhibitor of microsomal drug metabolism , increased entity2begin altretamine entity2end s half - life and toxicity in a rat model . 
false chemical chemical Concurrent administration of HEXALEN and entity1begin antidepressants of the MAO inhibitor class entity1end may cause severe orthostatic hypotension. entity2begin Cimetidine entity2end , an inhibitor of microsomal drug metabolism , increased altretamines half - life and toxicity in a rat model . 
false chemical chemical Concurrent administration of HEXALEN and entity1begin antidepressants of the MAO inhibitor class entity1end may cause severe orthostatic hypotension.Cimetidine , an inhibitor of microsomal drug metabolism , increased entity2begin altretamine entity2end s half - life and toxicity in a rat model . 
true chemical chemical Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension. entity1begin Cimetidine entity1end , an inhibitor of microsomal drug metabolism , increased entity2begin altretamine entity2end s half - life and toxicity in a rat model . 
true chemical chemical Data from a randomized trial of entity1begin HEXALEN entity1end and entity2begin cisplatin entity2end plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity ; 
false chemical chemical Data from a randomized trial of entity1begin HEXALEN entity1end and cisplatin plus or minus entity2begin pyridoxine entity2end in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity ; 
false chemical chemical Data from a randomized trial of entity1begin HEXALEN entity1end and cisplatin plus or minus pyridoxine in ovarian cancer indicated that entity2begin pyridoxine entity2end significantly reduced neurotoxicity ; 
false chemical chemical Data from a randomized trial of HEXALEN and entity1begin cisplatin entity1end plus or minus entity2begin pyridoxine entity2end in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity ; 
false chemical chemical Data from a randomized trial of HEXALEN and entity1begin cisplatin entity1end plus or minus pyridoxine in ovarian cancer indicated that entity2begin pyridoxine entity2end significantly reduced neurotoxicity ; 
false chemical chemical Data from a randomized trial of HEXALEN and cisplatin plus or minus entity1begin pyridoxine entity1end in ovarian cancer indicated that entity2begin pyridoxine entity2end significantly reduced neurotoxicity ; 
true chemical chemical however , it adversely affected response duration suggesting that entity1begin pyridoxine entity1end should not be administered with entity2begin HEXALEN entity2end and / or cisplatin.1 
true chemical chemical however , it adversely affected response duration suggesting that entity1begin pyridoxine entity1end should not be administered with HEXALEN and / or entity2begin cisplatin entity2end .1 
false chemical chemical however , it adversely affected response duration suggesting that pyridoxine should not be administered with entity1begin HEXALEN entity1end and / or entity2begin cisplatin entity2end .1 
true chemical chemical Careful observation is required when entity1begin amantadine entity1end is administered concurrently with entity2begin central nervous system stimulants entity2end . 
true chemical chemical Special consideration should be given to the administration of entity1begin ETHYOL entity1end in patients receiving entity2begin antihypertensive medications entity2end or other drugs that could cause or potentiate hypotension . 
true chemical chemical When entity1begin amiloride entity1end HCl is administered concomitantly with an entity2begin angiotensin - converting enzyme inhibitor entity2end , the risk of hyperkalemia may be increased . 
true chemical chemical entity1begin Lithium entity1end generally should not be given with entity2begin diuretics entity2end because they reduce its renal clearance and add a high risk of lithium toxicity . 
true chemical chemical In some patients , the administration of a entity1begin non - steroidal anti - inflammatory agent entity1end can reduce the diuretic , natriuretic , and antihypertensive effects of loop , potassium - sparing and entity2begin thiazide diuretics entity2end . 
true chemical chemical Therefore , when entity1begin MIDAMOR entity1end and entity2begin non - steroidal anti - inflammatory agents entity2end are used concomitantly , the patient should be observed closely to determine if the desired effect of the diuretic is obtained . 
false chemical chemical Therefore , when entity1begin MIDAMOR entity1end and non - steroidal anti - inflammatory agents are used concomitantly , the patient should be observed closely to determine if the desired effect of the entity2begin diuretic entity2end is obtained . 
false chemical chemical Therefore , when MIDAMOR and entity1begin non - steroidal anti - inflammatory agents entity1end are used concomitantly , the patient should be observed closely to determine if the desired effect of the entity2begin diuretic entity2end is obtained . 
true chemical chemical Since entity1begin indomethacin entity1end and entity2begin potassium - sparing diuretics entity2end , including MIDAMOR , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently . 
true chemical chemical Since entity1begin indomethacin entity1end and potassium - sparing diuretics , including entity2begin MIDAMOR entity2end , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently . 
false chemical chemical Since indomethacin and entity1begin potassium - sparing diuretics entity1end , including entity2begin MIDAMOR entity2end , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently . 
true chemical chemical entity1begin Cytadren entity1end accelerates the metabolism of entity2begin dexamethasone entity2end ; 
false chemical chemical therefore , if entity1begin glucocorticoid entity1end replacement is needed , entity2begin hydrocortisone entity2end should be prescribed . 
true chemical chemical entity1begin Aminoglutethimide entity1end diminishes the effect of entity2begin coumarin entity2end and warfarin . 
true chemical chemical entity1begin Aminoglutethimide entity1end diminishes the effect of coumarin and entity2begin warfarin entity2end . 
false chemical chemical Aminoglutethimide diminishes the effect of entity1begin coumarin entity1end and entity2begin warfarin entity2end . 
true chemical chemical Renal clearance measurements of entity1begin PAH entity1end cannot be made with any significant accuracy in patients receiving entity2begin sulfonamides entity2end , procaine , or thiazolesulfone . 
true chemical chemical Renal clearance measurements of entity1begin PAH entity1end cannot be made with any significant accuracy in patients receiving sulfonamides , entity2begin procaine entity2end , or thiazolesulfone . 
true chemical chemical Renal clearance measurements of entity1begin PAH entity1end cannot be made with any significant accuracy in patients receiving sulfonamides , procaine , or entity2begin thiazolesulfone entity2end . 
false chemical chemical Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving entity1begin sulfonamides entity1end , entity2begin procaine entity2end , or thiazolesulfone . 
false chemical chemical Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving entity1begin sulfonamides entity1end , procaine , or entity2begin thiazolesulfone entity2end . 
false chemical chemical Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides , entity1begin procaine entity1end , or entity2begin thiazolesulfone entity2end . 
true chemical chemical entity1begin Probenecid entity1end depresses tubular secretion of certain weak acids such as entity2begin PAH entity2end . 
true chemical chemical Therefore , patients receiving entity1begin probenecid entity1end will have erroneously low ERPF and Tm entity2begin PAH entity2end values . 
false chemical chemical It is , however , possible that concomitant use of other known entity1begin photosensitizing agents entity1end such as entity2begin griseofulvin entity2end , thiazide diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known entity1begin photosensitizing agents entity1end such as griseofulvin , entity2begin thiazide diuretics entity2end , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known entity1begin photosensitizing agents entity1end such as griseofulvin , thiazide diuretics , entity2begin sulfonylureas entity2end , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known entity1begin photosensitizing agents entity1end such as griseofulvin , thiazide diuretics , sulfonylureas , entity2begin phenothiazines entity2end , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known entity1begin photosensitizing agents entity1end such as griseofulvin , thiazide diuretics , sulfonylureas , phenothiazines , entity2begin sulfonamides entity2end and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known entity1begin photosensitizing agents entity1end such as griseofulvin , thiazide diuretics , sulfonylureas , phenothiazines , sulfonamides and entity2begin tetracyclines entity2end might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
true chemical chemical It is , however , possible that concomitant use of other known entity1begin photosensitizing agents entity1end such as griseofulvin , thiazide diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the entity2begin LEVULAN KERASTICK entity2end for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as entity1begin griseofulvin entity1end , entity2begin thiazide diuretics entity2end , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as entity1begin griseofulvin entity1end , thiazide diuretics , entity2begin sulfonylureas entity2end , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as entity1begin griseofulvin entity1end , thiazide diuretics , sulfonylureas , entity2begin phenothiazines entity2end , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as entity1begin griseofulvin entity1end , thiazide diuretics , sulfonylureas , phenothiazines , entity2begin sulfonamides entity2end and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as entity1begin griseofulvin entity1end , thiazide diuretics , sulfonylureas , phenothiazines , sulfonamides and entity2begin tetracyclines entity2end might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
true chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as entity1begin griseofulvin entity1end , thiazide diuretics , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the entity2begin LEVULAN KERASTICK entity2end for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , entity1begin thiazide diuretics entity1end , entity2begin sulfonylureas entity2end , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , entity1begin thiazide diuretics entity1end , sulfonylureas , entity2begin phenothiazines entity2end , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , entity1begin thiazide diuretics entity1end , sulfonylureas , phenothiazines , entity2begin sulfonamides entity2end and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , entity1begin thiazide diuretics entity1end , sulfonylureas , phenothiazines , sulfonamides and entity2begin tetracyclines entity2end might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
true chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , entity1begin thiazide diuretics entity1end , sulfonylureas , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the entity2begin LEVULAN KERASTICK entity2end for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , thiazide diuretics , entity1begin sulfonylureas entity1end , entity2begin phenothiazines entity2end , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , thiazide diuretics , entity1begin sulfonylureas entity1end , phenothiazines , entity2begin sulfonamides entity2end and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , thiazide diuretics , entity1begin sulfonylureas entity1end , phenothiazines , sulfonamides and entity2begin tetracyclines entity2end might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
true chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , thiazide diuretics , entity1begin sulfonylureas entity1end , phenothiazines , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the entity2begin LEVULAN KERASTICK entity2end for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , thiazide diuretics , sulfonylureas , entity1begin phenothiazines entity1end , entity2begin sulfonamides entity2end and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , thiazide diuretics , sulfonylureas , entity1begin phenothiazines entity1end , sulfonamides and entity2begin tetracyclines entity2end might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
true chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , thiazide diuretics , sulfonylureas , entity1begin phenothiazines entity1end , sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the entity2begin LEVULAN KERASTICK entity2end for Topical Solution . 
false chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , thiazide diuretics , sulfonylureas , phenothiazines , entity1begin sulfonamides entity1end and entity2begin tetracyclines entity2end might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution . 
true chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , thiazide diuretics , sulfonylureas , phenothiazines , entity1begin sulfonamides entity1end and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the entity2begin LEVULAN KERASTICK entity2end for Topical Solution . 
true chemical chemical It is , however , possible that concomitant use of other known photosensitizing agents such as griseofulvin , thiazide diuretics , sulfonylureas , phenothiazines , sulfonamides and entity1begin tetracyclines entity1end might increase the photosensitivity reaction of actinic keratoses treated with the entity2begin LEVULAN KERASTICK entity2end for Topical Solution . 
true chemical chemical entity1begin Aminosalicylic acid entity1end may decrease the amount of entity2begin digoxin entity2end ( Lanoxin , Lanoxicaps ) that gets absorbed into your body . 
true chemical chemical entity1begin Aminosalicylic acid entity1end may decrease the amount of digoxin ( entity2begin Lanoxin entity2end , Lanoxicaps ) that gets absorbed into your body . 
false chemical chemical entity1begin Aminosalicylic acid entity1end may decrease the amount of digoxin ( Lanoxin , entity2begin Lanoxicaps entity2end ) that gets absorbed into your body . 
false chemical chemical Aminosalicylic acid may decrease the amount of entity1begin digoxin entity1end ( entity2begin Lanoxin entity2end , Lanoxicaps ) that gets absorbed into your body . 
false chemical chemical Aminosalicylic acid may decrease the amount of entity1begin digoxin entity1end ( Lanoxin , entity2begin Lanoxicaps entity2end ) that gets absorbed into your body . 
false chemical chemical Aminosalicylic acid may decrease the amount of digoxin ( entity1begin Lanoxin entity1end , entity2begin Lanoxicaps entity2end ) that gets absorbed into your body . 
true chemical chemical In the case that you are taking entity1begin digoxin entity1end while taking entity2begin aminosalicylic acid entity2end , higher doses of digoxin may be needed . 
false chemical chemical In the case that you are taking entity1begin digoxin entity1end while taking aminosalicylic acid , higher doses of entity2begin digoxin entity2end may be needed . 
false chemical chemical In the case that you are taking digoxin while taking entity1begin aminosalicylic acid entity1end , higher doses of entity2begin digoxin entity2end may be needed . 
true chemical chemical entity1begin Aminosalicylic acid entity1end may also decrease the absorption of entity2begin vitamin B12 entity2end , which can lead to a deficiency . 
true chemical chemical Therefore you may need to take a entity1begin vitamin B12 entity1end supplement while taking entity2begin aminosalicylic acid entity2end . 
false chemical chemical entity1begin Amiodarone entity1end is metabolized to entity2begin desethylamiodarone entity2end by the cytochrome P450 ( CYP450 ) enzyme group , specifically cytochromes P450 3A4 ( CYP3A4 ) and CYP2C8 . 
false chemical chemical In view of the long and variable half - life of entity1begin amiodarone entity1end , potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of entity2begin amiodarone entity2end . 
false chemical chemical Since entity1begin amiodarone entity1end is a substrate for CYP3A4 and CYP2C8 , drugs / substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of entity2begin amiodarone entity2end . 
false chemical chemical Reported examples include the following : entity1begin Protease Inhibitors entity1end : entity2begin Protease inhibitors entity2end are known to inhibit CYP3A4 to varying degrees . 
true chemical chemical A case report of one patient taking entity1begin amiodarone entity1end 200 mg and entity2begin indinavir entity2end 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg / L to 1.3 mg / L . 
false chemical chemical A case report of one patient taking entity1begin amiodarone entity1end 200 mg and indinavir 800 mg three times a day resulted in increases in entity2begin amiodarone entity2end concentrations from 0.9 mg / L to 1.3 mg / L . 
false chemical chemical A case report of one patient taking amiodarone 200 mg and entity1begin indinavir entity1end 800 mg three times a day resulted in increases in entity2begin amiodarone entity2end concentrations from 0.9 mg / L to 1.3 mg / L . 
false chemical chemical Monitoring for entity1begin amiodarone entity1end toxicity and serial measurement of entity2begin amiodarone entity2end serum concentration during concomitant protease inhibitor therapy should be considered . 
false chemical chemical Monitoring for entity1begin amiodarone entity1end toxicity and serial measurement of amiodarone serum concentration during concomitant entity2begin protease inhibitor entity2end therapy should be considered . 
true chemical chemical Monitoring for amiodarone toxicity and serial measurement of entity1begin amiodarone entity1end serum concentration during concomitant entity2begin protease inhibitor entity2end therapy should be considered . 
true chemical chemical entity1begin Histamine H2 antagonists entity1end : entity2begin Cimetidine entity2end inhibits CYP3A4 and can increase serum amiodarone levels . 
false chemical chemical entity1begin Histamine H2 antagonists entity1end : Cimetidine inhibits CYP3A4 and can increase serum entity2begin amiodarone entity2end levels . 
false chemical chemical Histamine H2 antagonists : entity1begin Cimetidine entity1end inhibits CYP3A4 and can increase serum entity2begin amiodarone entity2end levels . 
false chemical chemical Other substances : Grapefruit juice given to healthy volunteers increased entity1begin amiodarone entity1end AUC by 50 % and Cmax by 84 % , resulting in increased plasma levels of entity2begin amiodarone entity2end . 
false chemical chemical This information should be considered when changing from intravenous entity1begin amiodarone entity1end to oral entity2begin amiodarone entity2end . 
false chemical chemical entity1begin Amiodarone entity1end may suppress certain CYP450 enzymes , including entity2begin CYP1A2 entity2end , CYP2C9 , CYP2D6 , and CYP3A4 . 
false chemical chemical entity1begin Amiodarone entity1end may suppress certain CYP450 enzymes , including CYP1A2 , entity2begin CYP2C9 entity2end , CYP2D6 , and CYP3A4 . 
false chemical chemical entity1begin Amiodarone entity1end may suppress certain CYP450 enzymes , including CYP1A2 , CYP2C9 , entity2begin CYP2D6 entity2end , and CYP3A4 . 
false chemical chemical entity1begin Amiodarone entity1end may suppress certain CYP450 enzymes , including CYP1A2 , CYP2C9 , CYP2D6 , and entity2begin CYP3A4 entity2end . 
false chemical chemical Amiodarone may suppress certain CYP450 enzymes , including entity1begin CYP1A2 entity1end , entity2begin CYP2C9 entity2end , CYP2D6 , and CYP3A4 . 
false chemical chemical Amiodarone may suppress certain CYP450 enzymes , including entity1begin CYP1A2 entity1end , CYP2C9 , entity2begin CYP2D6 entity2end , and CYP3A4 . 
false chemical chemical Amiodarone may suppress certain CYP450 enzymes , including entity1begin CYP1A2 entity1end , CYP2C9 , CYP2D6 , and entity2begin CYP3A4 entity2end . 
false chemical chemical Amiodarone may suppress certain CYP450 enzymes , including CYP1A2 , entity1begin CYP2C9 entity1end , entity2begin CYP2D6 entity2end , and CYP3A4 . 
false chemical chemical Amiodarone may suppress certain CYP450 enzymes , including CYP1A2 , entity1begin CYP2C9 entity1end , CYP2D6 , and entity2begin CYP3A4 entity2end . 
false chemical chemical Amiodarone may suppress certain CYP450 enzymes , including CYP1A2 , CYP2C9 , entity1begin CYP2D6 entity1end , and entity2begin CYP3A4 entity2end . 
false chemical chemical Reported examples of this interaction include the following : entity1begin Immunosuppressive entity1end s : entity2begin Cyclosporine entity2end ( CYP3A4 substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of cyclosporine . 
false chemical chemical Reported examples of this interaction include the following : entity1begin Immunosuppressive entity1end s : Cyclosporine ( entity2begin CYP3A4 entity2end substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of cyclosporine . 
false chemical chemical Reported examples of this interaction include the following : entity1begin Immunosuppressive entity1end s : Cyclosporine ( CYP3A4 substrate ) administered in combination with oral entity2begin amiodarone entity2end has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of cyclosporine . 
false chemical chemical Reported examples of this interaction include the following : entity1begin Immunosuppressive entity1end s : Cyclosporine ( CYP3A4 substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of entity2begin cyclosporine entity2end resulting in elevated creatinine , despite reduction in dose of cyclosporine . 
false chemical chemical Reported examples of this interaction include the following : entity1begin Immunosuppressive entity1end s : Cyclosporine ( CYP3A4 substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of entity2begin cyclosporine entity2end . 
false chemical chemical Reported examples of this interaction include the following : Immunosuppressives : entity1begin Cyclosporine entity1end ( entity2begin CYP3A4 entity2end substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of cyclosporine . 
false chemical chemical Reported examples of this interaction include the following : Immunosuppressives : entity1begin Cyclosporine entity1end ( CYP3A4 substrate ) administered in combination with oral entity2begin amiodarone entity2end has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of cyclosporine . 
false chemical chemical Reported examples of this interaction include the following : Immunosuppressives : entity1begin Cyclosporine entity1end ( CYP3A4 substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of entity2begin cyclosporine entity2end resulting in elevated creatinine , despite reduction in dose of cyclosporine . 
false chemical chemical Reported examples of this interaction include the following : Immunosuppressives : entity1begin Cyclosporine entity1end ( CYP3A4 substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of entity2begin cyclosporine entity2end . 
false chemical chemical Reported examples of this interaction include the following : Immunosuppressives : Cyclosporine ( entity1begin CYP3A4 entity1end substrate ) administered in combination with oral entity2begin amiodarone entity2end has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of cyclosporine . 
false chemical chemical Reported examples of this interaction include the following : Immunosuppressives : Cyclosporine ( entity1begin CYP3A4 entity1end substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of entity2begin cyclosporine entity2end resulting in elevated creatinine , despite reduction in dose of cyclosporine . 
false chemical chemical Reported examples of this interaction include the following : Immunosuppressives : Cyclosporine ( entity1begin CYP3A4 entity1end substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of entity2begin cyclosporine entity2end . 
false chemical chemical Reported examples of this interaction include the following : Immunosuppressives : Cyclosporine ( CYP3A4 substrate ) administered in combination with oral entity1begin amiodarone entity1end has been reported to produce persistently elevated plasma concentrations of entity2begin cyclosporine entity2end resulting in elevated creatinine , despite reduction in dose of cyclosporine . 
false chemical chemical Reported examples of this interaction include the following : Immunosuppressives : Cyclosporine ( CYP3A4 substrate ) administered in combination with oral entity1begin amiodarone entity1end has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of entity2begin cyclosporine entity2end . 
false chemical chemical Reported examples of this interaction include the following : Immunosuppressives : Cyclosporine ( CYP3A4 substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of entity1begin cyclosporine entity1end resulting in elevated creatinine , despite reduction in dose of entity2begin cyclosporine entity2end . 
false chemical chemical entity1begin HMG - CoA Reductase Inhibitors entity1end : entity2begin Simvastatin entity2end ( CYP3A4 substrate ) in combination with amiodarone has been associated with reports of myopathy / rhabdomyolysis . 
false chemical chemical entity1begin HMG - CoA Reductase Inhibitors entity1end : Simvastatin ( entity2begin CYP3A4 entity2end substrate ) in combination with amiodarone has been associated with reports of myopathy / rhabdomyolysis . 
false chemical chemical entity1begin HMG - CoA Reductase Inhibitors entity1end : Simvastatin ( CYP3A4 substrate ) in combination with entity2begin amiodarone entity2end has been associated with reports of myopathy / rhabdomyolysis . 
false chemical chemical HMG - CoA Reductase Inhibitors : entity1begin Simvastatin entity1end ( entity2begin CYP3A4 entity2end substrate ) in combination with amiodarone has been associated with reports of myopathy / rhabdomyolysis . 
false chemical chemical HMG - CoA Reductase Inhibitors : entity1begin Simvastatin entity1end ( CYP3A4 substrate ) in combination with entity2begin amiodarone entity2end has been associated with reports of myopathy / rhabdomyolysis . 
false chemical chemical HMG - CoA Reductase Inhibitors : Simvastatin ( entity1begin CYP3A4 entity1end substrate ) in combination with entity2begin amiodarone entity2end has been associated with reports of myopathy / rhabdomyolysis . 
false chemical chemical Cardiovasculars : entity1begin Cardiac glycosides entity1end : In patients receiving entity2begin digoxin entity2end therapy , administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity . 
false chemical chemical Cardiovasculars : entity1begin Cardiac glycosides entity1end : In patients receiving digoxin therapy , administration of oral entity2begin amiodarone entity2end regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity . 
false chemical chemical Cardiovasculars : entity1begin Cardiac glycosides entity1end : In patients receiving digoxin therapy , administration of oral amiodarone regularly results in an increase in serum entity2begin digoxin entity2end concentration that may reach toxic levels with resultant clinical toxicity . 
false chemical chemical Cardiovasculars : Cardiac glycosides : In patients receiving entity1begin digoxin entity1end therapy , administration of oral entity2begin amiodarone entity2end regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity . 
false chemical chemical Cardiovasculars : Cardiac glycosides : In patients receiving entity1begin digoxin entity1end therapy , administration of oral amiodarone regularly results in an increase in serum entity2begin digoxin entity2end concentration that may reach toxic levels with resultant clinical toxicity . 
false chemical chemical Cardiovasculars : Cardiac glycosides : In patients receiving digoxin therapy , administration of oral entity1begin amiodarone entity1end regularly results in an increase in serum entity2begin digoxin entity2end concentration that may reach toxic levels with resultant clinical toxicity . 
false chemical chemical entity1begin Amiodarone entity1end taken concomitantly with entity2begin digoxin entity2end increases the serum digoxin concentration by 70 % after one day . 
false chemical chemical entity1begin Amiodarone entity1end taken concomitantly with digoxin increases the serum entity2begin digoxin entity2end concentration by 70 % after one day . 
false chemical chemical Amiodarone taken concomitantly with entity1begin digoxin entity1end increases the serum entity2begin digoxin entity2end concentration by 70 % after one day . 
true chemical chemical On administration of oral entity1begin amiodarone entity1end , the need for entity2begin digitalis entity2end therapy should be reviewed and the dose reduced by approximately 50 % or discontinued . 
false chemical chemical entity1begin Antiarrhythmics entity1end : Other entity2begin antiarrhythmic entity2end drugs , such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone . 
false chemical chemical entity1begin Antiarrhythmics entity1end : Other antiarrhythmic drugs , such as entity2begin quinidine entity2end , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone . 
false chemical chemical entity1begin Antiarrhythmics entity1end : Other antiarrhythmic drugs , such as quinidine , entity2begin procainamide entity2end , disopyramide , and phenytoin , have been used concurrently with amiodarone . 
false chemical chemical entity1begin Antiarrhythmics entity1end : Other antiarrhythmic drugs , such as quinidine , procainamide , entity2begin disopyramide entity2end , and phenytoin , have been used concurrently with amiodarone . 
false chemical chemical entity1begin Antiarrhythmics entity1end : Other antiarrhythmic drugs , such as quinidine , procainamide , disopyramide , and entity2begin phenytoin entity2end , have been used concurrently with amiodarone . 
false chemical chemical entity1begin Antiarrhythmics entity1end : Other antiarrhythmic drugs , such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with entity2begin amiodarone entity2end . 
false chemical chemical Antiarrhythmics : Other entity1begin antiarrhythmic entity1end drugs , such as entity2begin quinidine entity2end , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone . 
false chemical chemical Antiarrhythmics : Other entity1begin antiarrhythmic entity1end drugs , such as quinidine , entity2begin procainamide entity2end , disopyramide , and phenytoin , have been used concurrently with amiodarone . 
false chemical chemical Antiarrhythmics : Other entity1begin antiarrhythmic entity1end drugs , such as quinidine , procainamide , entity2begin disopyramide entity2end , and phenytoin , have been used concurrently with amiodarone . 
false chemical chemical Antiarrhythmics : Other entity1begin antiarrhythmic entity1end drugs , such as quinidine , procainamide , disopyramide , and entity2begin phenytoin entity2end , have been used concurrently with amiodarone . 
false chemical chemical Antiarrhythmics : Other entity1begin antiarrhythmic entity1end drugs , such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with entity2begin amiodarone entity2end . 
false chemical chemical Antiarrhythmics : Other antiarrhythmic drugs , such as entity1begin quinidine entity1end , entity2begin procainamide entity2end , disopyramide , and phenytoin , have been used concurrently with amiodarone . 
false chemical chemical Antiarrhythmics : Other antiarrhythmic drugs , such as entity1begin quinidine entity1end , procainamide , entity2begin disopyramide entity2end , and phenytoin , have been used concurrently with amiodarone . 
false chemical chemical Antiarrhythmics : Other antiarrhythmic drugs , such as entity1begin quinidine entity1end , procainamide , disopyramide , and entity2begin phenytoin entity2end , have been used concurrently with amiodarone . 
false chemical chemical Antiarrhythmics : Other antiarrhythmic drugs , such as entity1begin quinidine entity1end , procainamide , disopyramide , and phenytoin , have been used concurrently with entity2begin amiodarone entity2end . 
false chemical chemical Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , entity1begin procainamide entity1end , entity2begin disopyramide entity2end , and phenytoin , have been used concurrently with amiodarone . 
false chemical chemical Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , entity1begin procainamide entity1end , disopyramide , and entity2begin phenytoin entity2end , have been used concurrently with amiodarone . 
false chemical chemical Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , entity1begin procainamide entity1end , disopyramide , and phenytoin , have been used concurrently with entity2begin amiodarone entity2end . 
false chemical chemical Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , procainamide , entity1begin disopyramide entity1end , and entity2begin phenytoin entity2end , have been used concurrently with amiodarone . 
false chemical chemical Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , procainamide , entity1begin disopyramide entity1end , and phenytoin , have been used concurrently with entity2begin amiodarone entity2end . 
false chemical chemical Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , procainamide , disopyramide , and entity1begin phenytoin entity1end , have been used concurrently with entity2begin amiodarone entity2end . 
false chemical chemical There have been case reports of increased steady - state levels of entity1begin quinidine entity1end , entity2begin procainamide entity2end , and phenytoin during concomitant therapy with amiodarone . 
false chemical chemical There have been case reports of increased steady - state levels of entity1begin quinidine entity1end , procainamide , and entity2begin phenytoin entity2end during concomitant therapy with amiodarone . 
false chemical chemical There have been case reports of increased steady - state levels of entity1begin quinidine entity1end , procainamide , and phenytoin during concomitant therapy with entity2begin amiodarone entity2end . 
false chemical chemical There have been case reports of increased steady - state levels of quinidine , entity1begin procainamide entity1end , and entity2begin phenytoin entity2end during concomitant therapy with amiodarone . 
false chemical chemical There have been case reports of increased steady - state levels of quinidine , entity1begin procainamide entity1end , and phenytoin during concomitant therapy with entity2begin amiodarone entity2end . 
false chemical chemical There have been case reports of increased steady - state levels of quinidine , procainamide , and entity1begin phenytoin entity1end during concomitant therapy with entity2begin amiodarone entity2end . 
false chemical chemical entity1begin Amiodarone entity1end taken concomitantly with entity2begin quinidine entity2end increases quinidine serum concentration by 33 % after two days . 
false chemical chemical entity1begin Amiodarone entity1end taken concomitantly with quinidine increases entity2begin quinidine entity2end serum concentration by 33 % after two days . 
false chemical chemical Amiodarone taken concomitantly with entity1begin quinidine entity1end increases entity2begin quinidine entity2end serum concentration by 33 % after two days . 
false chemical chemical entity1begin Amiodarone entity1end taken concomitantly with entity2begin procainamide entity2end for less than seven days increases plasma concentrations of procainamide and n - acetyl procainamide by 55 % and 33 % , respectively . 
false chemical chemical entity1begin Amiodarone entity1end taken concomitantly with procainamide for less than seven days increases plasma concentrations of entity2begin procainamide entity2end and n - acetyl procainamide by 55 % and 33 % , respectively . 
false chemical chemical entity1begin Amiodarone entity1end taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n - acetyl entity2begin procainamide entity2end by 55 % and 33 % , respectively . 
false chemical chemical Amiodarone taken concomitantly with entity1begin procainamide entity1end for less than seven days increases plasma concentrations of entity2begin procainamide entity2end and n - acetyl procainamide by 55 % and 33 % , respectively . 
false chemical chemical Amiodarone taken concomitantly with entity1begin procainamide entity1end for less than seven days increases plasma concentrations of procainamide and n - acetyl entity2begin procainamide entity2end by 55 % and 33 % , respectively . 
false chemical chemical Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of entity1begin procainamide entity1end and n - acetyl entity2begin procainamide entity2end by 55 % and 33 % , respectively . 
false chemical chemical entity1begin Quinidine entity1end and procainamide doses should be reduced by one - third when either is administered with entity2begin amiodarone entity2end . 
false chemical chemical Plasma levels of entity1begin flecainide entity1end have been reported to increase in the presence of oral entity2begin amiodarone entity2end ; 
false chemical chemical because of this , the dosage of entity1begin flecainide entity1end should be adjusted when these entity2begin drugs entity2end are administered concomitantly . 
false chemical chemical Combination of entity1begin amiodarone entity1end with other entity2begin antiarrhythmic entity2end therapy should be reserved for patients with life - threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone . 
false chemical chemical Combination of entity1begin amiodarone entity1end with other antiarrhythmic therapy should be reserved for patients with life - threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to entity2begin amiodarone entity2end . 
false chemical chemical Combination of amiodarone with other entity1begin antiarrhythmic entity1end therapy should be reserved for patients with life - threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to entity2begin amiodarone entity2end . 
false chemical chemical During transfer to oral entity1begin amiodarone entity1end , the dose levels of previously administered agents should be reduced by 30 to 50 % several days after the addition of oral entity2begin amiodarone entity2end . 
false chemical chemical The continued need for the other entity1begin antiarrhythmic entity1end agent should be reviewed after the effects of entity2begin amiodarone entity2end have been established , and discontinuation ordinarily should be attempted . 
false chemical chemical In entity1begin amiodarone entity1end - treated patients who require additional entity2begin antiarrhythmic entity2end therapy , the initial dose of such agents should be approximately half of the usual recommended dose . 
false chemical chemical entity1begin Antihypertensives entity1end : entity2begin Amiodarone entity2end should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical entity1begin Antihypertensives entity1end : Amiodarone should be used with caution in patients receiving - entity2begin receptor entity2end blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical entity1begin Antihypertensives entity1end : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , entity2begin propranolol entity2end , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical entity1begin Antihypertensives entity1end : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a entity2begin CYP3A4 entity2end inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical entity1begin Antihypertensives entity1end : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or entity2begin calcium channel entity2end antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical entity1begin Antihypertensives entity1end : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , entity2begin verapamil entity2end , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical entity1begin Antihypertensives entity1end : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a entity2begin CYP3A4 entity2end substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical entity1begin Antihypertensives entity1end : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and entity2begin diltiazem entity2end , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical entity1begin Antihypertensives entity1end : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a entity2begin CYP3A4 entity2end inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : entity1begin Amiodarone entity1end should be used with caution in patients receiving - entity2begin receptor entity2end blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : entity1begin Amiodarone entity1end should be used with caution in patients receiving - receptor blocking agents ( e.g. , entity2begin propranolol entity2end , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : entity1begin Amiodarone entity1end should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a entity2begin CYP3A4 entity2end inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : entity1begin Amiodarone entity1end should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or entity2begin calcium channel entity2end antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : entity1begin Amiodarone entity1end should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , entity2begin verapamil entity2end , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : entity1begin Amiodarone entity1end should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a entity2begin CYP3A4 entity2end substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : entity1begin Amiodarone entity1end should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and entity2begin diltiazem entity2end , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : entity1begin Amiodarone entity1end should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a entity2begin CYP3A4 entity2end inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - entity1begin receptor entity1end blocking agents ( e.g. , entity2begin propranolol entity2end , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - entity1begin receptor entity1end blocking agents ( e.g. , propranolol , a entity2begin CYP3A4 entity2end inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - entity1begin receptor entity1end blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or entity2begin calcium channel entity2end antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - entity1begin receptor entity1end blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , entity2begin verapamil entity2end , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - entity1begin receptor entity1end blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a entity2begin CYP3A4 entity2end substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - entity1begin receptor entity1end blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and entity2begin diltiazem entity2end , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - entity1begin receptor entity1end blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a entity2begin CYP3A4 entity2end inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , entity1begin propranolol entity1end , a entity2begin CYP3A4 entity2end inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , entity1begin propranolol entity1end , a CYP3A4 inhibitor ) or entity2begin calcium channel entity2end antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , entity1begin propranolol entity1end , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , entity2begin verapamil entity2end , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , entity1begin propranolol entity1end , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a entity2begin CYP3A4 entity2end substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , entity1begin propranolol entity1end , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and entity2begin diltiazem entity2end , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , entity1begin propranolol entity1end , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a entity2begin CYP3A4 entity2end inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a entity1begin CYP3A4 entity1end inhibitor ) or entity2begin calcium channel entity2end antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a entity1begin CYP3A4 entity1end inhibitor ) or calcium channel antagonists ( e.g. , entity2begin verapamil entity2end , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a entity1begin CYP3A4 entity1end inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a entity2begin CYP3A4 entity2end substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a entity1begin CYP3A4 entity1end inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and entity2begin diltiazem entity2end , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a entity1begin CYP3A4 entity1end inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a entity2begin CYP3A4 entity2end inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or entity1begin calcium channel entity1end antagonists ( e.g. , entity2begin verapamil entity2end , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or entity1begin calcium channel entity1end antagonists ( e.g. , verapamil , a entity2begin CYP3A4 entity2end substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or entity1begin calcium channel entity1end antagonists ( e.g. , verapamil , a CYP3A4 substrate , and entity2begin diltiazem entity2end , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or entity1begin calcium channel entity1end antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a entity2begin CYP3A4 entity2end inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , entity1begin verapamil entity1end , a entity2begin CYP3A4 entity2end substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , entity1begin verapamil entity1end , a CYP3A4 substrate , and entity2begin diltiazem entity2end , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , entity1begin verapamil entity1end , a CYP3A4 substrate , and diltiazem , a entity2begin CYP3A4 entity2end inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a entity1begin CYP3A4 entity1end substrate , and entity2begin diltiazem entity2end , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a entity1begin CYP3A4 entity1end substrate , and diltiazem , a entity2begin CYP3A4 entity2end inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical Antihypertensives : Amiodarone should be used with caution in patients receiving - receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and entity1begin diltiazem entity1end , a entity2begin CYP3A4 entity2end inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ; 
false chemical chemical entity1begin Anticoagulants entity1end : Potentiation of entity2begin warfarin entity2end - type ( CYP2C9 and CYP3A4 substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding . 
false chemical chemical entity1begin Anticoagulants entity1end : Potentiation of warfarin - type ( entity2begin CYP2C9 entity2end and CYP3A4 substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding . 
false chemical chemical entity1begin Anticoagulants entity1end : Potentiation of warfarin - type ( CYP2C9 and entity2begin CYP3A4 entity2end substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding . 
false chemical chemical entity1begin Anticoagulants entity1end : Potentiation of warfarin - type ( CYP2C9 and CYP3A4 substrate ) entity2begin anticoagulant entity2end response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding . 
false chemical chemical entity1begin Anticoagulants entity1end : Potentiation of warfarin - type ( CYP2C9 and CYP3A4 substrate ) anticoagulant response is almost always seen in patients receiving entity2begin amiodarone entity2end and can result in serious or fatal bleeding . 
false chemical chemical Anticoagulants : Potentiation of entity1begin warfarin entity1end - type ( entity2begin CYP2C9 entity2end and CYP3A4 substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding . 
false chemical chemical Anticoagulants : Potentiation of entity1begin warfarin entity1end - type ( CYP2C9 and entity2begin CYP3A4 entity2end substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding . 
false chemical chemical Anticoagulants : Potentiation of entity1begin warfarin entity1end - type ( CYP2C9 and CYP3A4 substrate ) entity2begin anticoagulant entity2end response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding . 
false chemical chemical Anticoagulants : Potentiation of entity1begin warfarin entity1end - type ( CYP2C9 and CYP3A4 substrate ) anticoagulant response is almost always seen in patients receiving entity2begin amiodarone entity2end and can result in serious or fatal bleeding . 
false chemical chemical Anticoagulants : Potentiation of warfarin - type ( entity1begin CYP2C9 entity1end and entity2begin CYP3A4 entity2end substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding . 
false chemical chemical Anticoagulants : Potentiation of warfarin - type ( entity1begin CYP2C9 entity1end and CYP3A4 substrate ) entity2begin anticoagulant entity2end response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding . 
false chemical chemical Anticoagulants : Potentiation of warfarin - type ( entity1begin CYP2C9 entity1end and CYP3A4 substrate ) anticoagulant response is almost always seen in patients receiving entity2begin amiodarone entity2end and can result in serious or fatal bleeding . 
false chemical chemical Anticoagulants : Potentiation of warfarin - type ( CYP2C9 and entity1begin CYP3A4 entity1end substrate ) entity2begin anticoagulant entity2end response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding . 
false chemical chemical Anticoagulants : Potentiation of warfarin - type ( CYP2C9 and entity1begin CYP3A4 entity1end substrate ) anticoagulant response is almost always seen in patients receiving entity2begin amiodarone entity2end and can result in serious or fatal bleeding . 
false chemical chemical Anticoagulants : Potentiation of warfarin - type ( CYP2C9 and CYP3A4 substrate ) entity1begin anticoagulant entity1end response is almost always seen in patients receiving entity2begin amiodarone entity2end and can result in serious or fatal bleeding . 
false chemical chemical Since the concomitant administration of entity1begin warfarin entity1end with entity2begin amiodarone entity2end increases the prothrombin time by 100 % after 3 to 4 days , the dose of the anticoagulant should be reduced by one - third to one - half , and prothrombin times should be monitored closely . 
false chemical chemical Since the concomitant administration of entity1begin warfarin entity1end with amiodarone increases the prothrombin time by 100 % after 3 to 4 days , the dose of the entity2begin anticoagulant entity2end should be reduced by one - third to one - half , and prothrombin times should be monitored closely . 
false chemical chemical Since the concomitant administration of warfarin with entity1begin amiodarone entity1end increases the prothrombin time by 100 % after 3 to 4 days , the dose of the entity2begin anticoagulant entity2end should be reduced by one - third to one - half , and prothrombin times should be monitored closely . 
false chemical chemical Some entity1begin drugs entity1end / substances are known to accelerate the metabolism of entity2begin amiodarone entity2end by stimulating the synthesis of CYP3A4 ( enzyme induction ) . 
false chemical chemical Some entity1begin drugs entity1end / substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of entity2begin CYP3A4 entity2end ( enzyme induction ) . 
false chemical chemical Some drugs / substances are known to accelerate the metabolism of entity1begin amiodarone entity1end by stimulating the synthesis of entity2begin CYP3A4 entity2end ( enzyme induction ) . 
false chemical chemical Reported examples of this interaction include the following : entity1begin Antibiotics entity1end : entity2begin Rifampin entity2end is a potent inducer of CYP3A4 . 
false chemical chemical Reported examples of this interaction include the following : entity1begin Antibiotics entity1end : Rifampin is a potent inducer of entity2begin CYP3A4 entity2end . 
false chemical chemical Reported examples of this interaction include the following : Antibiotics : entity1begin Rifampin entity1end is a potent inducer of entity2begin CYP3A4 entity2end . 
false chemical chemical Administration of entity1begin rifampin entity1end concomitantly with oral entity2begin amiodarone entity2end has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone . 
false chemical chemical Administration of entity1begin rifampin entity1end concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of entity2begin amiodarone entity2end and desethylamiodarone . 
false chemical chemical Administration of entity1begin rifampin entity1end concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and entity2begin desethylamiodarone entity2end . 
false chemical chemical Administration of rifampin concomitantly with oral entity1begin amiodarone entity1end has been shown to result in decreases in serum concentrations of entity2begin amiodarone entity2end and desethylamiodarone . 
false chemical chemical Administration of rifampin concomitantly with oral entity1begin amiodarone entity1end has been shown to result in decreases in serum concentrations of amiodarone and entity2begin desethylamiodarone entity2end . 
false chemical chemical Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of entity1begin amiodarone entity1end and entity2begin desethylamiodarone entity2end . 
false chemical chemical Since entity1begin amiodarone entity1end is a substrate for entity2begin CYP3A4 entity2end , there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels . 
false chemical chemical Since entity1begin amiodarone entity1end is a substrate for CYP3A4 , there is the potential that the use of St. John s Wort in patients receiving entity2begin amiodarone entity2end could result in reduced amiodarone levels . 
false chemical chemical Since entity1begin amiodarone entity1end is a substrate for CYP3A4 , there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced entity2begin amiodarone entity2end levels . 
false chemical chemical Since amiodarone is a substrate for entity1begin CYP3A4 entity1end , there is the potential that the use of St. John s Wort in patients receiving entity2begin amiodarone entity2end could result in reduced amiodarone levels . 
false chemical chemical Since amiodarone is a substrate for entity1begin CYP3A4 entity1end , there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced entity2begin amiodarone entity2end levels . 
false chemical chemical Since amiodarone is a substrate for CYP3A4 , there is the potential that the use of St. John s Wort in patients receiving entity1begin amiodarone entity1end could result in reduced entity2begin amiodarone entity2end levels . 
false chemical chemical Other reported interactions with entity1begin amiodarone entity1end : entity2begin Fentanyl entity2end ( CYP3A4 substrate ) in combination with amiodarone may cause hypotension , bradycardia , and decreased cardiac output . 
false chemical chemical Other reported interactions with entity1begin amiodarone entity1end : Fentanyl ( entity2begin CYP3A4 entity2end substrate ) in combination with amiodarone may cause hypotension , bradycardia , and decreased cardiac output . 
false chemical chemical Other reported interactions with entity1begin amiodarone entity1end : Fentanyl ( CYP3A4 substrate ) in combination with entity2begin amiodarone entity2end may cause hypotension , bradycardia , and decreased cardiac output . 
false chemical chemical Other reported interactions with amiodarone : entity1begin Fentanyl entity1end ( entity2begin CYP3A4 entity2end substrate ) in combination with amiodarone may cause hypotension , bradycardia , and decreased cardiac output . 
false chemical chemical Other reported interactions with amiodarone : entity1begin Fentanyl entity1end ( CYP3A4 substrate ) in combination with entity2begin amiodarone entity2end may cause hypotension , bradycardia , and decreased cardiac output . 
false chemical chemical Other reported interactions with amiodarone : Fentanyl ( entity1begin CYP3A4 entity1end substrate ) in combination with entity2begin amiodarone entity2end may cause hypotension , bradycardia , and decreased cardiac output . 
false chemical chemical Sinus bradycardia has been reported with oral entity1begin amiodarone entity1end in combination with entity2begin lidocaine entity2end ( CYP3A4 substrate ) given for local anesthesia . 
false chemical chemical Sinus bradycardia has been reported with oral entity1begin amiodarone entity1end in combination with lidocaine ( entity2begin CYP3A4 entity2end substrate ) given for local anesthesia . 
false chemical chemical Sinus bradycardia has been reported with oral entity1begin amiodarone entity1end in combination with lidocaine ( CYP3A4 substrate ) given for local entity2begin anesthesia entity2end . 
false chemical chemical Sinus bradycardia has been reported with oral amiodarone in combination with entity1begin lidocaine entity1end ( entity2begin CYP3A4 entity2end substrate ) given for local anesthesia . 
false chemical chemical Sinus bradycardia has been reported with oral amiodarone in combination with entity1begin lidocaine entity1end ( CYP3A4 substrate ) given for local entity2begin anesthesia entity2end . 
false chemical chemical Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine ( entity1begin CYP3A4 entity1end substrate ) given for local entity2begin anesthesia entity2end . 
false chemical chemical Seizure , associated with increased entity1begin lidocaine entity1end concentrations , has been reported with concomitant administration of intravenous entity2begin amiodarone entity2end . 
false chemical chemical entity1begin Dextromethorphan entity1end is a substrate for both entity2begin CYP2D6 entity2end and CYP3A4 . 
false chemical chemical entity1begin Dextromethorphan entity1end is a substrate for both CYP2D6 and entity2begin CYP3A4 entity2end . 
false chemical chemical Dextromethorphan is a substrate for both entity1begin CYP2D6 entity1end and entity2begin CYP3A4 entity2end . 
false chemical chemical entity1begin Amiodarone entity1end inhibits entity2begin CYP2D6 entity2end . 
false chemical chemical entity1begin Cholestyramine entity1end increases enterohepatic elimination of entity2begin amiodarone entity2end and may reduce its serum levels and t1 / 2 . 
false chemical chemical entity1begin Cholestyramine entity1end increases enterohepatic elimination of amiodarone and may reduce its serum levels and entity2begin t1 entity2end / 2 . 
false chemical chemical Cholestyramine increases enterohepatic elimination of entity1begin amiodarone entity1end and may reduce its serum levels and entity2begin t1 entity2end / 2 . 
false chemical chemical entity1begin Fluoroquinolones entity1end , entity2begin macrolide antibiotics entity2end , and azoles are known to cause QTc prolongation . 
false chemical chemical There have been reports of QTc prolongation , with or without TdP , in patients taking entity1begin amiodarone entity1end when entity2begin fluoroquinolones entity2end , macrolide antibiotics , or azoles were administered concomitantly . 
false chemical chemical There have been reports of QTc prolongation , with or without TdP , in patients taking entity1begin amiodarone entity1end when fluoroquinolones , entity2begin macrolide antibiotics entity2end , or azoles were administered concomitantly . 
false chemical chemical There have been reports of QTc prolongation , with or without TdP , in patients taking amiodarone when entity1begin fluoroquinolones entity1end , entity2begin macrolide antibiotics entity2end , or azoles were administered concomitantly . 
false chemical chemical Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with entity1begin propranolol entity1end , entity2begin diltiazem entity2end , and verapamil . 
false chemical chemical Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with entity1begin propranolol entity1end , diltiazem , and entity2begin verapamil entity2end . 
false chemical chemical Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol , entity1begin diltiazem entity1end , and entity2begin verapamil entity2end . 
false chemical chemical In addition to the interactions noted above , chronic ( 2 weeks ) oral entity1begin Cordarone entity1end administration impairs metabolism of entity2begin phenytoin entity2end , dextromethorphan , and methotrexate . 
false chemical chemical In addition to the interactions noted above , chronic ( 2 weeks ) oral entity1begin Cordarone entity1end administration impairs metabolism of phenytoin , entity2begin dextromethorphan entity2end , and methotrexate . 
false chemical chemical In addition to the interactions noted above , chronic ( 2 weeks ) oral entity1begin Cordarone entity1end administration impairs metabolism of phenytoin , dextromethorphan , and entity2begin methotrexate entity2end . 
false chemical chemical In addition to the interactions noted above , chronic ( 2 weeks ) oral Cordarone administration impairs metabolism of entity1begin phenytoin entity1end , entity2begin dextromethorphan entity2end , and methotrexate . 
false chemical chemical In addition to the interactions noted above , chronic ( 2 weeks ) oral Cordarone administration impairs metabolism of entity1begin phenytoin entity1end , dextromethorphan , and entity2begin methotrexate entity2end . 
false chemical chemical In addition to the interactions noted above , chronic ( 2 weeks ) oral Cordarone administration impairs metabolism of phenytoin , entity1begin dextromethorphan entity1end , and entity2begin methotrexate entity2end . 
false chemical chemical Poor metabolizers have higher than expected plasma concentrations of entity1begin tricyclic antidepressants entity1end ( entity2begin TCAs entity2end ) when given usual doses . 
false chemical chemical entity1begin cimetidine entity1end ) and many that are substrates for P450 2D6 ( many other entity2begin antidepressants entity2end , phenothiazines , and the Type 1C antiarrhythmics propafenone and flecainide ) . 
false chemical chemical entity1begin cimetidine entity1end ) and many that are substrates for P450 2D6 ( many other antidepressants , entity2begin phenothiazines entity2end , and the Type 1C antiarrhythmics propafenone and flecainide ) . 
false chemical chemical entity1begin cimetidine entity1end ) and many that are substrates for P450 2D6 ( many other antidepressants , phenothiazines , and the entity2begin Type 1C antiarrhythmics entity2end propafenone and flecainide ) . 
false chemical chemical entity1begin cimetidine entity1end ) and many that are substrates for P450 2D6 ( many other antidepressants , phenothiazines , and the Type 1C antiarrhythmics entity2begin propafenone entity2end and flecainide ) . 
false chemical chemical entity1begin cimetidine entity1end ) and many that are substrates for P450 2D6 ( many other antidepressants , phenothiazines , and the Type 1C antiarrhythmics propafenone and entity2begin flecainide entity2end ) . 
false chemical chemical cimetidine ) and many that are substrates for P450 2D6 ( many other entity1begin antidepressants entity1end , entity2begin phenothiazines entity2end , and the Type 1C antiarrhythmics propafenone and flecainide ) . 
false chemical chemical cimetidine ) and many that are substrates for P450 2D6 ( many other entity1begin antidepressants entity1end , phenothiazines , and the entity2begin Type 1C antiarrhythmics entity2end propafenone and flecainide ) . 
false chemical chemical cimetidine ) and many that are substrates for P450 2D6 ( many other entity1begin antidepressants entity1end , phenothiazines , and the Type 1C antiarrhythmics entity2begin propafenone entity2end and flecainide ) . 
false chemical chemical cimetidine ) and many that are substrates for P450 2D6 ( many other entity1begin antidepressants entity1end , phenothiazines , and the Type 1C antiarrhythmics propafenone and entity2begin flecainide entity2end ) . 
false chemical chemical cimetidine ) and many that are substrates for P450 2D6 ( many other antidepressants , entity1begin phenothiazines entity1end , and the entity2begin Type 1C antiarrhythmics entity2end propafenone and flecainide ) . 
false chemical chemical cimetidine ) and many that are substrates for P450 2D6 ( many other antidepressants , entity1begin phenothiazines entity1end , and the Type 1C antiarrhythmics entity2begin propafenone entity2end and flecainide ) . 
false chemical chemical cimetidine ) and many that are substrates for P450 2D6 ( many other antidepressants , entity1begin phenothiazines entity1end , and the Type 1C antiarrhythmics propafenone and entity2begin flecainide entity2end ) . 
false chemical chemical cimetidine ) and many that are substrates for P450 2D6 ( many other antidepressants , phenothiazines , and the entity1begin Type 1C antiarrhythmics entity1end entity2begin propafenone entity2end and flecainide ) . 
false chemical chemical cimetidine ) and many that are substrates for P450 2D6 ( many other antidepressants , phenothiazines , and the entity1begin Type 1C antiarrhythmics entity1end propafenone and entity2begin flecainide entity2end ) . 
false chemical chemical cimetidine ) and many that are substrates for P450 2D6 ( many other antidepressants , phenothiazines , and the Type 1C antiarrhythmics entity1begin propafenone entity1end and entity2begin flecainide entity2end ) . 
false chemical chemical While all the selective entity1begin serotonin reuptake inhibitors entity1end ( entity2begin SSRIs entity2end ) , e.g. , fluoxetine , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition . 
false chemical chemical While all the selective entity1begin serotonin reuptake inhibitors entity1end ( SSRIs ) , e.g. , entity2begin fluoxetine entity2end , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition . 
false chemical chemical While all the selective entity1begin serotonin reuptake inhibitors entity1end ( SSRIs ) , e.g. , fluoxetine , entity2begin sertraline entity2end , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition . 
false chemical chemical While all the selective entity1begin serotonin reuptake inhibitors entity1end ( SSRIs ) , e.g. , fluoxetine , sertraline , and entity2begin paroxetine entity2end , inhibit P450 2D6 , they may vary in the extent of inhibition . 
false chemical chemical While all the selective serotonin reuptake inhibitors ( entity1begin SSRIs entity1end ) , e.g. , entity2begin fluoxetine entity2end , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition . 
false chemical chemical While all the selective serotonin reuptake inhibitors ( entity1begin SSRIs entity1end ) , e.g. , fluoxetine , entity2begin sertraline entity2end , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition . 
false chemical chemical While all the selective serotonin reuptake inhibitors ( entity1begin SSRIs entity1end ) , e.g. , fluoxetine , sertraline , and entity2begin paroxetine entity2end , inhibit P450 2D6 , they may vary in the extent of inhibition . 
false chemical chemical While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , entity1begin fluoxetine entity1end , entity2begin sertraline entity2end , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition . 
false chemical chemical While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , entity1begin fluoxetine entity1end , sertraline , and entity2begin paroxetine entity2end , inhibit P450 2D6 , they may vary in the extent of inhibition . 
false chemical chemical While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , fluoxetine , entity1begin sertraline entity1end , and entity2begin paroxetine entity2end , inhibit P450 2D6 , they may vary in the extent of inhibition . 
true chemical chemical The extent to which entity1begin SSRI entity1end - entity2begin TCA entity2end interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved . 
false chemical chemical The extent to which entity1begin SSRI entity1end - TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the entity2begin SSRI entity2end involved . 
false chemical chemical The extent to which SSRI - entity1begin TCA entity1end interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the entity2begin SSRI entity2end involved . 
true chemical chemical Nevertheless , caution is indicated in the coadministration of entity1begin TCAs entity1end with any of the entity2begin SSRIs entity2end and also in switching from one class to the other . 
false chemical chemical Concomitant use of entity1begin tricyclic antidepressants entity1end with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the entity2begin tricyclic antidepressant entity2end or the other drug . 
false chemical chemical It is desirable to monitor entity1begin TCA entity1end plasma levels whenever a entity2begin TCA entity2end is going to be coadministered with another drug known to be an inhibitor of P450 2D6 . 
false chemical chemical entity1begin Monoamine Oxidase Inhibitors entity1end : entity2begin Guanethidine entity2end or similarly acting compounds ; 
false chemical chemical entity1begin alcohol entity1end , entity2begin barbiturates entity2end and other CNS depressants ; 
false chemical chemical entity1begin alcohol entity1end , barbiturates and other entity2begin CNS depressants entity2end ; 
false chemical chemical alcohol , entity1begin barbiturates entity1end and other entity2begin CNS depressants entity2end ; 
false chemical chemical and entity1begin disulfiram entity1end When entity2begin amitriptyline HCl entity2end is given with anticholinergic agents or sympathomimetic drugs , including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required . 
false chemical chemical and entity1begin disulfiram entity1end When amitriptyline HCl is given with entity2begin anticholinergic entity2end agents or sympathomimetic drugs , including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required . 
false chemical chemical and entity1begin disulfiram entity1end When amitriptyline HCl is given with anticholinergic agents or entity2begin sympathomimetic entity2end drugs , including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required . 
false chemical chemical and entity1begin disulfiram entity1end When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs , including entity2begin epinephrine entity2end combined with local anesthetics , close supervision and careful adjustment of dosages are required . 
false chemical chemical and entity1begin disulfiram entity1end When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs , including epinephrine combined with local entity2begin anesthetics entity2end , close supervision and careful adjustment of dosages are required . 
false chemical chemical and disulfiram When entity1begin amitriptyline HCl entity1end is given with entity2begin anticholinergic entity2end agents or sympathomimetic drugs , including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required . 
false chemical chemical and disulfiram When entity1begin amitriptyline HCl entity1end is given with anticholinergic agents or entity2begin sympathomimetic entity2end drugs , including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required . 
false chemical chemical and disulfiram When entity1begin amitriptyline HCl entity1end is given with anticholinergic agents or sympathomimetic drugs , including entity2begin epinephrine entity2end combined with local anesthetics , close supervision and careful adjustment of dosages are required . 
false chemical chemical and disulfiram When entity1begin amitriptyline HCl entity1end is given with anticholinergic agents or sympathomimetic drugs , including epinephrine combined with local entity2begin anesthetics entity2end , close supervision and careful adjustment of dosages are required . 
false chemical chemical and disulfiram When amitriptyline HCl is given with entity1begin anticholinergic entity1end agents or entity2begin sympathomimetic entity2end drugs , including epinephrine combined with local anesthetics , close supervision and careful adjustment of dosages are required . 
false chemical chemical and disulfiram When amitriptyline HCl is given with entity1begin anticholinergic entity1end agents or sympathomimetic drugs , including entity2begin epinephrine entity2end combined with local anesthetics , close supervision and careful adjustment of dosages are required . 
false chemical chemical and disulfiram When amitriptyline HCl is given with entity1begin anticholinergic entity1end agents or sympathomimetic drugs , including epinephrine combined with local entity2begin anesthetics entity2end , close supervision and careful adjustment of dosages are required . 
false chemical chemical and disulfiram When amitriptyline HCl is given with anticholinergic agents or entity1begin sympathomimetic entity1end drugs , including entity2begin epinephrine entity2end combined with local anesthetics , close supervision and careful adjustment of dosages are required . 
false chemical chemical and disulfiram When amitriptyline HCl is given with anticholinergic agents or entity1begin sympathomimetic entity1end drugs , including epinephrine combined with local entity2begin anesthetics entity2end , close supervision and careful adjustment of dosages are required . 
false chemical chemical and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs , including entity1begin epinephrine entity1end combined with local entity2begin anesthetics entity2end , close supervision and careful adjustment of dosages are required . 
true chemical chemical Hyperpyrexia has been reported when entity1begin amitriptyline HCl entity1end is administered with entity2begin anticholinergic entity2end agents or with neuroleptic drugs , particularly during hot weather . 
false chemical chemical Hyperpyrexia has been reported when entity1begin amitriptyline HCl entity1end is administered with anticholinergic agents or with entity2begin neuroleptic entity2end drugs , particularly during hot weather . 
false chemical chemical Hyperpyrexia has been reported when amitriptyline HCl is administered with entity1begin anticholinergic entity1end agents or with entity2begin neuroleptic entity2end drugs , particularly during hot weather . 
true chemical chemical Paralytic ileus may occur in patients taking entity1begin tricyclic antidepressants entity1end in combination with entity2begin anticholinergic entity2end - type drugs . 
true chemical chemical entity1begin Cimetidine entity1end is reported to reduce hepatic metabolism of certain entity2begin tricyclic antidepressants entity2end , thereby delaying elimination and increasing steady - state concentrations of these drugs . 
false chemical chemical entity1begin Cimetidine entity1end is reported to reduce hepatic metabolism of certain tricyclic antidepressants , thereby delaying elimination and increasing steady - state concentrations of these entity2begin drugs entity2end . 
false chemical chemical Cimetidine is reported to reduce hepatic metabolism of certain entity1begin tricyclic antidepressants entity1end , thereby delaying elimination and increasing steady - state concentrations of these entity2begin drugs entity2end . 
true chemical chemical Clinically significant effects have been reported with the entity1begin tricyclic antidepressants entity1end when used concomitantly with entity2begin cimetidine entity2end . 
false chemical chemical Increases in plasma levels of entity1begin tricyclic antidepressants entity1end , and in the frequency and severity of side effects , particularly entity2begin anticholinergic entity2end , have been reported when cimetidine was added to the drug regimen . 
true chemical chemical Increases in plasma levels of entity1begin tricyclic antidepressants entity1end , and in the frequency and severity of side effects , particularly anticholinergic , have been reported when entity2begin cimetidine entity2end was added to the drug regimen . 
false chemical chemical Increases in plasma levels of entity1begin tricyclic antidepressants entity1end , and in the frequency and severity of side effects , particularly anticholinergic , have been reported when cimetidine was added to the entity2begin drug entity2end regimen . 
false chemical chemical Increases in plasma levels of tricyclic antidepressants , and in the frequency and severity of side effects , particularly entity1begin anticholinergic entity1end , have been reported when entity2begin cimetidine entity2end was added to the drug regimen . 
false chemical chemical Increases in plasma levels of tricyclic antidepressants , and in the frequency and severity of side effects , particularly entity1begin anticholinergic entity1end , have been reported when cimetidine was added to the entity2begin drug entity2end regimen . 
false chemical chemical Increases in plasma levels of tricyclic antidepressants , and in the frequency and severity of side effects , particularly anticholinergic , have been reported when entity1begin cimetidine entity1end was added to the entity2begin drug entity2end regimen . 
false chemical chemical Discontinuation of entity1begin cimetidine entity1end in well - controlled patients receiving entity2begin tricyclic antidepressants entity2end and cimetidine may decrease the plasma levels and efficacy of the antidepressants . 
false chemical chemical Discontinuation of entity1begin cimetidine entity1end in well - controlled patients receiving tricyclic antidepressants and entity2begin cimetidine entity2end may decrease the plasma levels and efficacy of the antidepressants . 
false chemical chemical Discontinuation of entity1begin cimetidine entity1end in well - controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the entity2begin antidepressants entity2end . 
true chemical chemical Discontinuation of cimetidine in well - controlled patients receiving entity1begin tricyclic antidepressants entity1end and entity2begin cimetidine entity2end may decrease the plasma levels and efficacy of the antidepressants . 
false chemical chemical Discontinuation of cimetidine in well - controlled patients receiving entity1begin tricyclic antidepressants entity1end and cimetidine may decrease the plasma levels and efficacy of the entity2begin antidepressants entity2end . 
false chemical chemical Discontinuation of cimetidine in well - controlled patients receiving tricyclic antidepressants and entity1begin cimetidine entity1end may decrease the plasma levels and efficacy of the entity2begin antidepressants entity2end . 
true chemical chemical Transient delirium has been reported in patients who were treated with one gram of entity1begin ethchlorvynol entity1end and 75 - 150 mg of entity2begin amitriptyline HCl entity2end . 
true chemical chemical When administered concurrently , the following drugs may interact with entity1begin amphotericin B entity1end : entity2begin Antineoplastic agents entity2end : may enhance the potential for renal toxicity , bronchospasm and hypotension . 
false chemical chemical entity1begin Antineoplastic agents entity1end ( e. g. , entity2begin nitrogen mustard entity2end , etc. ) should be given concomitantly only with great caution . 
false chemical chemical entity1begin Corticosteroids entity1end and entity2begin Corticotropin entity2end ( ACTH ) : may potentiate amphotericin B - induced hypokalemia which may predispose the patient to cardiac dysfunction . 
false chemical chemical entity1begin Corticosteroids entity1end and Corticotropin ( entity2begin ACTH entity2end ) : may potentiate amphotericin B - induced hypokalemia which may predispose the patient to cardiac dysfunction . 
true chemical chemical entity1begin Corticosteroids entity1end and Corticotropin ( ACTH ) : may potentiate entity2begin amphotericin B entity2end - induced hypokalemia which may predispose the patient to cardiac dysfunction . 
false chemical chemical Corticosteroids and entity1begin Corticotropin entity1end ( entity2begin ACTH entity2end ) : may potentiate amphotericin B - induced hypokalemia which may predispose the patient to cardiac dysfunction . 
true chemical chemical Corticosteroids and entity1begin Corticotropin entity1end ( ACTH ) : may potentiate entity2begin amphotericin B entity2end - induced hypokalemia which may predispose the patient to cardiac dysfunction . 
true chemical chemical Corticosteroids and Corticotropin ( entity1begin ACTH entity1end ) : may potentiate entity2begin amphotericin B entity2end - induced hypokalemia which may predispose the patient to cardiac dysfunction . 
false chemical chemical entity1begin Digitalis glycosides entity1end : entity2begin amphotericin B entity2end - induced hypokalemia may potentiate digitalis toxicity . 
false chemical chemical entity1begin Digitalis glycosides entity1end : amphotericin B - induced hypokalemia may potentiate entity2begin digitalis entity2end toxicity . 
true chemical chemical Digitalis glycosides : entity1begin amphotericin B entity1end - induced hypokalemia may potentiate entity2begin digitalis entity2end toxicity . 
false chemical chemical entity1begin Flucytosine entity1end : while a synergistic relationship with entity2begin amphotericin B entity2end has been reported , concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and / or impairing its renal excretion . 
false chemical chemical entity1begin Flucytosine entity1end : while a synergistic relationship with amphotericin B has been reported , concomitant use may increase the toxicity of entity2begin flucytosine entity2end by possibly increasing its cellular uptake and / or impairing its renal excretion . 
true chemical chemical Flucytosine : while a synergistic relationship with entity1begin amphotericin B entity1end has been reported , concomitant use may increase the toxicity of entity2begin flucytosine entity2end by possibly increasing its cellular uptake and / or impairing its renal excretion . 
false chemical chemical entity1begin Imidazoles entity1end ( e. g. , entity2begin ketoconazole entity2end , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical entity1begin Imidazoles entity1end ( e. g. , ketoconazole , entity2begin miconazole entity2end , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical entity1begin Imidazoles entity1end ( e. g. , ketoconazole , miconazole , entity2begin clotrimazole entity2end , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical entity1begin Imidazoles entity1end ( e. g. , ketoconazole , miconazole , clotrimazole , entity2begin fluconazole entity2end , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical entity1begin Imidazoles entity1end ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of entity2begin amphotericin B entity2end and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical entity1begin Imidazoles entity1end ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and entity2begin imidazoles entity2end suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical entity1begin Imidazoles entity1end ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that entity2begin imidazoles entity2end may induce fungal resistance to amphotericin B . 
false chemical chemical entity1begin Imidazoles entity1end ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to entity2begin amphotericin B entity2end . 
false chemical chemical Imidazoles ( e. g. , entity1begin ketoconazole entity1end , entity2begin miconazole entity2end , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , entity1begin ketoconazole entity1end , miconazole , entity2begin clotrimazole entity2end , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , entity1begin ketoconazole entity1end , miconazole , clotrimazole , entity2begin fluconazole entity2end , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , entity1begin ketoconazole entity1end , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of entity2begin amphotericin B entity2end and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , entity1begin ketoconazole entity1end , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and entity2begin imidazoles entity2end suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , entity1begin ketoconazole entity1end , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that entity2begin imidazoles entity2end may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , entity1begin ketoconazole entity1end , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to entity2begin amphotericin B entity2end . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , entity1begin miconazole entity1end , entity2begin clotrimazole entity2end , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , entity1begin miconazole entity1end , clotrimazole , entity2begin fluconazole entity2end , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , entity1begin miconazole entity1end , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of entity2begin amphotericin B entity2end and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , entity1begin miconazole entity1end , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and entity2begin imidazoles entity2end suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , entity1begin miconazole entity1end , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that entity2begin imidazoles entity2end may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , entity1begin miconazole entity1end , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to entity2begin amphotericin B entity2end . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , entity1begin clotrimazole entity1end , entity2begin fluconazole entity2end , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , entity1begin clotrimazole entity1end , fluconazole , etc. ) : in vitro and animal studies with the combination of entity2begin amphotericin B entity2end and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , entity1begin clotrimazole entity1end , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and entity2begin imidazoles entity2end suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , entity1begin clotrimazole entity1end , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that entity2begin imidazoles entity2end may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , entity1begin clotrimazole entity1end , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to entity2begin amphotericin B entity2end . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , entity1begin fluconazole entity1end , etc. ) : in vitro and animal studies with the combination of entity2begin amphotericin B entity2end and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , entity1begin fluconazole entity1end , etc. ) : in vitro and animal studies with the combination of amphotericin B and entity2begin imidazoles entity2end suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , entity1begin fluconazole entity1end , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that entity2begin imidazoles entity2end may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , entity1begin fluconazole entity1end , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to entity2begin amphotericin B entity2end . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of entity1begin amphotericin B entity1end and entity2begin imidazoles entity2end suggest that imidazoles may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of entity1begin amphotericin B entity1end and imidazoles suggest that entity2begin imidazoles entity2end may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of entity1begin amphotericin B entity1end and imidazoles suggest that imidazoles may induce fungal resistance to entity2begin amphotericin B entity2end . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and entity1begin imidazoles entity1end suggest that entity2begin imidazoles entity2end may induce fungal resistance to amphotericin B . 
false chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and entity1begin imidazoles entity1end suggest that imidazoles may induce fungal resistance to entity2begin amphotericin B entity2end . 
true chemical chemical Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc. ) : in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that entity1begin imidazoles entity1end may induce fungal resistance to entity2begin amphotericin B entity2end . 
false chemical chemical Other nephrotoxic medications : agents such as entity1begin aminoglycosides entity1end , entity2begin cyclosporine entity2end , and pentamidine may enhance the potential for drug - induced renal toxicity , and should be used concomitantly only with great caution . 
false chemical chemical Other nephrotoxic medications : agents such as entity1begin aminoglycosides entity1end , cyclosporine , and entity2begin pentamidine entity2end may enhance the potential for drug - induced renal toxicity , and should be used concomitantly only with great caution . 
false chemical chemical Other nephrotoxic medications : agents such as aminoglycosides , entity1begin cyclosporine entity1end , and entity2begin pentamidine entity2end may enhance the potential for drug - induced renal toxicity , and should be used concomitantly only with great caution . 
false chemical chemical entity1begin Skeletal muscle relaxants entity1end : entity2begin amphotericin B entity2end - induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants ( e.g. , tubocurarine ) . 
false chemical chemical entity1begin Skeletal muscle relaxants entity1end : amphotericin B - induced hypokalemia may enhance the curariform effect of entity2begin skeletal muscle relaxants entity2end ( e.g. , tubocurarine ) . 
false chemical chemical entity1begin Skeletal muscle relaxants entity1end : amphotericin B - induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants ( e.g. , entity2begin tubocurarine entity2end ) . 
true chemical chemical Skeletal muscle relaxants : entity1begin amphotericin B entity1end - induced hypokalemia may enhance the curariform effect of entity2begin skeletal muscle relaxants entity2end ( e.g. , tubocurarine ) . 
true chemical chemical Skeletal muscle relaxants : entity1begin amphotericin B entity1end - induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants ( e.g. , entity2begin tubocurarine entity2end ) . 
false chemical chemical Skeletal muscle relaxants : amphotericin B - induced hypokalemia may enhance the curariform effect of entity1begin skeletal muscle relaxants entity1end ( e.g. , entity2begin tubocurarine entity2end ) . 
false chemical chemical entity1begin Leukocyte transfusions entity1end : acute pulmonary toxicity has been reported in patients receiving intravenous entity2begin amphotericin B entity2end and leukocyte transfusions . 
false chemical chemical entity1begin Leukocyte transfusions entity1end : acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and entity2begin leukocyte transfusions entity2end . 
true chemical chemical Leukocyte transfusions : acute pulmonary toxicity has been reported in patients receiving intravenous entity1begin amphotericin B entity1end and entity2begin leukocyte transfusions entity2end . 
false chemical chemical entity1begin Bacteriostatic Antibiotics entity1end : entity2begin Chloramphenicol entity2end , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins . 
false chemical chemical entity1begin Bacteriostatic Antibiotics entity1end : Chloramphenicol , entity2begin erythromycins entity2end , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins . 
false chemical chemical entity1begin Bacteriostatic Antibiotics entity1end : Chloramphenicol , erythromycins , entity2begin sulfonamides entity2end , or tetracyclines may interfere with the bactericidal effect of penicillins . 
false chemical chemical entity1begin Bacteriostatic Antibiotics entity1end : Chloramphenicol , erythromycins , sulfonamides , or entity2begin tetracyclines entity2end may interfere with the bactericidal effect of penicillins . 
false chemical chemical entity1begin Bacteriostatic Antibiotics entity1end : Chloramphenicol , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of entity2begin penicillins entity2end . 
false chemical chemical Bacteriostatic Antibiotics : entity1begin Chloramphenicol entity1end , entity2begin erythromycins entity2end , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins . 
false chemical chemical Bacteriostatic Antibiotics : entity1begin Chloramphenicol entity1end , erythromycins , entity2begin sulfonamides entity2end , or tetracyclines may interfere with the bactericidal effect of penicillins . 
false chemical chemical Bacteriostatic Antibiotics : entity1begin Chloramphenicol entity1end , erythromycins , sulfonamides , or entity2begin tetracyclines entity2end may interfere with the bactericidal effect of penicillins . 
true chemical chemical Bacteriostatic Antibiotics : entity1begin Chloramphenicol entity1end , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of entity2begin penicillins entity2end . 
false chemical chemical Bacteriostatic Antibiotics : Chloramphenicol , entity1begin erythromycins entity1end , entity2begin sulfonamides entity2end , or tetracyclines may interfere with the bactericidal effect of penicillins . 
false chemical chemical Bacteriostatic Antibiotics : Chloramphenicol , entity1begin erythromycins entity1end , sulfonamides , or entity2begin tetracyclines entity2end may interfere with the bactericidal effect of penicillins . 
true chemical chemical Bacteriostatic Antibiotics : Chloramphenicol , entity1begin erythromycins entity1end , sulfonamides , or tetracyclines may interfere with the bactericidal effect of entity2begin penicillins entity2end . 
false chemical chemical Bacteriostatic Antibiotics : Chloramphenicol , erythromycins , entity1begin sulfonamides entity1end , or entity2begin tetracyclines entity2end may interfere with the bactericidal effect of penicillins . 
true chemical chemical Bacteriostatic Antibiotics : Chloramphenicol , erythromycins , entity1begin sulfonamides entity1end , or tetracyclines may interfere with the bactericidal effect of entity2begin penicillins entity2end . 
true chemical chemical Bacteriostatic Antibiotics : Chloramphenicol , erythromycins , sulfonamides , or entity1begin tetracyclines entity1end may interfere with the bactericidal effect of entity2begin penicillins entity2end . 
true chemical chemical entity1begin Probenecid entity1end : May decrease renal tubular secretion of entity2begin ampicillin entity2end resulting in increased blood levels and / or ampicillin toxicity . 
false chemical chemical entity1begin Probenecid entity1end : May decrease renal tubular secretion of ampicillin resulting in increased blood levels and / or entity2begin ampicillin entity2end toxicity . 
false chemical chemical Probenecid : May decrease renal tubular secretion of entity1begin ampicillin entity1end resulting in increased blood levels and / or entity2begin ampicillin entity2end toxicity . 
false chemical chemical Drug / Laboratory Test Interaction After treatment with entity1begin ampicillin entity1end , a false - positive reaction for glucose in the urine may occur with entity2begin copper sulfate entity2end tests ( Benedicts solution , Fehlings solution , or Clinitest tablets ) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP . 
false chemical chemical entity1begin HIV Protease Inhibitors entity1end : The effect of entity2begin amprenavir entity2end on total drug concentrations of other HIV protease inhibitors in subjects receiving both agents was evaluated using comparisons to historical data . 
false chemical chemical entity1begin HIV Protease Inhibitors entity1end : The effect of amprenavir on total drug concentrations of other entity2begin HIV protease inhibitors entity2end in subjects receiving both agents was evaluated using comparisons to historical data . 
false chemical chemical HIV Protease Inhibitors : The effect of entity1begin amprenavir entity1end on total drug concentrations of other entity2begin HIV protease inhibitors entity2end in subjects receiving both agents was evaluated using comparisons to historical data . 
true chemical chemical entity1begin Indinavir entity1end steady - state Cmax , A.C. and Cmin were decreased by 22 % , 38 % , and 27 % , respectively , by concomitant entity2begin amprenavir entity2end . 
true chemical chemical entity1begin Saquinavir entity1end steady - state Cmax , A.C. and Cmin were increased 21 % , decreased 19 % , and decreased 48 % , respectively , by concomitant entity2begin amprenavir entity2end . 
true chemical chemical entity1begin Nelfinavir entity1end steady - state Cmax , A.C. and Cmin were increased by 12 % , 15 % , and 14 % , respectively , by concomitant entity2begin amprenavir entity2end . 
false chemical chemical entity1begin Methadone entity1end : Coadministration of entity2begin amprenavir entity2end and methadone can decrease plasma levels of methadone . 
false chemical chemical entity1begin Methadone entity1end : Coadministration of amprenavir and entity2begin methadone entity2end can decrease plasma levels of methadone . 
false chemical chemical entity1begin Methadone entity1end : Coadministration of amprenavir and methadone can decrease plasma levels of entity2begin methadone entity2end . 
true chemical chemical Methadone : Coadministration of entity1begin amprenavir entity1end and entity2begin methadone entity2end can decrease plasma levels of methadone . 
false chemical chemical Methadone : Coadministration of entity1begin amprenavir entity1end and methadone can decrease plasma levels of entity2begin methadone entity2end . 
false chemical chemical Methadone : Coadministration of amprenavir and entity1begin methadone entity1end can decrease plasma levels of entity2begin methadone entity2end . 
true chemical chemical Coadministration of entity1begin amprenavir entity1end and entity2begin methadone entity2end as compared to a non - matched historicalcontrol group resulted in a 30 % , 27 % , and 25 % decrease in serum amprenavir AUC , Cmax , andCmin , respectively . 
false chemical chemical Coadministration of entity1begin amprenavir entity1end and methadone as compared to a non - matched historicalcontrol group resulted in a 30 % , 27 % , and 25 % decrease in serum entity2begin amprenavir entity2end AUC , Cmax , andCmin , respectively . 
false chemical chemical Coadministration of amprenavir and entity1begin methadone entity1end as compared to a non - matched historicalcontrol group resulted in a 30 % , 27 % , and 25 % decrease in serum entity2begin amprenavir entity2end AUC , Cmax , andCmin , respectively . 
true chemical chemical Laboratory Tests : The combination of entity1begin Amprenavir entity1end and low - dose entity2begin ritonavir entity2end has been associated with elevations of cholesterol and triglycerides , SGOT ( AST ) , and SGPT ( ALT ) in some patients . 
true chemical chemical Appropriate laboratory testing should be considered prior to initiating combination therapy with entity1begin Amprenavir entity1end and entity2begin ritonavir entity2end and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy . 
false chemical chemical For comprehensive information concerning laboratory test alterations associated with entity1begin ritonavir entity1end , physicians should refer to the complete prescribing information for entity2begin NORVIR entity2end ( ritonavir ) . 
false chemical chemical For comprehensive information concerning laboratory test alterations associated with entity1begin ritonavir entity1end , physicians should refer to the complete prescribing information for NORVIR ( entity2begin ritonavir entity2end ) . 
false chemical chemical For comprehensive information concerning laboratory test alterations associated with ritonavir , physicians should refer to the complete prescribing information for entity1begin NORVIR entity1end ( entity2begin ritonavir entity2end ) . 
true chemical chemical Taking entity1begin amyl nitrite entity1end after drinking entity2begin alcohol entity2end may worsen side effects and may cause severe hypotension and cardiovascular collapse . 
false chemical chemical In vivo interaction studies in humans have demonstrated that entity1begin digoxin entity1end and entity2begin warfarin entity2end do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or warfarin . 
false chemical chemical In vivo interaction studies in humans have demonstrated that entity1begin digoxin entity1end and warfarin do not affect the PK properties of entity2begin anagrelide entity2end , nor does anagrelide affect the PK properties of digoxin or warfarin . 
false chemical chemical In vivo interaction studies in humans have demonstrated that entity1begin digoxin entity1end and warfarin do not affect the PK properties of anagrelide , nor does entity2begin anagrelide entity2end affect the PK properties of digoxin or warfarin . 
false chemical chemical In vivo interaction studies in humans have demonstrated that entity1begin digoxin entity1end and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of entity2begin digoxin entity2end or warfarin . 
false chemical chemical In vivo interaction studies in humans have demonstrated that entity1begin digoxin entity1end and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or entity2begin warfarin entity2end . 
false chemical chemical In vivo interaction studies in humans have demonstrated that digoxin and entity1begin warfarin entity1end do not affect the PK properties of entity2begin anagrelide entity2end , nor does anagrelide affect the PK properties of digoxin or warfarin . 
false chemical chemical In vivo interaction studies in humans have demonstrated that digoxin and entity1begin warfarin entity1end do not affect the PK properties of anagrelide , nor does entity2begin anagrelide entity2end affect the PK properties of digoxin or warfarin . 
false chemical chemical In vivo interaction studies in humans have demonstrated that digoxin and entity1begin warfarin entity1end do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of entity2begin digoxin entity2end or warfarin . 
false chemical chemical In vivo interaction studies in humans have demonstrated that digoxin and entity1begin warfarin entity1end do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of digoxin or entity2begin warfarin entity2end . 
false chemical chemical In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of entity1begin anagrelide entity1end , nor does entity2begin anagrelide entity2end affect the PK properties of digoxin or warfarin . 
false chemical chemical In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of entity1begin anagrelide entity1end , nor does anagrelide affect the PK properties of entity2begin digoxin entity2end or warfarin . 
false chemical chemical In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of entity1begin anagrelide entity1end , nor does anagrelide affect the PK properties of digoxin or entity2begin warfarin entity2end . 
false chemical chemical In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does entity1begin anagrelide entity1end affect the PK properties of entity2begin digoxin entity2end or warfarin . 
false chemical chemical In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does entity1begin anagrelide entity1end affect the PK properties of digoxin or entity2begin warfarin entity2end . 
false chemical chemical In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide , nor does anagrelide affect the PK properties of entity1begin digoxin entity1end or entity2begin warfarin entity2end . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with entity1begin anagrelide entity1end in clinical trials were entity2begin aspirin entity2end , acetaminophen , furosemide , iron , ranitidine , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with entity1begin anagrelide entity1end in clinical trials were aspirin , entity2begin acetaminophen entity2end , furosemide , iron , ranitidine , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with entity1begin anagrelide entity1end in clinical trials were aspirin , acetaminophen , entity2begin furosemide entity2end , iron , ranitidine , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with entity1begin anagrelide entity1end in clinical trials were aspirin , acetaminophen , furosemide , entity2begin iron entity2end , ranitidine , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with entity1begin anagrelide entity1end in clinical trials were aspirin , acetaminophen , furosemide , iron , entity2begin ranitidine entity2end , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with entity1begin anagrelide entity1end in clinical trials were aspirin , acetaminophen , furosemide , iron , ranitidine , entity2begin hydroxyurea entity2end , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with entity1begin anagrelide entity1end in clinical trials were aspirin , acetaminophen , furosemide , iron , ranitidine , hydroxyurea , and entity2begin allopurinol entity2end . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were entity1begin aspirin entity1end , entity2begin acetaminophen entity2end , furosemide , iron , ranitidine , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were entity1begin aspirin entity1end , acetaminophen , entity2begin furosemide entity2end , iron , ranitidine , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were entity1begin aspirin entity1end , acetaminophen , furosemide , entity2begin iron entity2end , ranitidine , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were entity1begin aspirin entity1end , acetaminophen , furosemide , iron , entity2begin ranitidine entity2end , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were entity1begin aspirin entity1end , acetaminophen , furosemide , iron , ranitidine , entity2begin hydroxyurea entity2end , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were entity1begin aspirin entity1end , acetaminophen , furosemide , iron , ranitidine , hydroxyurea , and entity2begin allopurinol entity2end . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , entity1begin acetaminophen entity1end , entity2begin furosemide entity2end , iron , ranitidine , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , entity1begin acetaminophen entity1end , furosemide , entity2begin iron entity2end , ranitidine , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , entity1begin acetaminophen entity1end , furosemide , iron , entity2begin ranitidine entity2end , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , entity1begin acetaminophen entity1end , furosemide , iron , ranitidine , entity2begin hydroxyurea entity2end , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , entity1begin acetaminophen entity1end , furosemide , iron , ranitidine , hydroxyurea , and entity2begin allopurinol entity2end . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , entity1begin furosemide entity1end , entity2begin iron entity2end , ranitidine , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , entity1begin furosemide entity1end , iron , entity2begin ranitidine entity2end , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , entity1begin furosemide entity1end , iron , ranitidine , entity2begin hydroxyurea entity2end , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , entity1begin furosemide entity1end , iron , ranitidine , hydroxyurea , and entity2begin allopurinol entity2end . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , entity1begin iron entity1end , entity2begin ranitidine entity2end , hydroxyurea , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , entity1begin iron entity1end , ranitidine , entity2begin hydroxyurea entity2end , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , entity1begin iron entity1end , ranitidine , hydroxyurea , and entity2begin allopurinol entity2end . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , iron , entity1begin ranitidine entity1end , entity2begin hydroxyurea entity2end , and allopurinol . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , iron , entity1begin ranitidine entity1end , hydroxyurea , and entity2begin allopurinol entity2end . 
false chemical chemical Although additional drug interaction studies have not been conducted , the most common medications used concomitantly with anagrelide in clinical trials were aspirin , acetaminophen , furosemide , iron , ranitidine , entity1begin hydroxyurea entity1end , and entity2begin allopurinol entity2end . 
false chemical chemical An in vivo interaction study in humans demonstrated that a single 1mg dose of entity1begin anagrelide entity1end administered concomitantly with a single 900 mg dose of entity2begin aspirin entity2end was generally well tolerated . 
false chemical chemical No clinically relevant pharmacokinetic interactions between entity1begin anagrelide entity1end and entity2begin acetylsalicylic acid entity2end were observed . 
true chemical chemical entity1begin Anagrelide entity1end alone had no effect on platelet aggregation , but did slightly enhance the inhibition of platelet aggregation by entity2begin aspirin entity2end . 
true chemical chemical It is known that CYP1A2 is inhibited by several medicinal products , including entity1begin fluvoxamine entity1end , and such medicinal products could theoretically adversely influence the clearance of entity2begin anagrelide entity2end . 
true chemical chemical entity1begin Anagrelide entity1end demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. entity2begin theophylline entity2end . 
false chemical chemical The effects of medicinal products with similar properties such as inotropes entity1begin milrinone entity1end , entity2begin enoximone entity2end , amrinone , olprinone and cilostazol may be exacerbated by anagrelide . 
false chemical chemical The effects of medicinal products with similar properties such as inotropes entity1begin milrinone entity1end , enoximone , entity2begin amrinone entity2end , olprinone and cilostazol may be exacerbated by anagrelide . 
false chemical chemical The effects of medicinal products with similar properties such as inotropes entity1begin milrinone entity1end , enoximone , amrinone , entity2begin olprinone entity2end and cilostazol may be exacerbated by anagrelide . 
false chemical chemical The effects of medicinal products with similar properties such as inotropes entity1begin milrinone entity1end , enoximone , amrinone , olprinone and entity2begin cilostazol entity2end may be exacerbated by anagrelide . 
true chemical chemical The effects of medicinal products with similar properties such as inotropes entity1begin milrinone entity1end , enoximone , amrinone , olprinone and cilostazol may be exacerbated by entity2begin anagrelide entity2end . 
false chemical chemical The effects of medicinal products with similar properties such as inotropes milrinone , entity1begin enoximone entity1end , entity2begin amrinone entity2end , olprinone and cilostazol may be exacerbated by anagrelide . 
false chemical chemical The effects of medicinal products with similar properties such as inotropes milrinone , entity1begin enoximone entity1end , amrinone , entity2begin olprinone entity2end and cilostazol may be exacerbated by anagrelide . 
false chemical chemical The effects of medicinal products with similar properties such as inotropes milrinone , entity1begin enoximone entity1end , amrinone , olprinone and entity2begin cilostazol entity2end may be exacerbated by anagrelide . 
true chemical chemical The effects of medicinal products with similar properties such as inotropes milrinone , entity1begin enoximone entity1end , amrinone , olprinone and cilostazol may be exacerbated by entity2begin anagrelide entity2end . 
false chemical chemical The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , entity1begin amrinone entity1end , entity2begin olprinone entity2end and cilostazol may be exacerbated by anagrelide . 
false chemical chemical The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , entity1begin amrinone entity1end , olprinone and entity2begin cilostazol entity2end may be exacerbated by anagrelide . 
true chemical chemical The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , entity1begin amrinone entity1end , olprinone and cilostazol may be exacerbated by entity2begin anagrelide entity2end . 
false chemical chemical The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , amrinone , entity1begin olprinone entity1end and entity2begin cilostazol entity2end may be exacerbated by anagrelide . 
true chemical chemical The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , amrinone , entity1begin olprinone entity1end and cilostazol may be exacerbated by entity2begin anagrelide entity2end . 
true chemical chemical The effects of medicinal products with similar properties such as inotropes milrinone , enoximone , amrinone , olprinone and entity1begin cilostazol entity1end may be exacerbated by entity2begin anagrelide entity2end . 
true chemical chemical There is a single case report , which suggests that entity1begin sucralfate entity1end may interfere with entity2begin anagrelide entity2end absorption . 
false chemical chemical Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either entity1begin methotrexate entity1end or entity2begin Kineret entity2end when the two agents were administered together . 
true chemical chemical In a study in which patients with active RA were treated for up to 24 weeks with concurrent entity1begin Kineret entity1end and entity2begin etanercept entity2end therapy , a 7 % rate of serious infections was observed , which was higher than that observed with etanercept alone ( 0 % ) . 
false chemical chemical In a study in which patients with active RA were treated for up to 24 weeks with concurrent entity1begin Kineret entity1end and etanercept therapy , a 7 % rate of serious infections was observed , which was higher than that observed with entity2begin etanercept entity2end alone ( 0 % ) . 
false chemical chemical In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and entity1begin etanercept entity1end therapy , a 7 % rate of serious infections was observed , which was higher than that observed with entity2begin etanercept entity2end alone ( 0 % ) . 
true chemical chemical Two percent of patients treated concurrently with entity1begin Kineret entity1end and entity2begin etanercept entity2end developed neutropenia ( ANC 1 x 109 / L ) . 
false chemical chemical entity1begin Anastrozole entity1end did not alter the pharmacokinetics of entity2begin antipyrine entity2end . 
false chemical chemical Although there have been no formal interaction studies other than with entity1begin antipyrine entity1end , based on these in vivo and in vitro studies , it is unlikely that co - administration of a 1 mg dose of entity2begin ARIMIDEX entity2end with other drugs will result in clinically significant drug inhibition of cytochrome P450 - mediated metabolism of the other drugs . 
false chemical chemical An interaction study with entity1begin warfarin entity1end showed no clinically significant effect of entity2begin anastrozole entity2end on warfarin pharmacokinetics or anticoagulant activity . 
false chemical chemical An interaction study with entity1begin warfarin entity1end showed no clinically significant effect of anastrozole on entity2begin warfarin entity2end pharmacokinetics or anticoagulant activity . 
false chemical chemical An interaction study with warfarin showed no clinically significant effect of entity1begin anastrozole entity1end on entity2begin warfarin entity2end pharmacokinetics or anticoagulant activity . 
false chemical chemical At a median follow - up of 33 months , the combination of entity1begin ARIMIDEX entity1end and entity2begin tamoxifen entity2end did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor - positive subpopulation . 
false chemical chemical At a median follow - up of 33 months , the combination of entity1begin ARIMIDEX entity1end and tamoxifen did not demonstrate any efficacy benefit when compared with entity2begin tamoxifen entity2end in all patients as well as in the hormone receptor - positive subpopulation . 
false chemical chemical At a median follow - up of 33 months , the combination of ARIMIDEX and entity1begin tamoxifen entity1end did not demonstrate any efficacy benefit when compared with entity2begin tamoxifen entity2end in all patients as well as in the hormone receptor - positive subpopulation . 
true chemical chemical Based on clinical and pharmacokinetic results from the ATAC trial , entity1begin tamoxifen entity1end should not be administered with entity2begin anastrozole entity2end ( see CLINICAL PHARMACOLOGY Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections ) . 
true chemical chemical Co - administration of entity1begin anastrozole entity1end and entity2begin tamoxifen entity2end resulted in a reduction of anastrozole plasma levels by 27 % compared with those achieved with anastrozole alone . 
false chemical chemical Co - administration of entity1begin anastrozole entity1end and tamoxifen resulted in a reduction of entity2begin anastrozole entity2end plasma levels by 27 % compared with those achieved with anastrozole alone . 
false chemical chemical Co - administration of entity1begin anastrozole entity1end and tamoxifen resulted in a reduction of anastrozole plasma levels by 27 % compared with those achieved with entity2begin anastrozole entity2end alone . 
false chemical chemical Co - administration of anastrozole and entity1begin tamoxifen entity1end resulted in a reduction of entity2begin anastrozole entity2end plasma levels by 27 % compared with those achieved with anastrozole alone . 
false chemical chemical Co - administration of anastrozole and entity1begin tamoxifen entity1end resulted in a reduction of anastrozole plasma levels by 27 % compared with those achieved with entity2begin anastrozole entity2end alone . 
false chemical chemical Co - administration of anastrozole and tamoxifen resulted in a reduction of entity1begin anastrozole entity1end plasma levels by 27 % compared with those achieved with entity2begin anastrozole entity2end alone . 
true chemical chemical entity1begin Estrogen entity1end - containing therapies should not be used with entity2begin ARIMIDEX entity2end as they may diminish its pharmacologic action . 
true chemical chemical Caution should be observed when entity1begin anileridine entity1end is coadministered with other entity2begin opioids entity2end , sedatives , phenothiazines , or anesthetics , as these agents may increase respiratory and circulatory depression . 
true chemical chemical Caution should be observed when entity1begin anileridine entity1end is coadministered with other opioids , entity2begin sedatives entity2end , phenothiazines , or anesthetics , as these agents may increase respiratory and circulatory depression . 
true chemical chemical Caution should be observed when entity1begin anileridine entity1end is coadministered with other opioids , sedatives , entity2begin phenothiazines entity2end , or anesthetics , as these agents may increase respiratory and circulatory depression . 
true chemical chemical Caution should be observed when entity1begin anileridine entity1end is coadministered with other opioids , sedatives , phenothiazines , or entity2begin anesthetics entity2end , as these agents may increase respiratory and circulatory depression . 
false chemical chemical Caution should be observed when anileridine is coadministered with other entity1begin opioids entity1end , entity2begin sedatives entity2end , phenothiazines , or anesthetics , as these agents may increase respiratory and circulatory depression . 
false chemical chemical Caution should be observed when anileridine is coadministered with other entity1begin opioids entity1end , sedatives , entity2begin phenothiazines entity2end , or anesthetics , as these agents may increase respiratory and circulatory depression . 
false chemical chemical Caution should be observed when anileridine is coadministered with other entity1begin opioids entity1end , sedatives , phenothiazines , or entity2begin anesthetics entity2end , as these agents may increase respiratory and circulatory depression . 
false chemical chemical Caution should be observed when anileridine is coadministered with other opioids , entity1begin sedatives entity1end , entity2begin phenothiazines entity2end , or anesthetics , as these agents may increase respiratory and circulatory depression . 
false chemical chemical Caution should be observed when anileridine is coadministered with other opioids , entity1begin sedatives entity1end , phenothiazines , or entity2begin anesthetics entity2end , as these agents may increase respiratory and circulatory depression . 
false chemical chemical Caution should be observed when anileridine is coadministered with other opioids , sedatives , entity1begin phenothiazines entity1end , or entity2begin anesthetics entity2end , as these agents may increase respiratory and circulatory depression . 
false chemical chemical Addition or deletion of any drug from the therapeutic regimen of patients receiving oral entity1begin anticoagulants entity1end may affect patient response to the entity2begin anticoagulant entity2end . 
true chemical chemical For example , since entity1begin cholestyramine entity1end may reduce the gastrointestinal absorption of both the oral entity2begin anticoagulants entity2end and vitamin K , the net effects are unpredictable . 
true chemical chemical For example , since entity1begin cholestyramine entity1end may reduce the gastrointestinal absorption of both the oral anticoagulants and entity2begin vitamin K entity2end , the net effects are unpredictable . 
false chemical chemical For example , since cholestyramine may reduce the gastrointestinal absorption of both the oral entity1begin anticoagulants entity1end and entity2begin vitamin K entity2end , the net effects are unpredictable . 
true chemical chemical entity1begin Chloral hydrate entity1end may cause an increased prothrombin response by displacing the entity2begin anticoagulant entity2end from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction , thus leading to inter - patient variation in ultimate prothrombin effect . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : entity2begin adrenocortical steroids entity2end ; 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : entity2begin adrenocortical steroids entity2end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity2begin alcohol entity2end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity2begin antacids entity2end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity2begin antihistamines entity2end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity2begin barbiturates entity2end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity2begin carbamazepine entity2end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity2begin chloral hydrate entity2end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity2begin chlordiazepoxide entity2end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity2begin cholestyramine entity2end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity2begin vitamin K entity2end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity2begin diuretics entity2end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity2begin ethchlorvynol entity2end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
true chemical chemical Drugs that have been reported to diminish oral entity1begin anticoagulant entity1end response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; entity2begin alcohol entity2end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; entity2begin antacids entity2end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; entity2begin antihistamines entity2end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; entity2begin barbiturates entity2end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity2begin carbamazepine entity2end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity2begin chloral hydrate entity2end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity2begin chlordiazepoxide entity2end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity2begin cholestyramine entity2end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity2begin vitamin K entity2end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity2begin diuretics entity2end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity2begin ethchlorvynol entity2end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : entity1begin adrenocortical steroids entity1end ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; entity2begin antacids entity2end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; entity2begin antihistamines entity2end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; entity2begin barbiturates entity2end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; entity2begin carbamazepine entity2end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity2begin chloral hydrate entity2end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity2begin chlordiazepoxide entity2end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity2begin cholestyramine entity2end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity2begin vitamin K entity2end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity2begin diuretics entity2end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity2begin ethchlorvynol entity2end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; entity1begin alcohol entity1end * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; entity2begin antihistamines entity2end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; entity2begin barbiturates entity2end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; entity2begin carbamazepine entity2end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; entity2begin chloral hydrate entity2end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity2begin chlordiazepoxide entity2end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity2begin cholestyramine entity2end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity2begin vitamin K entity2end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity2begin diuretics entity2end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity2begin ethchlorvynol entity2end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; entity1begin antacids entity1end ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; entity2begin barbiturates entity2end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; entity2begin carbamazepine entity2end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; entity2begin chloral hydrate entity2end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; entity2begin chlordiazepoxide entity2end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity2begin cholestyramine entity2end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity2begin vitamin K entity2end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity2begin diuretics entity2end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity2begin ethchlorvynol entity2end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; entity1begin antihistamines entity1end ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; entity2begin carbamazepine entity2end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; entity2begin chloral hydrate entity2end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; entity2begin chlordiazepoxide entity2end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity2begin cholestyramine entity2end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity2begin vitamin K entity2end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity2begin diuretics entity2end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity2begin ethchlorvynol entity2end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; entity1begin barbiturates entity1end ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; entity2begin chloral hydrate entity2end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; entity2begin chlordiazepoxide entity2end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; entity2begin cholestyramine entity2end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity2begin vitamin K entity2end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity2begin diuretics entity2end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity2begin ethchlorvynol entity2end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; entity1begin carbamazepine entity1end ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; entity2begin chlordiazepoxide entity2end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; entity2begin cholestyramine entity2end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in entity2begin vitamin K entity2end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity2begin diuretics entity2end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity2begin ethchlorvynol entity2end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; entity1begin chloral hydrate entity1end * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; entity2begin cholestyramine entity2end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in entity2begin vitamin K entity2end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; entity2begin diuretics entity2end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity2begin ethchlorvynol entity2end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; entity1begin chlordiazepoxide entity1end ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in entity2begin vitamin K entity2end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; entity2begin diuretics entity2end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; diuretics * ; entity2begin ethchlorvynol entity2end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; entity1begin cholestyramine entity1end ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; entity2begin diuretics entity2end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; diuretics * ; entity2begin ethchlorvynol entity2end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; diuretics * ; ethchlorvynol ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; diuretics * ; ethchlorvynol ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in entity1begin vitamin K entity1end ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity1begin diuretics entity1end * ; entity2begin ethchlorvynol entity2end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity1begin diuretics entity1end * ; ethchlorvynol ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity1begin diuretics entity1end * ; ethchlorvynol ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity1begin diuretics entity1end * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity1begin diuretics entity1end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity1begin diuretics entity1end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity1begin diuretics entity1end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity1begin diuretics entity1end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity1begin diuretics entity1end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity1begin diuretics entity1end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity1begin diuretics entity1end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; entity1begin diuretics entity1end * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity1begin ethchlorvynol entity1end ; entity2begin glutethimide entity2end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity1begin ethchlorvynol entity1end ; glutethimide ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity1begin ethchlorvynol entity1end ; glutethimide ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity1begin ethchlorvynol entity1end ; glutethimide ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity1begin ethchlorvynol entity1end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity1begin ethchlorvynol entity1end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity1begin ethchlorvynol entity1end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity1begin ethchlorvynol entity1end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity1begin ethchlorvynol entity1end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity1begin ethchlorvynol entity1end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; entity1begin ethchlorvynol entity1end ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity1begin glutethimide entity1end ; entity2begin griseofulvin entity2end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity1begin glutethimide entity1end ; griseofulvin ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity1begin glutethimide entity1end ; griseofulvin ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity1begin glutethimide entity1end ; griseofulvin ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity1begin glutethimide entity1end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity1begin glutethimide entity1end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity1begin glutethimide entity1end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity1begin glutethimide entity1end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity1begin glutethimide entity1end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; entity1begin glutethimide entity1end ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity1begin griseofulvin entity1end ; entity2begin haloperidol entity2end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity1begin griseofulvin entity1end ; haloperidol ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity1begin griseofulvin entity1end ; haloperidol ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity1begin griseofulvin entity1end ; haloperidol ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity1begin griseofulvin entity1end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity1begin griseofulvin entity1end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity1begin griseofulvin entity1end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity1begin griseofulvin entity1end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; entity1begin griseofulvin entity1end ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity1begin haloperidol entity1end ; entity2begin meprobamate entity2end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity1begin haloperidol entity1end ; meprobamate ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity1begin haloperidol entity1end ; meprobamate ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity1begin haloperidol entity1end ; meprobamate ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity1begin haloperidol entity1end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity1begin haloperidol entity1end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity1begin haloperidol entity1end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; entity1begin haloperidol entity1end ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity1begin meprobamate entity1end ; oral entity2begin contraceptives entity2end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity1begin meprobamate entity1end ; oral contraceptives ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity1begin meprobamate entity1end ; oral contraceptives ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity1begin meprobamate entity1end ; oral contraceptives ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity1begin meprobamate entity1end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity1begin meprobamate entity1end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; entity1begin meprobamate entity1end ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity1begin contraceptives entity1end ; entity2begin paraldehyde entity2end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity1begin contraceptives entity1end ; paraldehyde ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity1begin contraceptives entity1end ; paraldehyde ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity1begin contraceptives entity1end ; paraldehyde ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity1begin contraceptives entity1end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral entity1begin contraceptives entity1end ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity1begin paraldehyde entity1end ; entity2begin primidone entity2end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity1begin paraldehyde entity1end ; primidone ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity1begin paraldehyde entity1end ; primidone ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity1begin paraldehyde entity1end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; entity1begin paraldehyde entity1end ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity1begin primidone entity1end ; entity2begin ranitidine entity2end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity1begin primidone entity1end ; ranitidine * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity1begin primidone entity1end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; entity1begin primidone entity1end ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity1begin ranitidine entity1end * ; entity2begin rifampin entity2end ; unreliable prothrombin time determinations ; vitamin C ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity1begin ranitidine entity1end * ; rifampin ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; entity1begin ranitidine entity1end * ; rifampin ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity1begin rifampin entity1end ; unreliable prothrombin time determinations ; entity2begin vitamin C entity2end ; warfarin sodium under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; entity1begin rifampin entity1end ; unreliable prothrombin time determinations ; vitamin C ; entity2begin warfarin sodium entity2end under - dosage . 
false chemical chemical Drugs that have been reported to diminish oral anticoagulant response , ie , decreased prothrom - bin time response , in man significantly include : adrenocortical steroids ; alcohol * ; antacids ; antihistamines ; barbiturates ; carbamazepine ; chloral hydrate * ; chlordiazepoxide ; cholestyramine ; diet high in vitamin K ; diuretics * ; ethchlorvynol ; glutethimide ; griseofulvin ; haloperidol ; meprobamate ; oral contraceptives ; paraldehyde ; primidone ; ranitidine * ; rifampin ; unreliable prothrombin time determinations ; entity1begin vitamin C entity1end ; entity2begin warfarin sodium entity2end under - dosage . 
true chemical chemical Drugs that reportedly may increase oral entity1begin anticoagulant entity1end response , ie , increased prothrombin response , in man include : entity2begin alcohol entity2end * ; 
true chemical chemical Oral entity1begin anticoagulants entity1end may potentiate the hypoglycemic action of entity2begin hypoglycemic agents entity2end , eg , tolbutamide and chlorpropamide , by inhibiting their metabolism in the liver . 
true chemical chemical Oral entity1begin anticoagulants entity1end may potentiate the hypoglycemic action of hypoglycemic agents , eg , entity2begin tolbutamide entity2end and chlorpropamide , by inhibiting their metabolism in the liver . 
true chemical chemical Oral entity1begin anticoagulants entity1end may potentiate the hypoglycemic action of hypoglycemic agents , eg , tolbutamide and entity2begin chlorpropamide entity2end , by inhibiting their metabolism in the liver . 
false chemical chemical Oral anticoagulants may potentiate the hypoglycemic action of entity1begin hypoglycemic agents entity1end , eg , entity2begin tolbutamide entity2end and chlorpropamide , by inhibiting their metabolism in the liver . 
false chemical chemical Oral anticoagulants may potentiate the hypoglycemic action of entity1begin hypoglycemic agents entity1end , eg , tolbutamide and entity2begin chlorpropamide entity2end , by inhibiting their metabolism in the liver . 
false chemical chemical Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents , eg , entity1begin tolbutamide entity1end and entity2begin chlorpropamide entity2end , by inhibiting their metabolism in the liver . 
